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	__________________	Figura	de	la	portada	-	Ovocito	humano	Metafase-II	en	la	fase	de	deshidratación	previa	al	enfriamiento	(arriba),	y	durante	la	rehidratación	posterior	al	recalentamiento	(abajo).	
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	Prefacio	
Desarrollar	una	tesis	doctoral	sobre	criobiología	en	la	Escuela	Superior	de	Ingenieros	 de	 Sevilla,	 concretamente	 enfocada	 en	 la	 criopreservación	 de	óvulos	 humanos,	 y	 compaginarla	 con	 el	 trabajo	 de	 embriólogo	 clínico	suponía	un	gran	desafío.	El	contexto	del	programa	de	doctorado	donde	se	ha	desarrollado	este	 trabajo	me	ha	obligado	a	 abordar	 la	 cuestión	desde	una	perspectiva	centrada	en	las	leyes	de	la	física	que	regulan	los	procesos	de	 criopreservación,	 en	 lugar	 de	 simplemente	 explicar	 el	 efecto	 de	 los	mismos	sobre	las	muestras	biológicas	sobre	las	que	se	aplican.		Sin	embargo,	esta	situación	que	a	priori	juzgaba	en	mi	contra,	ha	resultado	ser	un	punto	a	favor,	obligándome	a	salir	de	mi	zona	de	confort	científica,	y	adentrarme	—o	más	bien	mojar	 los	pies	 en	 la	 orilla—	en	otras	 áreas	de	conocimiento.	 En	mi	 perspectiva	 actual,	 después	 de	 esta	 inmersión	 de	 4	años	 en	 el	mundo	de	 la	 criobiología,	 veo	 que	mi	 situación	 no	 sólo	 no	 es	inusitada,	sino	que	es	de	hecho	el	recorrido	natural	de	esta	disciplina.	Si	se	echa	 la	vista	hacia	atrás,	muchos	de	 los	criobiólogos	que	han	 investigado	sobre	 la	 materia	 provienen	 de	 una	 formación	 en	 ciencias	 de	 la	 salud.	Sirven	 como	 ejemplo	 el	 considerado	 padre	 de	 la	 criobiología	moderna	 y	recientemente	 fallecido	 Peter	 Mazur,	 así	 como	 uno	 de	 los	 actuales	referentes	en	el	área,	Gregory	Fahy.	Ambos	licenciados	en	biología.			Sin	 embargo,	 no	 es	 fácil	 encontrar	 un	 contexto	 de	 investigación	interdisciplinar	 donde	 un	 profano	 en	 la	 materia	 pueda	 adquirir	 y	profundizar	en	los	conocimientos	relevantes	de	biofísica	de	la	criobiología,	especialmente	 en	 el	 ámbito	 nacional.	 Es	 por	 ello	 que	 aprovecho	 para	agradecer	 al	Dr.	Ramón	Risco	y	 a	 los	 Sres.	 Ingenieros	de	 la	 comisión	del	programa	de	doctorado	la	oportunidad	que	se	me	ha	brindado.		Sin	 más	 preámbulo,	 espero	 que	 los	 lectores	 de	 los	 diferentes	 gremios	científicos	puedan	disfrutar	de	este	trabajo.		
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	Resumen	en	castellano	
La	 criopreservación	 consiste	 en	 la	 reducción	 de	 la	 temperatura	 del	organismo,	 con	 el	 objetivo	de	detener	de	por	 completo	 la	 cinética	de	 las	reacciones	 biológicas	 que	 mantienen	 la	 homeostasis	 celular,	 y	 que	 al	mismo	 tiempo	 provocan	 el	 envejecimiento	 de	 las	mismas.	 Al	 arrestar	 el	metabolismo	 celular,	 se	 logra	 la	 preservación	 del	material	 biológico	 por	tiempo	indefinido.	El	principal	problema	asociado	a	la	disminución	de	la	temperatura	de	una	célula	 para	 tal	 propósito	 es	 la	 tendencia	 a	 la	 cristalización	 del	 medio	acuoso	 intracelular	 durante	 el	 enfriamiento.	 La	 configuración	 natural	 de	los	 grupos	 de	 moléculas	 de	 agua	 dentro	 de	 las	 células	 es	 el	 estado	desordenado	propio	del	estado	líquido.		Sin	embargo,	el	agua,	al	adquirir	la	estructura	cristalina	propia	del	hielo,	se	expande,	dañando	las	estructuras	biológicas	y	comprometiendo	su	viabilidad.		La	vitrificación	es	una	transición	de	fase	de	segundo	orden	alternativa	a	la	cristalización,	 en	 la	 que	 la	 solución	 acuosa	 adquiere	 propiedades	 de	 un	sólido	manteniendo	el	desorden	natural	de	las	moléculas	de	agua	y	solutos	presentes	 en	 el	 citosol.	 Debido	 a	 que	 no	 se	 produce	 la	 reconfiguración	molecular	 propia	 de	 la	 formación	 de	 hielo,	 permite	mantener	 el	 sistema	biológico	que	se	pretende	preservar	sin	alteraciones.	Por	lo	tanto,	para	la	criopreservación	de	material	biológico,	concretamente	óvulos	humanos	en	el	 caso	 de	 esta	 tesis,	 es	 necesario	 que	 el	 medio	 intracelular	 alcance	 el	estado	vítreo	y	se	evite	la	formación	de	hielo,	si	no	por	completo,	al	menos	cantidades	lesivas	del	mismo.	Existen	diferentes	estrategias	para	alcanzar	el	 estado	 vítreo,	 pero	 en	 esta	 tesis	 nos	 centraremos	 en	 la	 técnica	 de	vitrificación	ultrarápida.	Dicha	técnica	consiste	en	realizar	el	enfriamiento,	desde	 la	 temperatura	 ambiente	 hasta	 temperaturas	 criogénicas	 estables	(normalmente	 los	 -196	 ºC	 del	 nitrógeno	 líquido),	 y	 posteriormente	 el	recalentamiento,	a	altas	velocidades.		
	El	 gameto	 femenino	—el	óvulo—	es	 la	 célula	humana	de	mayor	 tamaño.	Para	 su	 criopreservación	 en	 el	 contexto	 de	 la	 reproducción	 humana	asistida,	 este	 se	 encuentra	 en	 un	 estado	 de	 arresto	 en	 la	metafase	 de	 la	segunda	división	meiótica,	preparado	para	la	fecundación.	Su	gran	tamaño	y	la	presencia	de	orgánulos	muy	sensibles	hacen	que	su	criopreservación	sea	 compleja,	 comparada	 con	 la	 de	 embriones	 en	 los	 primeros	 días	 de	desarrollo.	 Sólo	mediante	 la	 técnica	 de	 vitrificación	 ultrarápida,	 sobre	 la	que	 se	 trabaja	 en	 esta	 tesis,	 se	 consigue	 su	 criopreservación	 de	 forma	satisfactoria.			Durante	un	proceso	de	 vitrificación	ultrarápida,	 que	 se	produzca	o	no	 la	indeseada	 formación	 de	 hielo	 dependerá	 de	 las	 velocidades	 de	enfriamiento	 y	 recalentamiento	 alcanzadas,	 y	 de	 las	 propiedades	 de	 la	solución	—en	 este	 caso	 el	 citosol,	 la	 fracción	 líquida	 intracelular.	 Con	 la	concentración	de	solutos	y	viscosidad	del	citosol	de	los	óvulos	en	su	estado	natural,	las	velocidades	de	enfriamiento	y	recalentamiento	necesarias	para	evitar	 la	 formación	 de	 hielo	 serían	 muy	 difíciles	 de	 obtener.	 Por	 este	motivo,	 es	 necesario	 aumentar	 la	 tendencia	 a	 la	 vitrificación	 del	 citosol,	con	 un	 protocolo	 de	 preparación.	 Esta	 fase	 de	 preparación	 consiste	 en	aumentar	 la	 concentración	 intracelular	 de	 solutos	 y	 la	 viscosidad	 del	citosol,	hasta	un	punto	crítico	que	permita	alcanzar	la	transición	vítrea,	a	las	 velocidades	 de	 enfriamiento	 y	 recalentamiento	 obtenidas	 por	 los	soportes	 de	 vitrificación	 actualmente	 disponibles.	 Para	 ello,	 el	 óvulo	 se	expone	 a	 una	 serie	 de	 soluciones	 hipertónicas,	 que	 provocan	 la	permeación	de	solutos	hacia	el	interior	celular	y	la	salida	de	agua.	Una	vez	concluida	la	preparación,	el	óvulo	se	coloca	en	un	soporte	de	vitrificación	—pajuela—	y	se	procede	al	enfriamiento,	por	lo	general	por	inmersión	en	nitrógeno	líquido.		En	esta	tesis	se	describen	dos	estudios	prospectivos	con	óvulos	de	donante	llevados	a	cabo	en	una	clínica	de	fertilidad	(Ginemed	Sevilla),	en	los	que	se	estudia	la	eficacia	del	sistema	de	vitrificación	desarrollado	por	la	spin-off	
	de	 la	Universidad	de	 Sevilla	 Safepreservation,	 bajo	 la	 dirección	 científica	del	Dr.	Ramón	Risco.	En	el	primer	estudio,	se	emplea	un	kit	soluciones	de	vitrificación	 cuya	 novedad	 es	 su	 composición	 totalmente	 sintética,	 sin	 la	presencia	 de	 proteínas	 de	 origen	 humano	 como	 la	 albúmina,	 sustituidas	por	 el	 polímero	 hidroxipropil	 celulosa.	 Este	 tipo	 de	 moléculas	 son	generalmente	 empleadas	 como	 agentes	 surfactantes	 y	 también	desempeñan	actividad	osmótica.	Se	comparan	los	resultados	clínicos	de	un	grupo	de	óvulos	vitrificados	con	soluciones	sintéticas	 frente	a	otro	grupo	de	 óvulos,	 proveniente	 de	 la	 misma	 donante,	 no	 sometidos	 a	 la	vitrificación.	Se	comprueba	que	la	alternativa	desarrollada	por	el	grupo	de	Risco	obtiene	unos	resultados	satisfactorios,	similares	a	los	obtenidos	con	soluciones	 de	 vitrificación	 clásicas	 que	 incorporan	 en	 su	 formulación	proteínas	de	origen	humano	o	animal,	 sin	 las	desventajas	asociadas	a	 las	mismas,	como	lo	son	el	riesgo	de	contaminación	y	una	vida	útil	reducida.	En	 el	 segundo	 trabajo	 se	 emplea	 un	 diseño	 experimental	 similar	 al	 del	primer	estudio,	para	probar	la	eficacia	del	soporte	cerrado	de	vitrificación	SafeSpeed.	El	soporte	está	compuesto	por	un	capilar	ultrafino	unido	a	una	pajuela	de	resina	ionomérica.	El	capilar	donde	se	cargan	los	óvulos	para	la	vitrificación	 permite	 maximizar	 las	 tasas	 de	 enfriamiento	 y	recalentamiento,	 ya	 que	 la	 eficiencia	 térmica	 del	mismo	 es	 ampliamente	superior	 a	 la	 de	 otros	 soportes	 de	 vitrificación	 disponibles	 actualmente.	Cabe	resaltar	también	el	hecho	de	que	es	un	sistema	cerrado,	en	el	que	las	muestras	 biológicas	 no	 entran	 en	 contacto	 con	 el	 nitrógeno	 líquido	empleado	para	 el	 enfriamiento	y	 la	manipulación,	minimizando	el	 riesgo	de	 contaminación	por	agentes	patógenos	presentes	en	el	mismo.	En	este	caso	 también	 comprobamos	 que	 las	 tasas	 de	 supervivencia	 ovocitaria	 al	procedimiento	 de	 vitrificación	 con	 este	 soporte	 son	 excelentes,	 y	 que	 el	desarrollo	 de	 los	 embriones	 resultantes	 de	 los	 óvulos	 vitrificados	 es	similar	al	obtenido	con	óvulos	que	no	han	sido	sometidos	a	la	vitrificación.		
	Con	 estos	 resultados,	 queda	 patente	 que	 este	 sistema	 de	 vitrificación	desarrollado	en	la	Universidad	de	Sevilla	es	una	herramienta	muy	efectiva	que	 permite	 obtener	 resultados	 punteros	 en	 el	 contexto	 clínico.	 Sin	embargo,	los	protocolos	de	vitrificación	aún	son	susceptibles	de	mejora.	A	pesar	 de	 que	 el	 enfriamiento	 y	 el	 calentamiento	 de	 las	 muestras	 es	ultrarápido,	el	procedimiento	en	conjunto	requiere	mucho	tiempo,	ya	que	el	 tiempo	 estándar	 para	 preparar	 cada	 grupo	 de	 hasta	 3	 óvulos	 para	 la	vitrificación	 lleva	 de	 10	 a	 15	 minutos	 de	 exposición	 a	 soluciones	hipertónicas.	Es	deseable	una	 reducción	de	 la	duración	de	esta	 fase	para	mejorar	el	flujo	de	trabajo	en	el	laboratorio	de	FIV	y	reducir	el	tiempo	de	exposición	a	crioprotectores	potencialmente	tóxicos.	Con	 el	 objetivo	 de	 explorar	 esta	 posibilidad,	 decidimos	 estudiar	 la	dinámica	de	 la	permeación	de	crioproctectores	en	el	ovocito	humano.	En	primer	 lugar,	 con	 una	 aproximación	 in	 silico,	 mediante	 un	 programa	desarrollado	en	MatLab	para	integrar	las	dos	ecuaciones	diferenciales	que	describen	la	permeabilidad	de	la	membrana	plasmática	del	óvulo	según	un	modelo	 2-P.	 Estas	 simulaciones	 fueron	 complementadas	 con	observaciones	in	vivo	del	comportamiento	osmótico	de	los	ovocitos.	En	un	protocolo	de	preparación	de	óvulos	para	la	vitrificación	clásico,	en	primer	lugar	 se	 realiza	 una	 exposición	 prolongada	 (10-15	minutos)	 del	 óvulo	 a	una	solución	con	una	concentración	intermedia	de	crioprotectores	(≈25%	w/w),	 denominada	 solución	 no-vitrificante	 o	 solución	 de	 equilibrado,	seguida	de	una	segunda	exposición	corta	a	una	solución	vitrificante	(≈45%	w/w).	Comparamos	la	actividad	osmótica	que	se	produce	en	el	protocolo	estándar	contra	la	de	un	protocolo	corto,	basado	en	la	deshidratación,	en	el	 que	 la	 duración	 de	 la	 exposición	 de	 los	 óvulos	 tanto	 a	 la	 solución	 no-vitrificante	como	a	la	vitrificante	era	limitada	a	60	segundos.	Comprobamos	 que	 la	 deshidratación	 del	 óvulo	 tras	 la	 exposición	 a	soluciones	 de	 vitrificación	 ocurre	 muy	 rápido;	 el	 punto	 de	 volumen	mínimo	 de	 la	 curva	 de	 contracción	 y	 expansión	 resultante	 del	 gradiente	
	osmótico	se	alcanza	dentro	de	los	primeros	60	segundos.	En	ese	punto,	el	contenido	 de	 agua	 intracelular	 es	 mínimo,	 la	 penetración	 de	crioprotectores	de	bajo	peso	molecular	es	casi	completa	y,	como	resultado,	la	concentración	total	de	soluto	intracelular	es	alta.	Por	lo	tanto,	prolongar	la	primera	fase	de	exposición	hasta	15	minutos,	según	es	recomendado	en	los	 protocolos	 actuales,	 no	 produce	 una	 mejora	 significativa	 de	 la	tendencia	 a	 la	 vitrificación	 del	 citosol	 del	 ovocito,	 y	 no	 mejora	presumiblemente	 sus	 posibilidades	 de	 vitrificar	 a	 determinadas	 tasas	 de	enfriamiento	y	 recalentamiento.	 Los	 resultados	de	 las	pruebas	 en	óvulos	humanos	 y	 embriones,	 no	 aptos	 para	 uso	 clínico	 y	 donados	 para	 la	investigación,	muestran	que	la	tasa	de	supervivencia	a	la	vitrificación	no	se	ve	comprometida	por	reducir	los	tiempos	de	exposición,	confirmando	que	el	efecto	osmótico	deseado	se	produce	en	un	tiempo	reducido.		Las	 innovaciones	 en	 las	 técnicas	 empleadas	 para	 vitrificar	 las	 células	reproductivas	 se	 rigen	 por	 la	 premisa	 de	 que	 se	 debe	 mantener	 un	compromiso	 entre	 la	 seguridad	 y	 la	 eficacia;	 la	 técnica	 debe	 ser	 lo	 más	aséptica	 y	 efectiva	 posible.	 Se	 podría	 argumentar	 que	 SafeSpeed,	 como	soporte	 cerrado	 de	 virificación,	 cumple	 con	 este	 criterio	 de	 mejorar	 la	eficiencia	—eficiencia	térmica,	al	menos—	sin	comprometer	la	seguridad,	y	 como	 tal	podría	 considerarse	como	un	avance	en	 la	dirección	correcta.	Igualmente,	 el	 uso	 del	 polímero	 sintético	 hidroxipropil	 celulosa	 también	representa	una	alternativa	más	segura	y	más	estable	a	proteínas	derivadas	de	humano	o	animal.	Por	último,	 lo	mismo	podría	decirse	sobre	nuestros	intentos	 de	 acortar	 el	 protocolo	 de	 vitrificación:	 si	 los	 ovocitos	 y	embriones	 demuestran	 ser	 igualmente	 competentes,	 reducir	 la	 duración	de	 la	 exposición	 a	 crioprotectores	 potencialmente	 citotóxicos	 y	 a	temperaturas	 subóptimas	 debería	 ser	 más	 seguro.	 En	 última	 instancia,	para	cada	modificación	relevante	del	procedimiento,	se	debe	realizar	una	ruta	 de	 validación	 bien	 diseñada	 antes	 de	 su	 uso	 en	 el	 contexto	 clínico,	
	desde	 la	 etapa	 preclínica	 en	 modelos	 de	 mamíferos	 y	 material	 humano	donado,	hasta	estudios	clínicos	prospectivos	controlados.																					
	Abstract	
In	 the	 first	 part	 of	 this	 thesis,	 the	 effectiveness	 of	 a	 vitrification	 system,	developed	by	the	spin-off	of	the	University	of	Seville,	Safepreservation,	 is	studied.	Two	prospective	studies	with	donor	eggs,	carried	out	in	a	fertility	clinic	 (Ginemed	 Sevilla)	 were	 conducted.	 In	 the	 first	 study,	 we	 test	 a	vitrification	 solution	 of	 fully	 synthetic	 composition,	 free	 of	 proteins	 of	human	 origin	 such	 as	 albumin,	 which	 are	 substituted	 by	 the	 polymer	hydroxypropyl	 cellulose.	 This	 type	 of	 molecules	 are	 generally	 used	 as	surfactants	 and	 also	 perform	 osmotic	 activity.	 The	 clinical	 results	 of	 a	group	 of	 oocytes	 vitrified	 with	 these	 solutions	 are	 compared	 against	another	group	of	oocytes,	 coming	 from	 the	same	donor,	not	 subjected	 to	vitrification.	The	results	show	that	the	synthetic	alternative	developed	by	Risco's	group	provides	satisfactory	embriology	outcomes,	similar	to	those	obtained	 with	 classic	 vitrification	 solutions	 that	 incorporate	 in	 their	formulation	 proteins	 of	 human	 or	 animal	 origin.	 Yet,	 without	 the	disadvantages	associated	to	them,	such	as	the	risk	of	contamination	and	a	reduced	lifespan.	In	 the	 second	 work,	 an	 experimental	 design	 similar	 to	 that	 of	 the	 first	study	 is	 used	 to	 test	 the	 effectiveness	 of	 the	 closed	 vitrification	 carrier	"SafeSpeed".	 The	 carrier	 consists	 of	 an	 ultra-thin	 capillary	 attached	 to	 a	straw	of	 ionomeric	 resin.	The	capillary	where	 the	oocytes	are	 loaded	 for	vitrification	allows	to	maximize	the	rates	of	cooling	and	warming,	since	its	thermal	 efficiency	 is	 superior	 to	 that	 of	 other	 vitrification	 carriers	currently	 available.	 It	 should	 also	 be	 noted	 that	 it	 is	 a	 closed	 carrier,	 in	which	biological	samples	do	not	come	into	contact	with	the	liquid	nitrogen	used	 for	 cooling	 and	 storage,	 minimizing	 the	 risk	 of	 contamination	 by	pathogens.	 The	 outcomes	 of	 this	 study	 show	 that	 the	 ovocytary	 survival	rates	to	the	vitrification	procedure	with	this	carrier	meet	and	even	exceed	current	 standards,	 and	 that	 the	 development	 of	 the	 embryos	 resulting	
	from	the	vitrified	eggs	is	similar	to	that	of	embryos	from	eggs	that	have	not	undergone	vitrification.	The	results	of	this	two	studies	provide	initial	evidence	that	the	vitrification	system	developed	at	 the	University	of	 Seville	 is	 a	very	effective	 tool	 that	allows	 obtaining	 benchmark	 results	 in	 the	 clinical	 context.	However,	 the	vitrification	 protocols	 are	 still	 susceptible	 to	 improvement:	 although	 the	cooling	and	warming	of	 the	samples	 is	ultra	 fast,	 the	whole	procedure	 is	time	consuming,	since	each	group	of	up	to	3	oocytes	takes	from	10	to	15	minutes	 of	 exposure	 to	 hypertonic	 solutions	 with	 cryoprotectants	 to	 be	prepared	 for	 vitrification.	 A	 reduction	 in	 the	 duration	 of	 this	 phase	 is	desirable	 to	 improve	 workflow	 in	 the	 IVF	 laboratory	 and	 reduce	 the	exposure	time	to	potentially	toxic	cryoprotectants.	In	order	 to	 explore	 this	possibility,	we	decided	 to	 study	 the	dynamics	of	the	permeation	of	cryoprocectors	in	the	human	oocyte.	Firstly,	with	an	 in	
silico	 approach,	 through	a	program	developed	 in	MatLab	 to	 integrate	 the	two	 differential	 equations	 that	 describe	 the	 permeability	 of	 the	 plasma	membrane	of	 the	 human	Metaphase-II	 oocyte,	 according	 to	 a	 2-P	model.	These	 simulations	 were	 complemented	 with	 in	 vivo	 observations	 of	 the	osmotic	behavior	of	the	oocytes.	The	standard	protocol	for	the	preparation	of	 oocytes	 for	 vitrification	 consists	 on	 a	 prolonged	 exposure	 (10-15	minutes)	 to	 a	 solution	 with	 an	 intermediate	 concentration	 of	cryoprotectants	 (≈25%	 w/w),	 called	 a	 non-	 vitrifying,	 or	 equilibration,	solution.	 This	 is	 followed	 by	 a	 second	 short	 exposure	 to	 a	 vitrifying	solution	with	 higher	 CPA	 concentration	 (≈45%	w/w).	We	 compared	 the	osmotic	activity	that	occurs	in	the	standard	protocol	against	that	of	a	short	protocol,	based	on	dehydration,	 in	which	the	duration	of	exposure	of	 the	oocytes	 to	both	 the	non-vitrifying	 and	vitrifying	 solutions	was	 limited	 to	60	seconds	We	 verified	 that	 the	 dehydration	 of	 the	 oocyte	 after	 exposure	 to	vitrification	solutions	occurs	very	 fast;	 the	minimum	volume	point	of	 the	
	contraction	 and	 expansion	 curve	 resulting	 from	 the	 osmotic	 gradient	 is	reached	within	 the	 first	60	seconds.	At	 that	point,	 the	 intracellular	water	content	 is	 minimal,	 the	 penetration	 of	 low	 molecular	 weight	cryoprotectants	is	almost	complete	and,	as	a	result,	the	total	concentration	of	 intracellular	 solute	 is	 high.	 Therefore,	 prolonging	 the	 first	 exposure	phase	up	to	15	minutes,	as	recommended	in	the	current	protocols,	would	presumably	not	reduce	the	chance	of	 lethal	 ice	formation	at	certain	rates	of	 cooling	 and	 warming.	 The	 results	 of	 tests	 on	 human	 oocytes	 and	embryos,	 unsuitable	 for	 clinical	use	 and	donated	 for	 research,	 show	 that	the	 vitrification	 survival	 rate	 is	 not	 compromised	 by	 reducing	 the	exposure	 times,	 confirming	 that	 the	 desired	 osmotic	 effect	 occurs	 in	 a	reduced	time.	Innovations	 in	 the	 techniques	 used	 to	 vitrify	 reproductive	 cells	 are	governed	by	the	premise	that	a	compromise	must	be	maintained	between	safety	 and	 efficacy:	 the	 technique	 must	 be	 as	 aseptic	 and	 effective	 as	possible.	 It	 could	 be	 argued	 that	 SafeSpeed,	 as	 a	 closed	 support	 for	virification,	 meets	 this	 criterion	 of	 improving	 efficiency	 —thermal	efficiency,	 at	 least—	without	 compromising	 safety,	 and	 as	 such	 could	 be	considered	a	step	in	the	right	direction.	Likewise,	the	use	of	the	synthetic	polymer	hydroxypropyl	cellulose	also	represents	a	safer	and	more	stable	alternative	 to	 proteins	 derived	 from	 human	 or	 animal.	 Finally,	 the	 same	could	 be	 said	 about	 our	 attempts	 to	 shorten	 the	 vitrification	 protocol:	 if	oocytes	 and	 embryos	 prove	 to	 be	 equally	 competent,	 reducing	 the	duration	 of	 exposure	 to	 potentially	 cytotoxic	 cryoprotectants	 and	 at	suboptimal	 temperatures	 should	 be	 safer.	 Ultimately,	 for	 each	 relevant	modification	 of	 the	 procedure,	 a	well	 designed	 validation	 route	must	 be	performed	before	its	use	in	the	clinical	context,	from	the	preclinical	stage	in	 models	 of	 mammals	 and	 donated	 human	 material,	 to	 prospective	controlled	clinical	studies.		
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2	
1.	Introduction	
"Interestingly,	most	of	the	water	in	the	universe	may	exist	as	glass	rather	
than	ice,	as	a	result	of	vapor	deposition	on	dust	grains	in	the	coldness	of	
space."		
Bryan	Wowk			
1.1	The	vitreous	state,	and	its	potential	for	cryopreservation	Cooling	 a	 cell,	 tissue	 or	 organism	 can	 halt	 the	 ever-occurring	myriad	 of	chemical	 reactions	 that	maintain	homeostasis,	 effectively	 stopping	 life	 in	time,	 and	 avoiding	 its	 otherwise	 unavoidable	 decay	 (Tsujimoto	 et	 al.,	2016).	 However,	 the	 high	 content	 of	 water	 present	 in	 living	 organisms	tends	 to	 turn	 into	 ice	 when	 their	 temperature	 is	 decreased,	 disrupting	biological	 structures	 and	 damaging	 cells,	 making	 cryopreservation	 a	challenge	(Fahy	et	al.,	1984).			However,	 upon	 cooling,	 liquids	 can	 also,	 on	 the	 other	 hand,	 undergo	 a	second-order	phase	transition	and	become	amorphous	solids;	in	this	state	of	the	matter	molecules	are	found	in	the	disordered	arrangement	typical	of	the	liquid	state,	but	are	rigid	(Jenniskens	&	Blake,	1994;	Wowk,	2010).	The	process	 of	 formation	 of	 glass	 from	 the	 liquid	 state	 by	 cooling	 is	 called	vitrification.	The	potential	of	vitrification	as	a	mean	 for	cryopreservation	of	living	organisms	was	first	identified	by	Stiles	in	1930:	if	the	intracellular	water	 could	 become	 an	 amorphous	 solid	 upon	 cooling,	 instead	 of	 ice,	 it	should	 "give	 the	 original	 system	 again,	 without	 change",	 after	 warming	(Stiles,	1930).		Soon,	 Luyet	 would	 start	 actively	 pursuing	 vitrification	 as	 a	 means	 of	cryopreservation,	pioneering	 research	 in	 the	 field	and	 identifying	 critical	factors	to	avoid	the	formation	of	intracellular	ice	(Luyet,	1937).	However,	
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the	conditions	necessary	for	successful	vitrification	were	seemingly	either	unattainable	or	 incompatible	with	cellular	 life.	That	 is	until	Polge	 (1949)	and	 Smith	 (1950)	 described	 the	 cryoprotection	 ability	 of	 glycerol	 for	cryopreservation	 of	 fowl	 spermatozoa	 and	 red	 cells.	 As	 early	 as	 1963,	cryobiologist	 Peter	Mazur	would	 establish	 the	 thermodynamical	 basis	 of	the	 slow-freezing	 technique	 of	 cryopreservation,	 cooling	 cells	 in	 a	 slow,	controlled	fashion	(Mazur,	1963).	By	1980,	the	occurrence	of	intracellular	vitrification	was	demonstrated	by	Rall	and	colleagues	(Rall,	Reid,	&	Polge,	1984),	 and	 soon,	 with	 Fahy,	 he	 would	 achieve	 succesful	 vitrification	 of	mouse	embryos	by	ultrafast	cooling	and	warming	(Rall	&	Fahy,	1985).	This	milestone	 would	 not	 go	 unnoticed	 in	 the	 blooming	 field	 of	 human	embryology;	 the	 ability	 to	 produce	 embryos	 in	 vitro	 was	 perfectly	complemented	by	the	ability	to	cryopreserve	them	inexpensively	and	fast	by	vitrification	(Edwards,	Bavister	&	Steptoe;	1969).	This	sparked	interest	in	 the	 technique,	 and	 the	 rest	 is	 history:	 in	 2015,	 more	 than	 100,000	human	oocytes	and	embryos	were	cryopreserved	by	vitrification	in	Spain	alone,	 in	 the	 context	 of	 assisted	 reproduction	 treatments	 (Registro	 SEF,	2015).	
1.2	Vitrification	at	a	molecular	level	Vitrification	 is	 a	 phase	 transition	 that	 only	 occurs	 under	 very	 specific	conditions:	 the	 most	 common	 reaction	 of	 an	 aqueous	 solution	 upon	cooling	is	the	formation	of	ice,	as	the	melting	temperature	is,	in	most	cases,	higher	than	the	glass	transition	temperature	(Figure	4).	Ice	starts	to	form	by	 the	 stochastic	 process	 of	 ice	 nucleation,	 when	 a	 cluster	 of	 water	molecules	forms	a	structure	of	stable	hydrogen	bonds	—	a	nucleus	—	of	a	critical	 size	 that	 serves	 as	 a	 base	 from	where	 this	 sequence	 is	 repeated,	resulting	 in	 ice	growth	(Pradzynski	et	al.,	2012).	This	process	 is	 liable	 to	happen	when	the	solution	reaches	its	heterogeneous	melting	temperature,	meaning	that	it	is	always	catalysed	by	a	nucleating	agent,	usually	particles	
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present	in	the	solution	or	surfaces	the	solution	has	contact	with	(Fuller	&	Paynter,	2004).		As	ice	grows,	the	disordered	water	molecules	in	the	liquid	rearrange	into	the	 hexagonal	 shape	 of	 a	 solid	 crystal.	 When	 this	 process	 occurs	 in	 the	intracellular	 liquid	milieu	—the	 cytosol—	 ice	will	 rapidly	 grow	 to	 a	 size	that	 is	 physically	 damaging	 for	 the	 biological	 ultrastructures	 and	 will	compromise	 their	 viability,	 usually	 with	 lethal	 consequences	 (Leibo,	McGrath,	&	Cravalho,	1978).	The	formation	of	more	than	trace	amounts	of	ice	in	cells	is	a	lethal	event	(Karlsson	et	al.,	1993).	Conversely,	if	the	cytosol	undergoes	vitrification,	the	molecular	arrangement,	and	consequently	the	biological	 structures,	 will	 be	 preserved	 (Leibo	 et	 al.,	 1978;	 Luyet	 &	Gehenio,	1947;	Mazur,	1963).			However,	 it	 is	 no	 coincidence	 that	 vitrification	 is	 a	 phenomenon	predominant	 in	outer	 space,	 as	 the	 lack	of	heat	 is	 the	 factor	 that	 creates	the	 thermodynamic	 necessity	 of	 the	 vitreous	 state	 (Jenniskens	 &	 Blake,	1994;	Fahy, Vitrification in assisted reproduction, 2015, p.8).	At	a	molecular	level,	 as	 an	 aqueous	 solution	 is	 cooled,	 the	 kinetic	 energy	 of	 water	molecules,	 their	 constant	 agitation,	 is	 reduced,	 and	 hydrogen	 bonds	become	 more	 stable,	 favoring	 the	 formation	 of	 the	 crystaline	 structure.	However,	 if	 the translational and rotational degrees of freedom of the 
molecules in the liquid state are reduced by cooling to those of a solid, without 
ice forming in the process, the result is an amorphous rigid glass (Kauzmann; 
1948) by a second-order phase transition: vitrification. The achievement of 
such a state, especially in the aqueous media within a cell, poses however a 
challenge for many reasons, that will be described below.  
1.3	 How	 to	 attain	 the	 vitreous	 state:	 techniques	 for	 the	
cryopreservation	of	living	cells	As	previously	stated,	lowering	the	temperature	of	living	systems	is	a	very	effective	 mean	 to	 decelerate	 the	 rates	 at	 which	 biologic	 machinery	 is	
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working,	 as	 described	 by	 Arrhenius'	 equation.	 A	 practical	 example	 is	induced	 hypothermia	 for	 short-term	 preservation	 (Fuller	 &	 Lee,	 2007).	However,	 to	 accomplish	 total	 suspension	 of	 life,	 temperatures	 must	 be	reduced	 to	 the	 cryogenic	 range.	 When	 liquids	 present	 in	 biological	organisms	 are	 cooled	 for	 that	 purpose,	 they	 will	 reach	 their	 melting	temperatures	 and	 thermodynamically	 favour	 the	 transition	 to	 the	 solid	state	 by	 crystallisation,	 unless	 certain	 strategies	 are	 adopted	 to	 avoid	 it	(Wowk,	2010).			
	
Figure	1.	Mouse	ovum	cooled	at	3	ºC/min	to	0	(A),		-3	(B),	-5	[C),	-20	(D),	-28	(E),	 -48	 (F),	 -50	 (G),	 and	 -52	 °C	 (H).	The	microscopic	observations	 show	that	intracellular	 freezing	 generally	 occurred	 at	 about	 −40	 to	 −45	 °C.	 The	 sample	was	then	warmed	at	8	ºC/min	and	photographed	as	the	ice	melted	at	about	-4	°C	(I).	Reproduced	from	Leibo	et	al.	(1978).	
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Within	the	context	of	this	thesis,	we	will	be	working	within	a	very	specific	scenario,	 which	 is	 the	 cryopreservation	 of	 a	 single	 cell	 in	 the	 case	 of	human	 eggs,	 or	 early	 stage	 embryos	 formed	 by	 a	 small	 number	 of	 cells	with	 similar	 characteristics	 in	 terms	of	 osmotic	 sensitivity	 and	hydraulic	conductivity.	Tissues	and	organs,	dense	and	with	diverse	cell	types,	are	a	different	challenge	and	require	different	approaches	outside	the	scope	of	this	work	(Amorim	et	al.,	2011;	Fahy	et	al.,	2004;	Pegg,	Wang,	&	Vaughan,	2006).	
1.3.1	Controlled	rate	freezing	
The	first	cryopreservation	technique	that	was	applied	to	human	embryos,	and	with	very	limited	success	to	oocytes,	was	the	controlled	rate	freezing	(Whittingham,	 Leibo,	 &	 Mazur,	 1972).	 In	 this	 technique,	 cells	 are	suspended	in	a	solution	with	a	low	initial	concentration	of	cryoprotectant	agents;	 in	 the	 case	 of	 human	 embryos,	 the	 most	 commonly	 employed	cocktail	is	a	combination	of	1.5M	of	propylene	glycol	and	0.1M	of	sacarose.	This	 suspension	 is	 loaded	 in	 a	 straw	 of	 0,1-0,5	mL,	which	 is	 cooled	 in	 a	controlled,	slow	fashion	with	a	programmable	freezer:	a	common	protocol	is	to	employ	a	cooling	rate	of	2	°C/min	until	the	seeding	(manual	induction	of	 ice	 formation	 in	 the	 solution,	 usually	 by	 physical	 contact	 with	 a	 pre-cooled	forceps)	temperature	around	−7	°C.	After	seeding,	a	slower	cooling	rate	of	0.3–1.0	°C/min	is	usually	employed	until	temperatures	around	-70	°C	 are	 reached	 (Trounson	 &	 Mohr,	 1983;	 Lassale	 et	 al.,	 1985).	 This	technique	is	based	in	the	gradual	depression	of	the	freezing	point	resulting	of	 the	 increase	 in	 viscosity	 the	 solution	 experiences	 during	 cooling,	 and	most	 importantly,	 the	 increase	 in	 solute	 concentration	 produced	 by	extracellular	 ice	 formation.	 The	 temperature	 of	 the	 system	 is	 decreased	just	 above	 the	 rate	 of	 depression	 of	 the	 freezing	 point,	 until	 the	 glass	transition	 temperature	 is	 attained	 and	 the	 cytosol	 undergoes	 vitreous	solidification.	
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1.3.2	Ultra-fast	vitrification	
The	procedure	of	ultra-fast	vitrification	is	a	more	radical	approach,	as	the	temperature	 is	 lowered	below	 the	melting	point,	 all	 the	way	 to	 the	glass	transition	temperature.	It	relies	on	performing	the	cooling	of	the	cells,	and	most	 importantly,	 the	 warming,	 at	 such	 high	 rates	 (usually	 103	 to	 106	°C/min)	that	the	water	molecules	in	the	cytosol,	despite	being	below	their	melting	 point,	 do	 not	 have	 the	 necessary	 time	 to	 rearrange,	 form	 ice	crystals	and	grow	to	a	size	that	can	produce	cellular	injury	or	death	(Fahy	et	al.,	1984).	Before	this	happens,	the	solution	reaches	the	glass	transition	temperature	and	becomes	an	amorphous	solid,	preserving	the	disordered	molecular	configuration	of	the	living	state.		However,	 for	 vitrification	 of	 human	 eggs	 and	 embryos,	 and	 most	 other	cells	for	that	matter,	the	liquid	fraction	of	the	cells'	cytoplasm	must	acquire	certain	 characteristics	 that	 will	 favour	 the	 glass	 transition,	 such	 as	 low	free-water	 content,	 high	 viscosity	 and	 concentration	 of	 solutes.	 These	factors	will	affect	the	coligative	properties	of	the	solution,	decreasing	the	chances	of	ice	formation.	
1.4	Factors	that	determine	the	probability	of	vitrification	Ice	 nucleation	 and	 the	 kinetics	 of	 ice	 growth	 are	 complex	 physical	phenomena.	 For	 simplicity's	 sake,	 it	makes	 sense	 to	 separate	 the	 factors	that	 determine	 the	 probability	 of	 ice	 formation	 during	 a	 vitrification	procedure	 into	 two	 categories.	 On	 the	 one	 hand,	 the	 glass	 forming	tendency	of	the	liquid	part	of	the	system	—the	solution.	On	the	other	hand,	the	cooling	and	warming	rates	to	which	the	system	is	subjected.			
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	Figure	 2.	 	 Hypothetical	 examples	 of	 the	 paths	 of	 the	 slow	 freezing	 and	vitrification	approaches	on	a	glycerol–water	phase	diagram.	A)	Ultrafast	Vitrification:	cells	are	prepared	for	vitrification	by	increasing	their	solute	concentration	at	room	temperature,	and	afterwards	are	cooled	rapidly	to	avoid	 ice	 formation.	 B)	 Slow	 freezing:	 the	 cell	 suspension,	 with	 a	 low	initial	cryoprotectant	concentration,	is	supercooled	until	ice	formation	is	induced	 and	 latent	 heat	 is	 released.	 From	 that	 point	 on,	 solutes	concentrate	 as	 temperature	 decreases,	 so	 that	 the	 melting	 point	 of	remaining	 unfrozen	 solution	 equals	 the	 solution	 temperature	 until	vitrification	occurs.	Tm	is	the	equilibrium	melting	temperature	and	Tg	is	the	glass	transition	temperature.	Both	figures	adapted	from	Wowk,	2010.	
1.4.1	Cooling	and	warming	rates	For	cryopreservation,	 the	solution	 in	 the	system	has	 to	be	cooled	at	high	rates	 from	 Tm	 until	 Tg,	 in	 order	 to	 avoid	 ice	 formation.	 Similarly,	 the	warming	above	Td	until	Tm	must	be	carried	out	 fast	to	avoid	conversion	from	glass	to	ice	and	recrystallization	(Rall,	1987).	The	thermal	efficiency	of	the	carrier,	as	well	as	the	volume	of	solution	containing	the	suspended	cell	 that	 is	 loaded	 in	 it,	will	 influence	how	 fast	 the	 system	can	be	 cooled	and	warmed.	For	this	reason,	oocytes	are	usually	suspended	in	a	volume	of	≈1	 µL	 for	 loading	 in	 vitrification	 carriers.	 Also,	 the	 extracellular	 solution	
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must	 have	 a	 very	 specific	 composition,	 as	 this	 solution	 is	 in	 continuous	osmotic	exchange	with	the	cell	until	cooling	takes	place	(Shaw	et	al.,	1997).	
1.4.2	Glass	forming	tendency	of	the	solution	
The	formation	of	 ice	 is	 inhibited	by	the	presence	of	solutes	because	their	atoms	 directly	 interfere	 with	 the	 hydrogen	 bonding	 between	 water	molecules	 necessary	 for	 the	 crystalline	 structure	 to	 form.	 If	 the	 solutes	present	 also	 increase	 the	 viscosity	 of	 the	 solution,	 it	 reduces	 molecular	agitation	and	furtherly	challenges	the	union	of	water	molecules.	The	type	and	 quantity	 of	 solutes	 present	 and	 the	 viscosity	 of	 the	 solution	 will	determine	how	easily	the	water	molecules	can	re-arrange	into	ice	crystals,	determining	 how	 much	 time	 the	 solution	 can	 stay	 in	 the	 temperature	range	 below	 Tm	 and	 above	 Tg	 without	 ice	 formation.	Within	 a	 cell,	 the	glass	 forming	 tendency	 of	 the	 cytosolic	 milieu	 will	 determine	 if	 ice	 will	form	at	given	cooling	and	warming	rates	(Fahy	et	al.,	1984).	In	 conclussion,	 the	 rates	 of	 cooling	 and	warming	 necessary	 to	 avoid	 ice	formation	 are	 negatively	 correlated	 to	 the	 glass-forming	 tendency	 of	 the	solution;	 a	 solution	 with	 higher	 concentration	 of	 solutes	 and	 higher	viscosity	 can	 be	 cooled	 and	warmed	 at	 slower	 rates	 and	 still	 vitrify	 and	return	 to	 the	 liquid	state	without	 ice	 formation.	Very	dilute	solutions,	on	the	contrary,	would	require	extremely	high	cooling	and	warming	rates	to	avoid	ice	formation.							
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1.5	Mechanisms	of	ice	formation	during	the	temperature	excursion	of	
the	vitrification	procedure:	the	dominance	of	the	warming	rate	If	 the	warming	rate	 is	 the	dominant	variable	determining	 the	survival	 to	the	vitrification	procedure	(Seki	&	Mazur,	2009),	it	must	be	so	because	ice	is	more	 likely	to	reach	lethal	size	during	this	step.	When	we	examine	the	temperature	excursion	within	the	vitrification	procedure	in	a	hypothetical	two-phase	diagram,	we	can	elucidate	the	reason.		 											Figure	 3.	 Hypothetical	 phase	 diagram	 of	 the	 cytosol	 of	 a	 human	Metaphase-II	 oocyte	 during	 a	 vitrification	 procedure.	 The	 cell	 is	 loaded	with	 cryoprotectants	 at	 room	 temperature	 (RT;	 23-26	 ºC)	 during	 the	preparation	 phase.	 Then,	 the	 cell	 is	 cooled	 to	 -196	 ºC	 at	 a	 given	 solute	concentration.		Vitrification	occurs	when	the	glass	transition	temperature	(Tg)	 is	 reached.	 Ice	 may	 form	 below	 the	 heterogeneous	 (Tm)	 or	homogeneous	 (Th)	melting	 temperature.	During	warming,	 ice	may	 form	de	 novo	 above	 the	 devitrification	 temperature	 (Td)	 or	 may	 grow	 from	previously	formed	ice	crystals	(recrystallization).	The	diagram	is	adapted	from	Fahy	(Vitrification	in	assisted	reproduction	book,	2015,	p.8).	
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At	 the	 intracellular	 solute	 concentration	 hypothetically	 attained	 in	 the	cytosol	 of	 a	Metaphase-II	 oocyte	 after	 it's	 been	prepared	 for	 vitrification	(approximately	45%	of	 solutes	per	 total	mass	of	 solution),	 ice	 still	 has	 a	very	 high	 tendency	 to	 form	 during	 cooling.	 Ice	 formation	 starts	 being	thermodinamically	 favoured	below	the	melting	point	of	the	cytosol	(Tm),	until	the	solution	reaches	Tg.	However,	if	ice	does	form	during	cooling,	at	far	 below	 0	 °C	 temperatures	 (-50	 °C,	 for	 instance),	 the	 viscosity	 of	 the	solution	 at	 those	 temperatures	 has	 increased	 to	 such	 an	 extent	 that	 the	ince	 nucleus	 formed	 can	 hardly	 grow	 and	 may	 be	 innocuous.	 For	 that	reason,	 lethal	 ice	 formation	 during	 cooling	 is	 less	 likely	 to	 happen	 in	 a	vitrification	procedure.	Whereas	during	warming,	there	is	risk	of	de	novo	ice	formation	above	the	devitrification	temperature	(Td),	but	most	importantly,	there	is	the	risk	of	growth	 of	 ice	 crystals	 previously	 formed	 during	 cooling,	 known	 as	recrystallisation	(Seki	&	Mazur,	2009).	These	previously	formed	ice	nuclei	now	have	a	high	tendency	to	grow,	as	temperature	increases	and	viscosity	decreases.		That	is	the	reason	why,	as	mentioned	before,	warming	must	take	place	at	a	faster	rate	than	cooling:	first	to	avoid	de	novo	ice	formation	by	glass	to	ice	transition,	 but	 most	 importantly,	 to	 avoid	 recrystallisation.	 Therefore,	deletereous	ice	growth	during	cooling	will	usually	be	limited	because	the	nucleation	 process	 occurs	 at	 a	 temperature	 at	 which	 viscosity	 is	 high,	hindering	mobility	of	water	molecules	and	the	rate	of	ice	formation.	This,	ice	however,	will	grow	to	a	 lethal	size	 if	not	warmed	fast	enough.	Recent	research	points	to	the	fact	 that	the	degree	of	dehydration	of	 the	cell,	and	the	 level	 of	 hydrogen	 bonding	 between	 present	 water	 and	 intracellular	molecules	 seems	 to	 be	 the	most	 relevant	 parameter,	 more	 than	 type	 or	concentration	of	cryoprotectants	(Jin	&	Mazur,	2015).					
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	 Figure	 4.	 A)	 The	 survival	 of	 EAFS	 (ethylene	 glycol,	 acetamide,	 ficoll	 &	sucrose)	10/10-vitrified	oocytes	warmed	at	139,	476,	1220,	2170,	2950	°C/	min	as	a	function	of	the	cooling	rate.	(B)	The	survival	of	EAFS	10/10-vitrified	oocytes	cooled	at	37,	187,	522,	1827°C/min	as	a	function	of	the	warming	rate.	The	filled	symbols	depict	conditions	where	the	EAFS	10/10	solution	 froze;	 the	 open	 symbols	 depict	 where	 it	 vitrified.	 Figure	 from	(Seki	&	Mazur,	2009)		
1.6	 Intracellular	 ice	 can	 be	 present	 in	 successful	 vitrification	
procedures:	apparent	vitrification.	Vitrification	can	be	defined	as	the	transition	from	liquid	to	glass,	excluding	ice	 formation	 (Luyet,	 1937).	 However,	 in	 a	 vitrification	 procedure,	 as	discussed	 above,	 the	 possibility	 of	 ice	 formation	 cannot	 be	 completely	ruled	out	(Smith,	1954).	In	many	cases,	the	literature	defines	vitrification	as	a	procedure	that	yields	a	clear	transparent	medium	after	cooling	below	Tg,	as	opposed	to	an	opaque	sugar-like	appearance	(Vajta	et	al.,	2009).			 		
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	Table	1	Effect	of	warming	rate	on	the	survival	of	eight-cell	mouse	embryos	cooled	to	-196	Container		 Cooling	 rate	(°C	min-1)	 Warming	 rate	(°C	min-1)	 Total	 no.	 of	 embryos	(replicate	samples	)	 Survival	(%)	 s.e.m.	Embryos	cooled	in	VS1	Ministraw	 2,500	 2,500	 343	(13)	 87.8	 1.9	Minitraw	 20	 2,500	 110	(4)	 83.6	 3.9	Glass	tube	 500	 300	 171	(6)	 80.7	 4.0	Ministraw	 2,500	 10	 63	(3)	 0.0	 —		Table	1.	Murine	embryos	were	gradually	exposed	to	VS1	solution	(Me2SO,	acetamide,	propylene	glycol	and	polyethylene	glycol,	in	Dulbecco's	saline;	total	solute	concentration	of	the	solution	=	13M),	and	cooled	and	warmed	at	 different	 rates.	 Low	 warming	 rates	 resulted	 in	 lethal	 ice	 formation,	whereas	low	cooling	rates	did	not	lower	the	survival	rates	of	the	embryos.	Table	adapted	from	Rall	&	Fahy,	1985.		There	 is	 no	 evidence	 however,	 in	 almost	 all	 published	 literature	 on	 the	matter,	regarding	whether	the	formation	of	intracellular	ice	is	completely	avoided	 or	 not	 during	 a	 vitrification	 procedure.	 Ice	 formation	 can	 be	excluded,	 for	example,	by	 thermal	analysis	of	 the	presence	or	absence	of	latent	heat	of	fusion	(Rall	et	al.,	1984;	Seki	&	Mazur,	2009).	Nevertheless,	successful	 vitrification	 does	 not	 require	 that	 the	 whole	 system	 has	completely	 achieved	 a	 glassy	 state:	 survival	 to	 a	 vitrification	 procedure	does	 not	 exclude	 the	 formation	 of	 very	 small	 ice	 nuclei	 both	 inside	 and	outside	 the	 cells.	 As	 the	 solute	 concentration	 decreases,	 the	 cooling	 and	warming	 rates	 necessary	 to	 avoid	 ice	 formation	 increase	 dramatically	(Toner	et	al.,	1991).			
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		 						Figure	5.	Solidified	droplets	after	cooling	by	quenching	in	liquid	nitrogen.	A)	Solution	with	high	concentration	of	ethylene	glycol	(EG)	and	dimethyl	sulphoxide	(Me2SO),	showing	transparent,	glass-like	appearance.	B)	Low	concentration	 of	 dimethyl	 sulphoxide,	 showing	 an	 opaque,	 crystallized	look.	Adapted	from:	(Amorim	et	al.,	2011).		
1.	7	What	is,	then,	a	successful	vitrification	procedure?	A	 successful	 vitrification	 procedure	 should	 not	 be	 defined	 as	 one	 that	completely	avoids	any	extent	of	ice	nucleation,	inside	or	outside	the	cells,	first	of	all	because	it	 is	unlikely,	and	secondly	because	it	 is	challenging	to	observe	 experimentally.	 Instead,	 we	 say	 that	 a	 vitrification	 procedure	 is	successful	when	 the	 cell(s)	 subjected	 to	 it	 survive,	without	any	apparent	impairment	of	their	functional	and	developmental	ability.	There	are	three	main	mechanisms	by	which	a	cell	may	be	harmed	during	vitrification:	
i)	 Ice	 formation:	 the	 growth	 of	 ice	 deposits	 to	 a	 critical	 size	 that	lethally	disrupts	 the	cell	 structures	 is	 the	source	of	damage	 that	 is	hardest	 to	 overcome.	 There	 are	 a	 number	 of	mechanisms	 through	which	 ice	 can	 be	 formed	 during	 the	 temperature	 excursion	 of	 the	vitrification	 process.	 During	 cooling:	 a)	 crystallisation:	 de	 novo	formation	of	ice	from	a	liquid.	During	warming:	b)	devitrification:	de	
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novo	formation	of	ice	from	glass;	and	c)	recrystallisation:	ice	growth	from	already	existing	glass	nuclei.	
ii)	 Osmotic	 damage:	 during	 the	 preparation	 and	 rehydration	phases,	 cells	 are	 exposed	 to	 solutions	 of	 different	 solute	concentration	that	will	produce	rapid	outward	and	inward	flows	of	water	 and	 penetrant	 solutes	 that	 affect	 cell	 mechanisms	 and	produce	 stress.	 In	 addition,	 the	 resulting	 volumetric	 excursions,	shrinking	 and	 swelling,	 might	 physically	 damage	 the	 biological	structures,	when	above	a	certain	threshold	(Meryman,	2007).	 	
iii)	 Cytotoxicity	 of	 cryoprotectants:	 In	 addition	 to	 the	 possible	osmotic	 damage,	 permeating	 cryoprotectants	 can	 have	 a	 cytotoxic	effect.	This	will	depend	on	their	concentration	and	duration,	and	the	temperature	at	which	the	exposure	is	carried	out	(Fahy	et	al.,	1984)		
1.8	Phases	of	the	vitrification	procedure	Current	 ultra-fast	 vitrification	 protocols	 used	 in	 the	 context	 of	 human	assisted	reproduction	for	cryopreservation	of	oocytes	and	embryos	can	be	divided	into	six	phases:		
i)	Preparation	of	the	cells	for	vitrification:	The	cytosol	of	oocytes	and	embryos'	blastomers,	due	to	their	high	water	content,	does	not	vitrify	 at	 the	 rates	 currently	 attainable	 by	 vitrification	 carriers,	unlike	 spermatozoa.	 For	 this	 reason,	 the	 cells	 are	 subjected	 to	 a	preparation	protocol	prior	to	cooling,	to	reach	the	critical	cytosolic	solute	 concentration	 necessary	 to	 achieve	 vitrification.	 This	preparation	 consists	 of	 exposing	 cells	 to	 increasingly	 hypertonic	solutions	 with	 permeant	 and	 non	 permeant	 cryoprotectants;	 the	cells	 lose	 water	 by	 osmosis,	 and	 take	 cryoprotectants,	 increasing	their	glass	forming	tendency	(Rall	&	Fahy,	1985).					
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ii)	 Loading	 of	 the	 cells	 in	 the	 vitrification	 carrier.	 The	 cells,	usually	suspended	in	a	minimal	volume	of	vitrification	solution,	are	loaded	in	the	vitrification	carrier	(Katayama	et	al.,	2003).	The	total	volume	 of	 the	 system	 and	 the	 thermal	 performance	 of	 the	 carrier	will	determine	the	rates	of	cooling	and	warming.		
iii)	 Cooling:	 Once	 cells	 are	 loaded	 in	 a	 vitrification	 carrier,	 the	system	 has	 to	 be	 cooled,	 usually	 by	 direct	 quenching	 in	 liquid	nitrogen,	 despite	 there	 are	 other	 alternatives	 such	 as	 nitrogen	vapors	or	slush	nitrogen	(Isachenko	et	al.,	2018;	Yavin	et	al.,	2009).	The	 angle,	 depth	 and	 speed	 of	 the	 quenching	motion	 are	 relevant	parameters	 that	 shouldn't	 be	 overlooked	 (He	 et	 al.,	 2008).	 The	combination	of	 the	 cooling	 rate	 and	glass	 forming	 tendency	of	 the	solution	will	determine	if	the	system	can	attain	the	glass	transition	temperature	before	ice	forms.		
iv)	 Storage	 of	 the	 system	 at	 cryogenic	 temperatures:	 This	 is	essential	 for	maintaining	the	vitreous	state,	and	careful	handling	is	required,	to	avoid	accidental	warming.	
v)	Warming:	The	vitrification	carrier	containing	 the	cells	must	be	warmed	 from	 -196	 °C	 to	 37	 °C	 as	 fast	 as	 possible	 to	 avoid	devitrification	 and	 recrystallisation	 (Rall,	 1987;	 Seki	 &	 Mazur,	2009).	The	duration	of	the	warming	motion	(time	of	flight)	from	the	moment	 the	 carrier	 leaves	 the	 cold	 environment	 (usually	 a	 liquid	nitrogen	 container)	 until	 it	 reaches	 the	 warming	 solution	 is	therefore	critical	(Risco,	et	al.,	2007).	
vi)	Washing	 and	 rehydration:	 Cryoprotectants	 are	 removed	and	cells	 rehydrate	 by	 osmosis	 during	 short	 periods	 of	 exposure	 to	hypotonic	 solutions.	 The	 tonicity	 and	 times	 of	 exposure	 to	 these	rehydration	solutions	are	paramount,	to	avoid	an	excessive	inward	water	flow	and	damage	by	overswelling	(Hunter	et	al.,	1992).	
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Human	embryos,	 from	the	zygote	stage	 to	 the	expanded	blastocyst,	were	being	 cryopreserved	 with	 a	 moderate	 degree	 of	 success	 by	 the	 slow	freezing	 approach	 in	 the	 context	 of	 assisted	 reproduction	 treatments	(Borini	et	al.,	2006;	Fabbri	et	al.,	2001).	The	ultrafast	vitrification	strategy	gained	traction	when	it	proved	to	be	successful	in	cryopreserving	mature	human	oöcytes	at	the	Metaphase-II	stage,	very	sensitive	to	chilling	 injury	during	 the	 initial	 steps	 of	 the	 slow	 cooling	 process	 and	 for	 which	 very	limited	success	had	been	achieved	so	far	(Al-Hasani	et	al.,	2007).	Concerns	regarding	 the	 use	 of	 higher	 cryoprotectant	 concentrations	 in	 the	vitrification	procedure	were	proved	wrong	when	 it	was	determined	 that	the	 final	 intracellular	 cryoprotectant	 concentration	was	 lower	 in	oocytes	subjected	to	a	vitrification	protocol	than	those	subjected	to	a	slow	freezing	protocol	(Vanderzwalmen	et	al.,	2013;	Vanderzwalmen,	et	al.,	2010a).		It	was	not	until	2012,	when	it	was	already	being	used	extensively,	that	the	American	 Society	 of	 Reproductive	 Medicine	 removed	 the	 experimental	label	 of	 the	 technique	 (P.	 C.	 o.	 A.	 S.	 f.	 R.	Medicine	 &	 Technology,	 2013).	Despite	 both	 slow-freezing	 and	vitrification	 techniques	having	 their	 own	advantages	 and	 challenges	 for	 embryo	 cryopreservation	 (Edgar	 &	 Gook,	2012),	 vitrification	 is	 now	 prevalent	 and	 more	 successful	 than	 slow	freezing	in	the	human	assisted	reproduction	context,	and	is	essentially	the	only	effective	cryopreservation	technique	for	Metaphase-II	oocytes	(Rienzi	et	al.,	2017).	The	procedure,	however,	may	still	be	further	improved	(Vajta	&	Kuwayama,	2006).	Indeed,	the	body	of	work	in	this	thesis	is	focused	on	advancing	the	current	state	of	the	art	of	vitrification.						
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2.	 Ultrafast	 vitrification	 in	 the	 context	 of	 human	 assisted	
reproduction	Ultrafast	 vitrification	 is	 the	 most	 widely	 adopted	 method	 for	cryopreservation	 of	 oocytes	 and	 embryos	 in	 fertility	 clinics.	 It	 is	 a	 key	element	of	the	clinical	practice,	one	that	has	increased	their	efficiency	and	safety.	 It	 is	 so	 to	 such	 an	 extent	 that,	 currently,	 a	 large	 proportion	 of	treatments	 do	 not	 even	 involve	 the	 transfer	 of	 fresh	 embryos:	 all	 the	oocytes	or	embryos	of	a	patient	are	often	vitrified,	 such	as	 in	 the	case	of	oocyte	banking,	preimplantational	genetic	diagnosis	and	deferred	transfer	for	optimal	endometrial	receptivity	(Cobo	et	al;	2011;	Devroey,	Polyzos,	&	Blockeel,	2011;	Schoolcraft	et	al.,	2011).		Vitrification	 was	 pioneered	 in	 the	 clinical	 stage	 of	 assisted	 human	reproduction	in	1998,	with	cleavage-stage	embryos	(Mukaida	et	al.,	1998),	and	 soon	 was	 applied	 successfully	 to	 other	 developmental	 stages	(Kuleshova	 et	 al,.	 1999;	 Jelinkova	 et	 al.,	 2002).	 In	 general	 terms,	 current	vitrification	 protocols	 rely	 on	 exposing	 cells	 to	 high	 concentrations	 of	cryoprotectants,	loading	them	suspended	in	a	low	volume	of	solution	into	a	carrier,	and	cooling	and	warming	them	at	ultrafast	rates.	
2.1	Biological	features	of	the	human	Metaphase-II	oocyte		Oocytes,	 the	 largest	 cells	 in	 the	 human	 body,	 present	 certain	characteristics	 that	 make	 them	 more	 difficult	 to	 vitrify	 compared	 to	cleaved	 embryos	 and	 blastocysts.	Most	 importantly,	 their	 low	 surface	 to	volume	 ratio	 results	 in	 inefficient	 water	 exchange,	 and	 hence	 slower	dehydration	 and	 rehydration	 (Agca	 et	 al;	 1998)	 .	 Water	 and	 and	 low	molecular	weight	 cryoprotectants	only	 traverse	 the	oocyte's	 lipid	bilayer	membrane	 by	 simple	 passive	 difussion	 (Paynter	 et	 al.,	 1999a;	 1999b).	Surrounding	 the	oocyte	 there	 is	a	continuous	glycoprotein	coat,	 the	zona	pellucida.	 Its	 role	 in	 the	 osmotic	 behaviour	 of	 the	 oocyte	 is	 negligible.	However,	 vitrification	 can	 produce	 zona	 hardening	 by	 promoting	
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exocytosis	of	the	cortical	granules,	which	may	prevent	sperm	penetration	and	 hinder	 natural	 fertilisation.	 Nonetheless,	 this	 drawback	 can	 be	overcome	by	 intracytoplasmic	sperm	injection.	 (Sathananthan,	Trounson,	&	Freeman,	1987;	Gook	et	al.,	1995).	Additionally,	 oocytes	 in	 the	 Metaphase-II	 (M-II)	 stage	 possess	 very	sensitive	 structural	 features,	 specially	 the	 meiotic	 spindle	 (Agca	 et	 al.,	2000).	 These	 microtubules,	 attached	 to	 the	 chromosomes	 and	 lined	 up	along	the	equatorial	plate,	are	extremely	sensitive	to	temperature	changes.	During	vitrification,	the	oocyte	is	exposed	to	suboptimal	temperatures	and	volumetric	 changes,	 causing	 the	 breakdown	 of	 the	 structure.	 It	 will	however	 repolimerize	 and	 reassemble	 after	 the	vitrification	procedure	 if	the	oocyte	 is	 incubated	at	37	ºC,	allowing	to	maintain	the	developmental	competence	of	the	cell	(Ciotti	et	al.,	2009).		For	 these	 reasons,	 oocytes	 are	 arguably	 the	 most	 challenging	 cells	 to	cryopreserve	 in	 the	 context	 of	 AHR.	 In	 this	 thesis,	 oocytes	 will	 be	 the	model	upon	which	we	test	the	proposed	advancements	in	the	vitrification	procedure.	We	do	 so	under	 the	premise	 that,	what	works	 for	 the	oocyte	will	 generally	be	 applicable	 to	 embryos	 and	blastocysts,	 as	well	 as	 other	cell	types.		
2.2	Solutes	commonly	employed	in	solutions	for	preparation	of	cells	
for	vitrification:	the	cryoprotectants	As	 with	 most	 biological	 systems,	 the	 oocyte,	 as	 well	 as	 the	 embryo's	blastomers	 and	 blastocyst's	 cells	 must	 be	 modified	 in	 terms	 of	 solute	composition	 or	 concentration	 to	 achieve	 successful	 vitrification	 at	currently	attainable	cooling	and	warming	rates.	Their	osmotic	response	to	an	extracellular	medium	is	our	means	to	perform	this	manipulation,	which	is	 determined	 by	 i)	 the	 ratio	 of	 membrane	 surface	 area	 to	 cell	 water	volume;	 ii)	 The	 stage-specific	membrane	 permeability	 for	water;	 iii)	 the	
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stage-specific	 membrane	 permeability	 for	 CPAs	 in	 relation	 to	 their	respective	activation	energies	(A.	S.	I.	R.	Medicine,	2012).		Achieving	the	necessary	solute	concentration	for	vitrification	in	a	manner	that	does	not	kill	the	cells	was	initially	regarded	as	an	unsolvable	problem	(Luyet	 &	 Gehenio,	 1940;	 Boutron	 &	 Kaufmann,	 1979).	 Glycerol	 was	 the	first	 molecule	 whose	 cryoprotective	 attributes	 were	 identified	 (Polge,	Smith	&	Parkes,	1949).	Since	then,	other	cryoprotectant	agents	have	been	identified,	 such	 as	 Me2SO	 (Lovelock	 and	 Bishop,	 1959),	 ethylene	 glycol	(EG;	Kasai	et	al.,	1981	&	Kasai	et	al.,	1992)	and	1-2	propanediol	(Mukaida	et	 al.,	 1998),	 and	 are	 currently	 employed	 in	 vitrification	 solutions	 —	solutions	employed	to	prepare	and	carry	the	cells	during	vitrification	(Rall	&	Fahy,	1985).	The	ability	of	CPAs	 to	 avoid	 ice	 formation	 increases	with	concentration,	however	so	does	their	toxicity.	CPAs	can	have	a	toxic	effect	on	 cells	 due	 to	 their	 intrinsic	 cytotoxic	 properties,	 but,	 equally	 or	more	importantly,	will	produce	osmotic	 toxicity,	which	could	be	defined	as	 the	creation	 of	 an	 osmolarity	 that	 is	 not	 tolerated	 by	 the	 cells	 (Fahy,	 2010).	Both	 types	of	 toxicity	are	dependent	on	 temperature	and	the	duration	of	the	exposure,	so	these	parameters	are	carefully	controlled	 in	vitrification	protocols	(Ali	&	Shelton,	1993).	Currently,	most	CPA	 cocktails	 employed	 for	oocyte	vitrification	 feature	 a	synergic	combination	of	permeating	and	non-permeating	cryoprotectants	(A.	S.	I.	R.	Medicine,	2012).	Permeating	cryoprotectants,	small	compounds	that	 traverse	 easily	 the	 lipid	 bilayer,	 penetrate	 in	 the	 cytosol,	 replacing	water	in	the	cells	and	increasing	the	viscosity	of	the	intracellular	medium.	These	 molecules	 also	 have	 specific	 capabilities	 of	 blockage	 of	 ice	formation,	generally	by	hydrogen	bonding	with	water	molecules.	They	also	present	low	cellular	toxicity	and	high	solubility	at	low	temperatures	(A.	S.	I.	R.	Medicine,	2012).		For	 the	 role	of	non-permeating	cryoprotectants,	macromolecules	 such	as	disaccharides	—	sucrose	and	trehalose—	ficoll	and	dextran	are	commonly	
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employed	(A.	S.	I.	R.	Medicine,	2012).	Aside	from	direct	cryoprotection	by	increasing	 the	 viscosity	 of	 the	 vitrification	 solution	 and	 stabilising	 the	cellular	membrane,	they	act	as	osmotic	agents,	enhancing	dehydration	and	the	 cellular	 intake	 of	 penetrant	 CPAs	 (Kuleshova,	 Shaw,	 &	 Trounson,	2001).	Cellular	macromolecules	present	in	the	cytosol	of	oocytes,	such	as	proteins,	polysaccharides,	nucleic	acids	and	other	biopolymers,	also	play	a	cryoprotective	 role.	 For	 instance,	 when	 intracellular	 water	 is	 partially	removed,	the	volumetric	concentration	rises	and	may	be	enough	to	avoid	ice	 formation,	 albeit	 at	 very	 high	 rates	 of	 cooling	 and	 warming	 (Seki	 &	Mazur,	 2009).	 Vitrification	 solutions	 also	 feature	 surfactant	 agents	 that	increase	viscosity	and	prevent	the	oocytes	from	sticking	to	the	surfaces	of	dishes	 and	 pipettes	 used	 during	 in	 vitro	 manipulation.	 Proteins	 from	human	or	bovine	serum	albumin	are	the	most	common	surfactant	agents	employed;	 yet	 our	 group,	 among	 others,	 has introduced	 the	 synthetic	polymer	 hydroxypropyl	 cellulose	 as	 a	 safer	 and	 more	 stable	 alternative	(Gallardo	et	al.,	2015;	2016;	2017;	Mori	et	al.,	2015;	Coello	et	al;	2016)	In	conclusion,	despite	the	considerable	research	involved,	CPA	toxicity	has	not	been	either	avoided	or	neutralised.	Instead,	the	synergic	combinations	of	cryoprotectants	and	optimised	exposure	times	have	made	it	possible	to	surpass	CPA's	deleterious	effects,	enabling	 the	success	of	 these	protocols	(Fahy,	 2010).	 However,	 to	 prepare	 oocytes	 for	 vitrification,	 long	 (8-15	minutes)	 exposures	 to	 high	 concentrations	 of	 cryoprotectants	 at	suboptimal	temperatures	are	still	required.			
2.2.1	Removal	of	cryoprotectants	
So	far	we	have	discussed	mostly	the	introduction	of	CPAs	inside	the	cells	and	 removing	 water	 so	 ice	 formation	 is	 avoided	 during	 cooling	 and	warming.	 However,	 once	 this	 process	 has	 been	 completed,	 the	cryoprotectants	must	be	removed	and	the	original	water	content	restored.	In	 order	 to	 do	 so	 in	 a	 controlled	 fashion,	 the	 oocyte	 is	 exposed	 to	
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hypotonic	solutions	with	decreasing	concentrations	(usually	1M	followed	by	 0.5M)	 of	 non-penetrant	 cryoprotectants	 (usually	 sugars).	 The	extracellular	 osmotic	 agents	 compensate	 the	 osmotic	 gradient,	 avoiding	water	rushing	inside	the	oocyte	producing	lethal	over-swelling.	Water	and	CPAs	 are	 exchanged	 until	 the	 oocyte	 recovers	 its	 isotonic	 volume	 and	original	solute	content	(Shaw	&	Jones,	2003).	
2.3	The	evolution	of	vitrification	carriers		The	 seemingly	 easiest	 approach,	 to	 cool	 a	 solution	 with	 suspended	embryos	—small	droplets	freely	plunged	into	the	liquid	nitrogen	(Landa	&	Teplá,	 1990)—	 is	 a	 thermodynamically	 suboptimal	 and	 unpractical	approach.	 For	 that	 reason,	 vitrification	 carriers	 were	 needed.	 A	vitrification	 carrier	 could	 be	 defined	 as	 the	 physical	 support	 where	 the	embryos	are	placed	for	cooling	and	storage,	until	warming.	Cooling	usually	takes	place	by	quenching	in	liquid	nitrogen,	and	the	warming	in	a	volume	of	a	solution	at	37	°C	where	the	embryos	have	to	be	recovered	under	the	stereomicroscope.		As	vitrification	solutions	evolved	to	increase	cryoprotection	and	decrease	toxicity,	so	did	vitrification	carriers.	Initially,	the	evolution	was	completely	driven	towards	increasing	cooling	rates.	To	achieve	that	goal,	 the	volume	of	 vitrification	 solution	 carrying	 the	 cells	 loaded	 in	 the	 carrier	 had	 to	be	reduced	 (Arav,	 1992).	 Soon,	 scientists	 moved	 away	 from	 the	 0.25	 mL	straws	 that	 limited	 the	 cooling	 rates	 to	 2500	 °C/min.	 (Mukaida	 et	 al.,	1998).	 Placing	 a	 drop	 of	 a	 very	 small	 volume	 of	 solution	 (~1	 µL)	containing	the	embryos	on	a	thermally	efficient	carrier	was	the	solution	to	cool	 and	 warm	 the	 system	 faster.	 The	 initial	 array	 of	 carriers	 that	appeared	 can	 be	 designated	 open	 carriers,	 as	 the	 biological	 sample	 has	direct	 contact	 with	 liquid	 nitrogen	 during	 cooling	 and	 storage	 (Vajta,	Rienzi,	&	Ubaldi,	2015).		
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2.3.1	Examples	of	open	carriers:	
• Electron	 microscopy	 grids:	 Were	 initially	 used	 as	 carriers,	inspired	 by	 early	 cryofixation	 experiments	 in	 the	 field	 of	 electron	microscopy	 (Nei,	 1976).	 Inefficient	 handling	 and	 storage	 limited	their	application.			
• Open	 pulled	 straw:	 A	 0.25	 mL	 cryostraw,	 manually	 heated	 and	pulled	 to	 decrease	 its	 diameter	 and	 wall	 thickness,	 allowed	 to	achieve	warming	rates	of	20.000	 ºC/min.	Embryos	were	 loaded	by	capillarity	or	aspiration.	(Vajta,	1998;	Kuleshova	et	al.,	1999).		
	Figure	6:	8.5	cm	OPS	for	general	purpose.	Image	from:	www.open-pulled-straw.com/	
• Cryoloop:	A	nylon	cryoloop	 is	attached	to	the	lid	of	a	cryovial.	The	cells	 are	 loaded	 in	 the	 loop,	 coated	with	 a	 thin	 film	of	 vitrification	solution,	 and	 quenched	 in	 the	 cryovial	 filled	 with	 liquid	 nitrogen.	The	vial	is	sealed	for	storage	(Lane,	Schoolcraft,	&	Gardner,	1999).		
 Figure	 7:	 Illustration	 of	 the	 cryoloop.	 Image	 from	 (Lane	 et	 al.,	 1999)		
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• Open	 Hemi-Straw:	 consists	 of	 a	 standard	 0.25	 mL	 cryostraw,	cleaved	 in	 length,	 to	 hold	 a	 small	 volume	 of	 vitrification	 solution	containing	the	cells.		
	Figure	8:	Picture	of	the	tip	of	a	HemiStraw,	the	cells	are	placed	in	a	very	small	volume	of	cryoprotectant,	avoiding	the	 	 	 thermo-insulating	 	 	effect			of			a			conventional			straw.	The	carrier,	once	quenched	in	liquid	nitrogen,	can	be	encapsulted	inside	a	regular	cryopreservation	straw.	
• Flexi-pet	 denuding	 pipette:	 Denuding	 pipettes	 with	 a	 diameter	<250	 µm	 are	 routinely	 used	 for	 human	 embryology.	 Oocytes	 and	embryos	 can	 be	 loaded	 inside	 them	 with	 ~2	 μL	 of	 vitrification	solution	 and	 quenched	 in	 liquid	 nitrogen,	 and	 then	 introduced	inside	an	external	0.25	ml	regular	straw	for	storage	(Liebermann	et	al.,	2002).	
• Cryotop:	 Plastic	 handle	 with	 a	 fine,	 flat	 polypropylene	 strip	attached	 to	 it,	 where	 embryos	 are	 loaded	 in	 a	 microdrop	(Hamawaki,	1999).	
 
 Figure	9:	Most	recent	commercial	version	of	the	open	cryotop	carrier.	
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The	cryotop	concept,	as	a	minimum	drop	size	carrier	with	a	 long,	easy	to	manipulate	 body	 and	 storage-efficient	 dimensions,	 gained	 very	 wide	acceptation	 and	 eventually	 commercial	 success	 (Katayama	 et	 al.,	 2003;	Kuwayama,	2007)			
2.3.2	Closing	the	open	systems:	the	risk	of	contamination	
One	 drawback	 of	 the	 open-system	 approach	 is	 the	 hypothetical	 risk	 of	contamination	 by	 infectious	 microorganisms	 present	 in	 the	 liquid	nitrogen,	 and	 the	 risk	 of	 cross-contamination	 between	 patients’	 samples	(Bielanski	et	al.,		2000).	Infectious	agents	may	survive	the	cooling	process	and	spread	to	other	samples	stored	in	open	systems	through	the	liquid	or	vapour-phase	 nitrogen	 used	 for	 cooling	 and	 storage	 (Grout	 &	 Morris,	2009).	 However,	 despite	 the	 intensive	 use	 of	 carriers	 allowing	 direct	contact	with	 the	 possible	 contamination	 vector,	 as	 yet	 there	 hasn't	 been	any	cryopreservation-related	source	of	infection	transmission	reported	in	the	field	of	AHR	(Molina	et	al.,	2016).	Whether	 it	 is	preferable	to	use	open	or	closed	carriers	 is	a	hotly	debated	topic	in	the	AHR	field	(De	Munck	&	Vajta,	2017;	Vajta	et	al.,	2015;	Youm	et	al.,	2017).	European	directives	do	not	impose	the	use	of	closed	vitrification	systems,	 but	 recommend	 laboratories	 to	 minimise	 the	 risk	 of	contamination	of	tissues	and	cells	(EPC,	2006).	To	deal	with	this	concern,	carriers	have	been	developed	that	minimise	or	completely	avoid	exposure	to	 LN2	 (Bielanski	 &	 Vajta,	 2009).	 These	 are	 the	 semi-closed	 and	 closed	systems.	There	are	also	alternatives	in	which	liquid	nitrogen	is	sterilised,	but	they	remain	very	hard	to	implement	in	clinical	practice	(Isachenko	et	al.,	2018).				
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2.3.3	Examples	of	closed	carriers:	
i)	 Hermetically	 sealed	 into	 a	 container	 carrier:	 The	 carrier,	usually	 in	 the	 format	 of	 a	 thin-strip-attached-to-a-handle,	 is	introduced	 inside	 an	 outer	 cryostraw,	 which	 is	 sealed	 before	cooling.	It	 is	the	most	aseptic	vitrification	procedure,	but	results	 in	very	 low	 thermal	 efficiency	 due	 to	 the	 insulation	 and	 leindefrost	effect	 from	 the	 outer	 straw,	with	 speeds	 of	 cooling	 around	~2000	ºC/min	 (Isachenko	 et	 al.,	 2006;	 Kuleshova	 &	 Shaw,	 2000;	Vanderzwalmen	et	al.,	2009).	Alternatively,	 the	outer	straw	can	be	precooled	 in	 liquid	nitrogen	to	 improve	cooling	rates,	yet	reducing	asepsis	by	exposure	to	LN2	vapors	(Larman	&	Gardner,	2011;	Vajta	et	 al.,	 2015).	 Readiliy	 available	 consumables	 such	 a	 	 standard	denudation	pipette	and	an	ionomeric	resin	0.25	mL	cryo-straw	can	be	used	as	a	closed-system	kit	(Schiewe	et	al.,	2015;	Schiewe	et	al.,	2017)		
 Figure	10:	The	High	Security	Vitrification	device	is	composed	of	a	carrier	straw	(red),	 with	 a	 v-shaped	 tip	 in	 which	 the	 embryos	 are	 loaded	 with	 a	 minimum	volume	of	vehicle	solution	(*).	This	carrier	straw	is	then	introduced	in	the	outer	straw,	 which	 is	 sealed	 before	 plunging	 in	 liquid	 nitrogen	 for	 cooling.	 For	warming,	 the	 outer	 straw	 is	 cut	 open	 and	 the	 carrier	 straw	 extracted;	 the	embryos	are	re-warmed	by	immersion	of	the	tip	of	the	carrier	straw	in	1	mL	of	warming	solution	Adapted	from	(Guerrero,	et	al.,	2018).				
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ii)	Capillary-based	carriers:	A	capillary	is	attached	to	a	main	straw	body,	enabling	the	loading	of	the	cells	by	aspiration	and	capillarity.	The	tip	of	the	capillary	and	the	back	end	of	the	straw	can	be	sealed,	hermetically	 closing	 the	 system	 before	 contact	 with	 LN2.	 The	capillary,	 depending	 on	 its	 material	 and	 thickness,	 will	 have	 a	certain	 thermal	 efficiency	 (Risco	 et	 al.,	 2007;	 Kuwayama	 et	 al.,	2005).	 It	also	can	be	warmed	in	a	bigger	volume	of	water,	prior	to	cutting	and	releasing	the	cells	under	the	stereomicroscope,	allowing	maximizing	warming	rates.		
 Figure	 11:	 The	 SafeSpeed	 carrier	 (top)	 presents	 a	 capillary	 (*)	 where	 the	embryos,	while	floating	in	the	vehicle	solution	(vitrification	volution),	are	loaded	by	aspiration.	This	capillary	is	sealed	before	plunging	in	liquid	nitrogen	and	cut	open	 before	 expelling	 the	 embryos	 in	 warming	 solution.	 The	 sealed	 capillary	must	be	uncovered	by	the	protective	cap	(top)	during	cooling	in	liquid	nitrogen	and	warming	in	a	37	°C	water	bath.	During	storage	and	handling	it	is	protected	by	a	sliding	cover,	in	grey	(bottom).	Adapted	from	(Guerrero	et	al.,	2018).		
2.4	Modelling	the	osmotic	behaviour	of	the	Metaphase-II	oocyte	For	 a	 vitrification	 procedure	 to	 be	 successful	 at	 currently	 attainable	cooling	 and	 warming	 rates,	 it	 requires	 preparing	 the	 cells	 in	 order	 to	enhance	the	glass-forming	tendency	of	the	cytosol	(Boutron	&	Kaufmann,	1978;	Seki	&	Mazur,	2012).	 In	order	to	do	so,	we	osmotically	manipulate	the	oocyte	in	a	controlled	fashion,	subjecting	it	to	exposures	to	hypertonic	solutions	 made	 of	 various	 cryoprotectants	 and	 osmotic	 agents.	 The	
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osmometric	 behaviour	 of	 the	 oocyte	 depends	 on	 the	 permeability	 of	 the	plasma	membrane	to	water	and	each	solute	involved: 
• Permeability:	Determines	the	flow	of	a	permeable	substance	through	each	unit	of	the	cell	surface	as	a	function	of	time.		
• Activation	 Energy	 (EA):	 The	 required	 energy	 for	 the	 permeation	process	 of	 a	 particular	 substance	 to	 occur.	 A	 lower	 activation	 energy	implies	higher	permeability,	as	less	energy	is	necessary	for	the	process	to	 happen.	 For	 instance,	when	 exposed	 to	 a	 hypertonic	 solution	with	permeable	 cryoprotectants,	 dehydration	 is	 faster	 than	 CPA	 intake,	 as	𝐸!!!! <	𝐸!!"# (Paynter	et	al.,	1999a,b).	The	 two-parameter	 (2-P)	 transport	 formalism	 can	 be	 used	 to	 describe	membrane	permeability	of	the	Metaphase-II	oocyte	in	a	solution	of	water,	permeable	and	non-permeable	solutes,	as	 long	as	biophysical	parameters	of	 hydraulic	 conductivity	 (Lp),	 cryoprotectant	 permeability	 (PCPA)	 and	activation	energies	(𝐸!!"#)	are	known	(Kleinhans,	1998).		
2.5	Determining	permeability	characteristics	of	the	human	oocyte	The	 permeability	 parameters	 of	 human	 M-II	 oocytes	 to	 CPAs	 can	 be	determined	 by	 their	 response	 to	 hypertonic	 solutions	 with	 known	molarity	 of	 these	 solutes	 (Paynter	 et	 al.,	 1999a,b).	 By	 recording	 the	volumetric	excursion	of	an	oocyte	exposed	to	a	certain	solution	at	a	certain	temperature,	 its	 volume	 can	 be	 determined	 by	 measuring	 the	bidimensional	 area,	 radius,	 or	 diameter	 over	 time.	 Volume	 can	 then	 be	calculated	from	these	measurements,	assuming	that	the	oocyte	remains	in	perfect	spherical	shape	during	 the	process.	Once	 the	volumetric	data	has	been	 determined,	 the	 permeability	 variables	 can	 be	 cleared	 from	 the	equations	 described	 by	 fitting	 with	 this	 experimental	 data	 through	permeability	 models	 (Mullen	 et	 al;	 2008;	 Paynter	 et	 al.,	 1999a,b).	 The	permeability	 parameters	 of	 the	 oocyte's	 plasma	 membrane	 for	 relevant	cryoprotectants	 such	 as	 Me2SO	 and	 EG	 have	 already	 been	 determined	
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using	 this	 approach,	 as	 shown	 in	 Table	 2	 (Mullen	 et	 al.,	 2008;	 Paynter,	Cooper,	et	al.,	1999;	Paynter,	Fuller,	et	al.,	1999).		
 Figure	12:	Typical	osmotic	response	of	mature	mouse	oocyte	exposed	to	1.5	mol/liter	Me2SO.	Oocytes	were	exposed	at	30	ºC	(¤),	23	ºC	(w)	and	10	ºC	 (☐).	 The	 solid	 line	 for	 each	 case	 represents	 the	 predicted	 osmotic	response.	Adapted	from	Paynter	et	al.,	1997.		
2.5.1	The	shrink-swell	curve	
As	shown	in	Figure	12,	when	the	oocyte's	normalized	volume	is	plotted	on	a	 graph	 against	 time	 of	 exposure	 to	 a	 hypertonic	 solution,	we	 observe	 a	very	 distinctly	 shaped	 curve,	 known	 as	 the	 shrink-swell	 curve.	 Oocytes	quickly	shrink	to	a	minimum	volume,	as	water	leaves	the	cells	faster	than	cryoprotectants	 permeate	 them,	 as	 the	 hydraulic	 conductivity	 is	 higher	than	 the	 permeability	 to	 low	 molecular	 weight	 cryoprotectants.	 They	
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subsequently	 swell	 slowly	 towards	 their	 isotonic	 volume,	 describing	 an	asymptotic	curve,	as	cryoprotectant	permeates	and	water	re-enter	the	cell.	Once	these	parameters	have	been	established,	the	process	can	be	reversed	and	 the	 transport	 model	 can	 then	 be	 used	 to	 simulate	 the	 osmotic	response	 of	 oocytes	 under	 theoretical	 conditions,	 by	 integrating	 the	differential	equations	above.		Later,	we	describe	the	use	of	this	approach	to	analyse	 and	 optimise	 current	 protocols	 of	 preparation	 of	 oocytes	 for	vitrification.						
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3.	Aims	and	goals	of	the	thesis	Our	 main	 goal,	 during	 the	 four	 years	 of	 research	 involved	 in	 the	preparation	of	this	thesis,	has	been	to	take	a	step	back,	analyse	the	state	of	the	art	of	ultrafast	vitrification	as	applied	in	the	AHR	field,	and	develop	and	test	ways	of	 improving	 the	procedure.	Considering	 that	cryopreservation	of	 human	 oocytes	 and	 embryos	 is	 a	well-established	 technique,	 that	 has	been	the	object	of	ever	increasing	scientific	attention	since	its	inception,	it	has	posed	a	challenge	to	find	ways	to	improve	current	protocols	and	defy	the	 statu	 quo	 of	 vitrification;	 many	 would	 consider	 that	 progress	 had	already	peaked	and	that	the	technique	had	reached	its	efficiency	limits.	As	our	 group	 and	 others	 have	 been	 proving,	 the	 safety,	 duration	 and	repeatability	of	vitrification	procedures	may	still	be	optimised.	The	work	 in	 this	 thesis	was	 developed	 as	 a	member	 of	 the	 CryoBioTech	research	 group,	 in	 the	 Advanced	 School	 of	 Engineering	 of	 Seville	(University	of	Seville,	Spain),	founded	back	in	2004	by	Prof	Ramón	Risco,	with	 the	 goal	 of	 achieving	 a	 better	 understanding	 of	 the	 physical	 laws	behind	 the	 cryobiology	 field	 and	 applying	 them	 to	 improve	 the	 different	strategies	 of	 achieving	 the	 long-term	 cryostorage	 of	 biological	 material.	This	 research	 group	 led	 by	 Prof.	 Risco	 had	 already	 explored,	 in	collaboration	 with	 a	 team	 at	 The	 Centre	 for	 Engineering	 in	 Medicine	(Harvard	 Medical	 School,	 Massachusetts,	 USA),	 the	 enhancement	 of	thermal	rates	by	using	quartz	capillaries	as	vitrification	carriers	and	slush	nitrogen	as	a	cooling	agent	(Risco	et	al.,	2007).	At	 the	 time	 of	my	 inclusion	 in	 the	 research	 group,	 this	 line	 of	work	 had	already	 developed	 into	 a	 project	 that	 sought	 to	 bring	 these	 ideas	 into	 a	versatile,	 economically	 feasible	 vitrification	 carrier,	 to	 be	 commercially	exploited	 by	 university	 spin-off	 company	 SafePreservation.	 The	 original	fragile	 and	 unpractical	 quartz	 carriers	 were	 substituted	 by	 a	 flexible	polycarbonate	 capillary,	 attached	 to	 a	 main	 straw	 for	 easy	 handling,	sacrificing	 as	 little	 thermal	 conductivity	 as	 possible	
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(PCT/ES2013/000228).	The	exact	 features	of	 this	 vitrification	 carrier,	 as	well	as	 those	of	a	set	of	solutions	to	prepare	and	recover	human	oocytes	and	embryos	from	the	vitrification	procedure	are	further	described	in	the	original	research	articles	that	constitute	this	thesis'	main	body	of	work.	As	this	vitrification	system	of	carrier	and	solutions,	commercially	labelled	SafeSpeed,	was	already	at	a	very	advanced	stage	of	development	and	had	already	cleared	the	pre-clinical	validation	phase,	I	should	not	be	attributed	any	 intellectual	merit	 on	 their	design.	 I	was,	 however,	 very	 interested	 in	adapting	 the	 initial	 working	 prototypes	 into	 something	 that	 the	 clinical	embryologist	not	only	could	use,	but	also	would	like	to	use.	That	goal	was	only	 partially	 achieved,	 as	 some	 of	 my	 feedback	 was	 not	 shared	 by	 the	intellectual	owners	of	 the	technology	or	was	not	 financially	 feasible	 for	a	start-up	project.	The	 initial	 research	 described	 in	 this	 thesis	 has	 consisted	 mainly	 on	designing	and	conducting	the	studies	to	test	how	this	vitrification	system,	with	the	 innovative	 features	 it	 included,	namely	a	 thermally	efficient	and	aseptic	 capillary-based	 carrier	 and	 a	 protein-free,	 fully	 synthetic	 set	 of	vitrification	 solutions,	 performed	 on	 the	 clinical	 stage	 in	 the	 context	 of	AHR.	Firstly,	the	two	original	research	articles	published	in	the	context	of	this	thesis	are	reproduced	and	their	scope	and	impact	discussed.	First,	the	SafeSpeed	solutions	are	used	to	vitrify	top	quality	donor	eggs	in	a	standard	vitrification	 carrier,	 and	 the	 outcomes	 are	 compared	 with	 fresh	 sibling	donor	oocytes.	Then,	the	same	controlled	experimental	setting	is	repeated,	now	 employing	 both	 SafeSpeed	 set	 of	 vitrification	 solutions	 and	 the	SafeSpeed	 carrier,	 as	 well	 as	 analysing	 the	 thermal	 performance	 of	 the	latter.	 Secondly,	 we	 explore	 further	 possibilities	 to	 optimise	 the	vitrification	procedure	with	this	vitrification	kit.	We	studied	in	silico	and	in	
vivo	 osmotic	 behaviour	 of	 human	 metaphase-II	 oocytes,	 and	 propose	 a	method	 to	 significantly	 reduce	 the	 time	 needed	 to	 prepare	 human	 M-II	oocytes	for	vitrification,	with	very	promising	results.	
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4.	Main	results	In	 this	 chapter,	 the	 reader	 can	 find	 a	 brief	 summary	 of	 two	 original	research	 articles	 published	 in	 peer	 review	 specialized	 journals.	 The	 full	papers	are	 included	at	the	end	of	 the	thesis	as	supplemental	material	 for	further	 details	 on	 methodology	 and	 results.	 The	 section	 also	 includes	ongoing	unpublished	research	in	the	section	4.2.	
4.1	Validation	of	SafeSpeed	carrier	and	solutions.	
4.1.1	Summary	of	original	research	article	1:	Hydroxypropyl	cellulose	
supplementation	 in	 vitrification	 solutions:	 a	 prospective	 study	with	
donor	oocytes.	
______________________________________________________________________________________	M.	Gallardo	 et	 al.	 /	 Journal	 of	 assisted	 reproduction	 and	 genetics,	 34(3),	417-422	Springer	Science+Business	Media.	New	York.	2016		J	Assist	Reprod	Genet		DOI	10.1007/s10815-016-0841-y		______________________________________________________________________________________	The	 solutions	 employed	 for	 CPA	 loading	 of	 human	 oocytes	 prior	 to	vitrification,	 and	dilution	after	warming,	 require	 in	 their	 formulation	 the	presence	 a	 surfactant	 agent	 to	 enable	 in	 vitro	manipulation	 and	prevent	sticking	of	the	cells	to	the	surface	of	dishes	and	pipettes.	Most	commonly,	human-derived	protein	supplementation	is	used	for	this	task,	for	example	a	 combination	 of	 albumin	 and	 globulins.	 However,	 as	 a	 human-source	material,	 it	 presents	 risks	 of	 contamination	 and	 production	 variability	associated	 with	 it	 (Shaw	 et	 al.,	 1997),	 so	 a	 replacement	 synthetic	component	has	been	sought.		
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The	 set	 of	 solutions	 for	 vitrification	 and	 warming	 developed	 by	 Prof.	Risco's	 in	 the	University	of	Seville	 (PCT/ES2013/000228)	are	 free	of	 these	human	or	animal	components,	as	encouraged	by	 international	regulatory	policies.	 These	 macromolecules	 are	 substituted	 by	 hydroxypropyl	cellulose	 (HPC),	 a	 variable	 length	 polysaccharide	 that	 is	 listed	 as	pharmacopeia	 and	 is	 a	 common	 food	 additive	 and	 drug	 excipient.	SafeSpeed	 (SafePreservation,	 Spain)	 vitrification	 solutions	 are	supplemented	 with	 a	 range	 of	 0.06–0.125	 mg/mL	 of	 hydroxypropyl	cellulose	(pharmaceutical	standard,	80,000	Da	average	molecular	weight,	Sigma	Aldrich).	In	 order	 to	 test	 the	 efficacy	 of	 these	 solutions	 in	 the	 clinical	 setting,	 we	designed	 a	 prospective	 study	 with	 donor	 oocytes	 in	 Clínicas	 Ginemed	Seville's	 IVF	 Unit.	We	 compared	 the	 outcomes	 of	 two	 groups	 of	 oocytes	from	the	same	donor;	in	the	control	group,	oocytes	were	not	subjected	to	vitrification,	 whereas	 in	 the	 experimental	 group,	 oocytes	 were	 vitrified	using	 HPC-supplemented	 solutions	 and	 a	 standard	 open	 carrier.		Vitrification	 of	 the	 experimental	 group	 oocytes	 was	 performed	 at	laboratory	 room	 temperature	 (RT).	 The	 vitrification	 kit	 consists	 of	 three	solutions:	washing	solution	(WS,	no	CPAs),	equilibration	solution	(ES	7.5%	ethylene	glycol	and	7.5%	dimethyl	sulfoxide)	and	vitrification	solution	(VS	15%	ethylene	glycol;	15%	dimethyl	sulfoxide;	0.5M	sucrose).	All	solutions	were	exposed	at	 least	 for	an	hour	to	 laboratory	RT.	Oocytes	were	gradually	exposed	to	the	cryoprotective	agents	by	placing	them	in	a	first	droplet	of	50	μl	of	WS,	which	was	joined	with	the	tip	of	the	pipette	to	another	droplet	of	50	μl	of	ES.	After	2	min,	both	droplets	were	joined	with	a	 third	ES	 drop	 and	 allowed	 an	 additional	 2	min	 of	 CPA	diffusion	 to	 the	primary	droplet	where	the	oocytes	were	located.	Afterwards,	oocytes	were	transferred	 to	100	μl	of	ES,	where	 they	remained	up	 to	10	min,	until	 the	oocytes	 appeared	 to	 be	 fully	 re-expanded.	 Once	 the	 equilibration	 was	
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complete,	oocytes	were	transferred	to	a	200-μl	droplet	of	VS	and	washed	at	 least	 three	 times	 to	 eliminate	 any	 leftover	 ES.	 Then	 the	 oocytes	were	placed	 on	 the	 thin	 plastic	 strip	 of	 a	 Cryotop	 cryodevice,	 as	 described	 by	Kuwayama	 et	 al.	 (2005),	 and	 plunged	 vertically	 in	 liquid	 nitrogen.	 The	amount	 of	 time	 the	 oocytes	 remained	 in	 VS	 for	 washing	 and	 loading	purposes	before	plunging	in	liquid	nitrogen	was	approximately	60	s.		SafeSpeed	 warming	 media	 consists	 in	 three	 solutions:	 thawing	 solution	(TS)	 (1	 M	 sucrose),	 dilution	 solution	 (DS)	 (0.5	 M	 sucrose),	 and	WS	 (no	CPAs)	 [30].	 For	 at	 least	 1	h.,	 closed	 vials	 of	DS	 and	WS	were	 exposed	 to	laboratory	 RT,	 and	 TS	 vial	 was	 placed	 in	 the	 incubator	 at	 37	 °C.	 The	vitrification	 straw	 containing	 the	 oocytes	 was	 transferred	 from	 a	styrofoam	 box	 with	 liquid	 nitrogen	 to	 a	 double-well	 dish	 (Becton-Dickinson,	60	×	15	mm	Falcon	Center-Well	Organ	Culture	Dish)	containing	1	ml	of	TS	at	37	°C.	The	liquid	nitrogen	container	and	the	double-well	dish	used	for	warming	were	placed	as	close	as	possible	(10–20	cm)	to	allow	for	a	fast	transfer	(less	than	a	second),	to	facilitate	a	high	warming	rate.	After	1	min,	oocytes	were	carefully	moved	to	a	200-μl	droplet	of	DS,	where	they	remained	 3	min.	 Two	washing	 steps	 of	 5	 and	 1	min.,	 respectively,	were	performed	in	200	μl	droplets	of	WS.	Warmed	oocytes	remained	in	culture	for	2	h	prior	to	intracytoplasmic	sperm	injection	(ICSI).		We	 observed	 benchmark	 survival	 rates	 of	 the	 oocytes	 to	 the	 procedure,	and	no	differences	in	between	groups	in	the	primary	outcome	of	the	study,	the	 rates	 of	 fertilization	 after	 ICSI.	 Additionally,	 the	 embryos	 originated	from	 both	 groups	 of	 oocytes	 developed	 with	 similar	 quality,	 and	 the	implantation	 and	 ongoing	 pregnancy	 outcomes	 were	 satisfactory	irrespectively	if	embryos	from	fresh	or	vitrified	oocytes	were	transferred.	This	 design	 allowed	 us	 to	 evaluate	 the	 impact	 of	 vitrification	 on	 the	developmental	abilities	of	donor	oocytes	and	assess	the	performance	of	an	HPC-based	vitrification	formulation	for	its	use	in	daily	laboratory	practice.	
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The	 advantages	 that	 HPC-supplemented,	 protein-free	 solutions	 provide	are	 a	 reduced	 production	 cost	 and	 lot-to-lot	 variability,	 and	 the	elimination	of	the	hypothetical	risk	of	viral	contamination	associated	with	protein	 purified	 from	 blood	 (Shaw	 et	 al,.	 1997).	 The	 addition	 of	hydroxypropyl	 cellulose	 instead	 of	 serum	 to	 vitrification	 solutions	 can	provide	 the	 same	 viscosity	 that	 enables	 in	 vitro	 manipulation	 and	enhances	 the	 glass-forming	 tendency	 of	 the	 solution,	 without	 the	aforementioned	drawbacks	(Coello	et	al.,	2016).	The	prolonged	use	of	HPC	supplementation	of	 vitrification	 solutions	 in	a	controlled	 setting	 is	 necessary	 to	 further	 guarantee	 the	 effectiveness	 of	this	approach,	yet	the	results	reported	in	our	work	provide	initial	evidence	documenting	 the	 efficacy	 of	 the	 use	 of	 fully	 synthetic,	 protein-free	vitrification	solutions.												
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4.1.2.	 Summary	 of	 original	 research	 article	 2:	 Thermal	 and	 clinical	
performance	 of	 a	 closed	 device	 designed	 for	 human	 oocyte	
vitrification	based	on	the	optimization	of	the	warming	rate.		
______________________________________________________________________________________	M.	Gallardo	et	al.	/	Cryobiology	73	(2016)	40e46.	http://dx.doi.org/10.1016/j.cryobiol.2016.06.001	Published	by	Elsevier	Inc.		______________________________________________________________________________________	Although	it	was	qualitatively	pointed	out	by	Fahy	et	al.	(1984),	the	key	role	of	 the	 warming	 rates	 in	 non-equillibrium	 vitrification	 has	 only	 recently	been	 quantitatively	 established	 for	 murine	 oocytes	 by	 Mazur	 and	 Seki	(2011).	 The	 SafeSpeed	 vitrification	 carrier,	 composed	 of	 a	 thin	polycarbonate	capillary	attached	to	a	main	straw	was	developed	with	the	goal	 of	 maximizing	 thermal	 efficiency,	 specially	 towards	 optimizing	 the	warming	 rate	 (PCT/ES2013/000228).	 The	 capillary	 and	 rear-end	 of	 the	straw	are	hermetically	 sealed,	 completely	 isolating	 samples	 from	contact	with	liquid	nitrogen	and	any	pathogens	that	may	be	present	in	it.		The	geometry	of	the	capillary	and	the	thermal	conductivity	of	its	material	enables	very	 fast	 cooling	upon	quenching	 in	 liquid	nitrogen	 (Risco	et	 al.,	2007).	Additionally,	the	closed	capillary	allows	carrying	the	warming	in	a	large	 volume	 of	 water	 at	 37	 ºC,	 maximizing	 warming	 rates.	 Once	 the	sample	 has	 warmed,	 the	 capillary	 is	 cut	 and	 the	 samples	 expelled	 in	solutions	for	CPA	dilution.		We	measured	 the	warming	 rate	 using	 an	 ultra-thin	 thermocouple	 probe	(COCO-001;	 OMEGA	 Engineering	 Inc.,	 USA).	 Its	 signal	was	 amplified	 and	introduced	 in	 a	 DAC	 converter	 (USB.1208LS;	 Measurement	 Computing	
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Inc.,	USA).	Then,	a	program	written	in	Labview	6.0	(reading	rate	600	Hz)	gives	 us	 the	 whole	 thermal	 history	 of	 the	 thermocouple	 junction.	 The	process	 was	 recorded	 to	 determine	 with	 a	 temporal	 resolutions	 of	milliseconds	 the	duration	of	 the	 time	of	 flight:	 from	the	exit	of	 the	 liquid	nitrogen	to	the	entrance	in	the	warming	water	bath.	Interestingly,	there	is	an	 exponential	 increase	 in	 the	 warming	 rate	 as	 the	 time	 of	 flight	 is	reduced,	 with	 a	 critical	 point	 around	 300	 ms	 (Figure	 X,	 Gallardo	 et	 al.,	2017).	The	correlation	between	warming	rates	and	time	of	flight	between	the	 liquid	nitrogen	and	the	warm	water	bath	fits	 in	our	experiments	to	a	potential	curve	of	the	form:	𝐵(º𝐶/𝑚𝑖𝑛) ≈ 10!𝑡!! ,	where	B	is	the	warming	rate	 in	 (ºC/min)	 and	 t	 is	 the	 time	 of	 flight,	 in	 milliseconds	 (ms).	 The	exponential	 increase	 of	 the	 warming	 rate	 (B)	 with	 the	 reduction	 of	 the	duration	of	the	warming	motion	(t),	shows	the	relevancy	of	performing	a	fast	 rewarming	 of	 the	 vitrification	 carrier,	 as	 described	 in	 the	 section	warming	of	this	work.		We	 found	 that	 the	 warming	 motion	 must	 be	 completed	 very	 fast	 to	maximize	 warming	 rates	 (A.	 S.	 I.	 R.	 Medicine,	 2012).	 The	 carrier,	 when	loaded	with	vitrification	solution,	obtained	an	average	rate	of	warming	of	200.000	 ºC/min,	 very	 superior	 rates	 to	 other	 commercially	 available	vitrification	carriers.		The	performance	of	this	vitrification	carrier,	was	assessed	in	a	prospective	study	 with	 a	 similar	 setting	 as	 the	 one	 used	 for	 the	 HPC	 solutions:	 a	matched	 pair	 analysis	 with	 donor	 oocytes.	 In	 this	 case,	 a	 cohort	 of	 143	donor	MII	sibling	human	oocytes	was	split	into	two	groups:	control	(fresh)	and	vitrified	with	SafeSpeed	device.	The	survival	rate	obtained	was	in	the	excellent	 range:	 	 97.1	 %	 of	 the	 oocytes	 survived	 vitrification.	 Similar	results	 were	 found	 in	 both	 groups	 in	 terms	 of	 fertilization	 after	 ICSI	(74.7%	in	control	vs.	77.3%	in	vitrified)	and	good	quality	embryos	at	day	three	 of	 development	 (54.3%	 in	 control	 vs.	 58.1%	 in	 vitrified).	 The	
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pregnancy	 outcomes	 of	 embryos	 originated	 from	 vitrified	 oocytes	 were	also	satisfactory	(ESHRE,	2017).		
		Figure	13.	Relevance	of	the	re-warming	step.	The	graph	shows	the	typical	behavior	of	the	warming	rate	(ºC/min)	vs.	the	time	of	flight	(the	time	to	complete	 the	 warming	 motion	 from	 liquid	 nitrogen	 to	 the	 37	 C	 water	bath)	for	VS	vitrification	solution.	There	is	an	exponential	increase	of	the	warming	 rate	 as	 the	 time	 of	 flight	 is	 reduced.	 A	 plateau	 seems	 to	 be	reached	 for	 time	 of	 flights	 below	 300	 ms;	 in	 this	 area,	 the	 average	warming	rate	for	VS	vitrification	solution	is	200.000	ºC/min.	Figure	from	Gallardo	et	al.,	2017.		In	conclusion,		in	the	SafeSpeed	carrier	the	warming	rate	is	maximized	by	the	following	factors:	the	warming	is	performed	in	a	significant	volume	of	warm	 water,	 in	 a	 very	 fast	 motion,	 and	 the	 capillary	 yields	 excellent	thermal	 performance	 (Risco	 et	 al.,	 2007).	 The	 fact	 that	 the	 oocytes	 are	encapsulated	 inside	a	 capillary	 is	not	a	drawback,	but	on	 the	contrary,	 it	enables	this	improvement	in	the	warming	rate	by	allowing	the	possibility	of	warming	 in	 bigger	 volumes	 of	warm	media/water	without	 the	 risk	 of	
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losing	 the	 oocytes/embryos.	 It	 also	minimizes	 the	 risk	 of	 contamination	associated	with	direct	contact	with	liquid	nitrogen.	
4.1.3	Summary	of	results	
In	 the	 two	original	 articles	 that	 comprise	 the	 first	 part	 of	 this	 thesis,	we	report	on	the	outcomes	of	the	SafeSpeed	vitrification	carrier	—and	a	set	of	vitrification	solutions	developed	in	parallel—	that	was	designed	to	achieve	rates	of	cooling	and	warming	far	superior	to	those	of	other	commercially	available	carriers.	 It	proved	to	be	an	efficient	design,	yielding	benchmark	results	 for	 oocyte	 cryopreservation	 in	 the	 clinical	 context.	 However,	 the	procedure	 per	 se	 was	 not	 improved:	 the	 SafeSpeed	 technique	 described	has	a	similar	duration,	safety	and	efficiency	to	other	available	vitrification	protocols.	However,	with	this	optimized	tool	at	hand	we	could	now	study	introducing	advantageous	protocol	modifications	that	would	provide	practical	benefits	in	 the	 bench.	 With	 SafeSpeed's	 high	 cooling	 and	 warming	 rates,	 ice	formation	 could	 be	 theoretically	 avoided	 with	 lower	 intracellular	 solute	concentrations,	 just	 as	 Jin	&	Mazur	proved	 in	 2014	with	 a	 laser-assisted	warming	procedure,	 but	 in	 a	 lower	 scale.	With	 this	 is	mind	we	 analyzed	one	 of	 the	 most	 time-consuming	 parts	 of	 the	 vitrification	 protocol:	 the	preparation	 of	 the	 cells	 for	 vitrification	 by	 exposure	 to	 hypertonic	solutions.	 Oocytes	 are	 dehydrated	 and	 permeated	 by	 cryoprotectant	agents	 to	 reach	 the	 necessary	 intracellular	 solute	 concentration	 for	vitrification.	 However	 current	 protocols	 feature	 long	 exposure	 to	 these	hypertonic	 mediums,	 which	 may	 be	 inefficient,	 as	 developed	 in	 the	following	chapter.		
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4.2	 A	 two	minute	 protocol	 to	 prepare	 human	 oocytes	 and	 embryos	
for	ultrafast	vitrification	
4.2.1	Introduction	
The	vitrification	procedure	 is	a	key	element	of	 in	vitro	 fertilisation	units'	daily	 clinical	 practice:	 over	 one	 hundred	 thousand	 embryos	 and	 thirty	thousand	 oocytes	 originated	 in	 AHR	 treatments	 were	 cryopreserved	 in	Spain	 in	 2015	 (CNRHA,	 2015;	 (Rienzi	 et	 al.,	 2017).	 	 These	 cells	 are	cryopreserved	in	vitrification	carriers	that,	according	to	their	design,	will	have	variable	thermal	exchange	rates	(Vajta	et	al.,	2015).		The	cytosol	of	oocytes	and	embryos'	blastomers,	due	to	their	large	size	and	water	 content,	 does	 not	 vitrify	 at	 the	 rates	 currently	 attainable	 by	 those	vitrification	carriers,	unlike	spermatozoa	(Isachenko	et	al.,	2005).	For	that	reason,	the	cells	are	subjected	to	a	preparation	protocol	prior	to	cooling	in	which	 they	 lose	 water	 and	 are	 permeated	 by	 low	 molecular	 weight	cryoprotectants,	thereby	increasing	the	cytosol's	solute	concentration,	and	hence,	 its	 glass-forming	 tendency.	 As	 a	 result,	 the	 cooling	 and	 warming	rates	necessary	to	avoid	deleterious	ice	formation	are	lower.	Regardless	of	the	 chosen	 vitrification	 carrier,	 most	 preparation	 protocols	 to	 ready	oocytes	and	embryos	for	vitrification	are	very	similar.	They	usually	feature	two	 or	 more	 exposure	 phases	 —to	 decrease	 the	 osmotic	 shock—	 to	increasingly	 hypertonic	 solutions	 composed	 of	 permeating	 and	 non-permeating	 cryoprotectants.	 The	 composition	 of	 these	 solutions	 and	 the	duration	of	the	oocyte's	exposure	to	them	are	critical,	as	they	can	result	in	osmotic	 injury	 by	 excessive	 shrinking	 and	 swelling	 and	 cryoprotectant	toxicity	(A.	S.	I.	R.	Medicine,	2012).	Even	though	shorter	protocols	have	already	been	proposed	(Jin	&	Mazur,	2015;	 Karlsson	 et	 al.,	 2014;	 Vanderzwalmen	 et	 al.,	 2009),	 most	 of	 them	feature	an	initial,	 long	exposure	phase	lasting	from	10	to	15	minutes	to	a	non-vitrifying	 solution	 (with	 a	 concentration	 of	 solutes	 that	 would	 not	
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vitrify	 if	 cooled	with	 the	 intended	 carrier).	 Cells	 initially	 lose	water	 and	shrink	 to	 a	minimum	 volume	 very	 rapidly.	 After	 that	 point,	 they	 slowly	swell	 back	 towards	 their	 isotonic	 volume,	 as	 concentrations	 inside	 and	outside	 the	 cells	 tend	 to	 osmotic	 equilibrium	 (Kleinhans,	 1998).	 For	 this	reason,	this	phase	is	usually	termed	equilibration	or	partial	equilibration.	This	is	followed	by	a	short	exposure	to	a	more	concentrated	solution,	that	vitrifies	upon	cooling	(vitrification	solution)	(Fahy,	Levy,	&	Ali,	1987).	It	is	in	this	solution	that	 the	cells	are	suspended,	 loaded	 in	the	carrier	device,	and	 cooled.	 This	 second	 exposure	 is	 short,	 and	 cells	 are	 not	 allowed	 to	equilibrate;	they	shrink,	becoming	even	more	dehydrated	and	permeated	by	 cryoprotectants.	 The	 duration	 of	 the	 exposure	 has	 to	 be	 carefully	controlled	and	limited	to	60	seconds	to	avoid	an	excessive	osmotic	effect	(Fahy	et	al.,	1984;	Rall,	1987).	The	 equilibration,	 complete	 or	 partial,	 of	 the	 cells	 with	 non-vitrifying	solutions	 during	 their	 preparation	 for	 vitrification	 is	 what	 accounts	 for	most	 of	 the	 procedure's	 duration	 and	makes	 current	 protocols	 so	 time-consuming.	 However,	 shorter	 protocols	 of	 preparation	 of	 embryos	 and	oocytes	 for	 vitrification	 are	 feasible:	 the	 critical	 cytosolic	 solute	 content	necessary	 for	 successful	 vitrification	 at	 currently	 attainable	 cooling	 and	warming	 rates	 can	 be	 achieved	 faster.	 In	 this	 work,	 using	 in	 silico	 data	from	 a	 biophysical	 permeability	 model	 of	 human	 oocytes	 and	 in	 vivo	osmotic	 observations,	 we	 propose	 a	 short,	 dehydration-based	 protocol.	Using	a	standard	set	of	vitrification	solutions,	we	limit	the	duration	of	the	exposure	 to	 one	 minute,	 when	 cells	 are	 close	 to	 the	 minimum	 volume	point	of	their	shrink-swell	curve.	We	analyse	their	molarity	compared	to	a	standard	protocol,	 and	 test	 the	viability	of	discarded	human	oocytes	and	abnormally	fertilized	zygotes	subjected	to	it.			
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4.2.2	Materials	and	Methods	
4.2.2.1	Two-parameter	transport	formalism	model	The	two-parameter	transport	formalism	(2P)	model	has	been	used	in	this	work	 to	 perform	 the	 necessary	 simulations	 to	 analyse	 the	 oocyte	 mass	transfer	 dynamics	 in	 the	 presence	 of	 permeable	 and	 non-permeable	solutes	 (Kleinhans,	 1998).	 This	 model	 evaluates	 the	 flow	 of	 water	 and	solutes	through	the	cell	membrane	with	a	pair	of	coupled	linear	ordinary	differential	 equations,	 assuming	 that	 there	 is	 no	 intermembrane	interaction	between	water	and	the	permeable	solutes.		Nevertheless,	there	are	 publications	 (Paynter	 1999,	 Agca	 1999)	 that	 have	 shown	 that	 the	interaction	 factor	or	reflection	coefficient	 (σ)	of	 the	3-parameter	Kedem-Katchalsky	 formalism	 is	 insignificant	 in	 many	 membranes,	 oocytes	included.		The	2-P	model	 characterises	 the	permeability	of	 the	membrane	 to	water	with	 the	 parameter	 Lp	 (hydraulic	 conductivity),	 and	 the	 permeability	 of	the	membrane	to	permeant	solutes	with	the	parameter	Ps,	namely	solute	permeability.	It	is	well	known	that	permeability	depends	on	temperature,	and	 it	 is	 very	 common	 to	 define	 this	 relationship	 through	 an	 Arrhenius	equation:		 Eq. 1: 𝐿 = 𝐿! 𝑒!!"! !!"#$!!! 		The	water	transfer	dynamics	is	defined	by	the	equation		 Eq. 2: 𝑑𝑉𝑤𝑑𝑡 = −𝐿! • 𝐴 • 𝑅 • 𝑇 • 𝑀! −𝑀! 		
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The	 permeable	 solute	 transfer	 dynamics	 is	 defined	 by	 the	 following	equation:		 Eq.	3:	!"#!" = 𝑃𝑠 • 𝐴 • 𝑀!! −𝑀!! 		In	our	particular	case,	we	will	need	to	define	two	solute	equations,	one	for	Me2SO	and	another	for	EG.	This	means	that	we	will	have	to	solve	a	system	of	three	linear	ordinary	differential	equations,	with	three	parameters,	Vw	osmotically	intracellular	water,	NDMSO	intracellular	osmol	of	DMSO,	and	NEG	intracellular	 osmol	 of	 EG.	 In	 order	 to	 solve	 the	 system	 of	 differential	equations	we	developed	specific	software	in	MATLAB	version	R2014A.	In	particular	 we	 employ	 the	 built-in	 function	 ODE45	 based	 on	 the	 Runge-Kutta	method.		The	oocyte	was	assumed	to	be	of	perfect	spherical	shape,	with	a	radius	of	63	µm,	and	the	osmotically	inactive	volume	of	the	oocyte	was	considered	to	 be	 19%	 of	 its	 initial	 volume	 (Newton	 et	 al;	 1999).	 Values	 for	 the	permeability	of	 the	cell	membrane	to	water	(hydraulic	permeability;	Lp),	and	 to	 permeating	 cryoprotectants	 Me2SO	 and	 EG,	 and	 their	 respective	activation	energy	(Ea),	were	used	as	estimated	by	Paynter	et	al.	(1998a,b)	(Supplementary	Table	1).		As	in	previous	cell	dynamic	modelling	studies	(Mullen	et	al.,	2008;	Newton	et	 al.,	 1999;	 Saenz,	Toner,	&	Risco,	 2009),	 some	 simplifying	 assumptions	were	 made:	 i)	 the	 oocyte	 remained	 in	 perfect	 spherical	 shape	 during	shrinking	 and	 swelling,	 with	 an	 area	 determined	 by	 the	 cell	 radius	(𝐴 = 4 ∗ 𝜋 ∗ 𝑟!);	ii)	the	solutions	are	ideal;	iii)	hydrostatic	pressure	is	zero;	iv)	 the	osmotic	 coefficient	 for	 solutes	 are	 equal	 to	1,	 except	 for	 common	salt	 (NaCl),	 with	 molalities	 and	 osmolalities	 equivalent	 and	 linear	
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additivity	 of	 solute's	 osmolalities.	 The	 cytosol	was	 considered	 to	 contain	only	water	and	common	salt	(NaCl).		
4.2.2.3	Permeability	Modeling	First,	 a	 simulation	 of	 a	 standard	 vitrification	 preparation	 protocol,	 in	which	 cell	 are	 left	 to	 equilibrate	 in	 the	 first	 solution	 (equilibration	protocol,	EP)	was	run.	In	this	simulation,	the	oocyte	is	directly	exposed	to	a	 7.5%	 v/v	 EG	 and	 7.5%	 v/v	 Me2SO	 phosphate	 buffered	 saline	 (PBS)	solution	(solution	1,	S1)	for	10	minutes.	Next,	it	was	directly	exposed	to	a	15%	v/v	EG,	15%	v/v	Me2SO	and	0.5M	sucrose	PBS	solution	(Solution	2,	S2)	 with	 a	 duration	 of	 1	 minute.	 A	 second	 simulation	 was	 run	 with	 a	shorter	preparation	protocol	(short	protocol,	SP),	 for	which	the	exposure	of	the	oocyte	to	both	solutions	S1	and	S2	is	limited	to	1	minute	each.	Key	parameters	 for	 oocyte	 survival	 to	 vitrification,	 such	 as	 the	 volumetric	excursion	 of	 the	 oocyte,	 intracellular	 active	 water	 content,	 and	 total	cytosolic	 solute	 concentration	 were	 determined	 and	 compared	 between	the	two	approaches.	
4.2.2.4	In	vivo	Oocyte	Osmotic	Behaviour	To	 establish	 whether	 the	 model	 predictions	 were	 accurate,	 the	 in	 silico	dehydration	 profiles	 obtained	 with	 the	 theoretical	 models	 were	reproduced	with	 in	vivo	observations	of	 the	osmotic	behaviour	of	human	oocytes	 exposed	 to	 the	 standard	 and	 short	 preparation	 protocols.	Metaphase-II	human	oocytes	retrieved	in	a	private	IVF	setting	by	ovarian	hyperstimulation,	discarded	for	clinical	practice	due	to	 failed	 fertilisation	by	ICSI	and	donated	for	research,	were	employed	for	the	experiment.				
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Table 2. Definition of symbols employed in equations 1-3. 	
Perfusion	with	CPA	solutions	 	Drops	of	2	µL	of	iso-osmotic	PBS,	200	µL	of	S1	and	2	mL	of	S2	were	placed	near-contact	in	a	60	mm	Petri	dish.	The	Petri	dish	was	placed	on	a	heated	stage	 at	 25	 °C	 (INUG2H-TIZSH,	 Tokai,	 Japan)	 on	 an	 inverted	microscope	(Ti-U,	 Nikon,	 Japan)	 with	 an	 assembled	 micromanipulator	 (Narishige,	Japan).		For	each	experiment,	an	oocyte	was	placed	in	the	PBS	drop	with	a	capillary,	and	secured	by	suction	of	the	zona	pellucida	by	a	holding	pipette	
Symbol Meaning 
w, s, sol, 
cpa 
Subscripts (w, water; s, solutes; sol, cellular solutes; cpa, 
permeating cryoprotectants) 
e, i, superscripts; extracellular, intracellular 
d derivative of the function 
V Volume 
A Cell area 
R Universal gas constant   
T Absolute temperature 
TREF Reference temperature 
t Time 
Lp Water permeability (hydraulic conductivity) 
LO Permeability at a reference temperature 
M Osmolality   
n Number of moles 𝑉 Partial molar volume 
N Osmoles of solute 
Ps Solute permeability 
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(MPH-MED-30,	 Origio,	 Denmark).	 To	 avoid	 dissecation,	 time	 between	oocyte	placement	and	perfusion	of	the	solutions	was	minimised.	The	PBS	drop	and	adjacent	DS1	drop	were	merged	with	the	tip	of	 the	capillary	 to	trigger	the	osmotic	process.	Once	the	exposure	time	to	DS1	was	complete,	the	 drop	was	merged	with	 the	 adjacent	 DS2	 drop.	 EP	 and	 DP	 protocols	were	 replicated	 until	we	 recorded	 five	 oocytes	 that	 retained	 a	 spherical	morphology	and	presented	fewer	folds	and	creases	during	shrinking.	Out	of	 a	 total	of	22	oocytes	 subjected	 to	 the	experiment,	5	 replicates	of	 each	protocol	were	selected	for	analysis	and	calculation	of	the	cytoplasmic	area.	
4.2.2.5	Image	acquisition	and	quantitative	analysis	of	dehydration	The	process	was	 recorded	on	a	PC	 (Software	X)	with	a	video	acquisition	system	 connected	 to	 the	 inverted	 microscope	 (Sony,	 Japan),	 with	 400X	magnification.	A	video	 frame	of	every	 ten	 seconds	 for	 the	 first	minute	of	exposure	on	DS1	and	DS2,	and	every	60	seconds	after	the	first	minute	for	the	10-minute	exposure	to	DS1	was	extracted	and	analysed	to	determine	the	 volumetric	 excursion	 of	 the	 oocyte	 relative	 to	 the	 initial	 isotonic	volume.	Still	images	of	the	oocytes	were	processed	to	determine	their	area	for	 volume	 calculation,	 as	 described	 by	Mullen	 et	 al.,	 (2008).	 To	 reduce	skewing	 by	 irregularities	 in	 the	 spherical	 shape	 of	 the	 oocyte	 during	shrinking,	the	radius	was	calculated	from	the	oocyte's	bidimensional	area,	and	then	used	to	determine	the	oocyte's	volume,	assuming	that	a	perfect	spherical	shape	is	maintained	throughout	the	process.								
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Parameter value; uds; 25 ºC; 1 atm Reference. 𝐿𝑝	 0,69 µm/min 
 (Hunter et al., 1992) 𝐸!!!!	 14,42 kcal/mol 𝑃!"!!"	 15 µm/min 
(Paynter, et al., 1999a) 𝐸!!"!!"	 23,52 kcal/mol 𝑃!"  9,16 µm/min 
(Mullen et al., 2008) 𝐸!!"  21,20 kcal/mol 𝑉!!" 18,61 cm3/mol (Markarian,	Asatryan,	&	Zatikyan,	2005).	 𝑉!"#$ 16,68 cm3/mol (Pitzer,	Peiper,	&	Busey,	1984).	 𝑉!"!!" 64,323 cm3/mol (Markarian,	Asatryan,	&	Zatikyan,	2005).	 𝑉!"  55,31 cm3/mol (Ambrosone	et	al.,	1996).	 	
Table 3. Relevant parameters for permeability modeling of human Metaphase-
II oocytes 
 
4.2.2.6	Survival	and	competence	of	human	zygotes	after	dehydration-
based	protocol.	The	 dehydration	 protocol	 was	 tested	 on	 discarded	 unfertilized	 human	oocytes,	and	abnormally	fertilised	human	zygotes,	showing	≥2	pronuclei	at	the	fertilisation	check	17±2	hours	after	in	vitro	fertilisation.	These	oocytes	and	 zygotes	 were	 discarded	 from	 clinical	 practice	 and	 donated	 for	
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research.	In	order	to	detect,	with	80%	power	and	an	alpha	level	of	0.05,	a	15%	one-sided	difference	 from	a	benchmark	survival	rate	 to	vitrification	of	 95%	 (A.	 S.	 I.	 R.	 Medicine,	 2012),	 30	 oocytes	 and	 27	 zygotes	 were	included	in	the	study.	Oocytes	 and	 zygotes	 were	 prepared	 for	 vitrification	 following	 the	 short	protocol	(SP)	and	loaded	in	a	closed	vitrification	carrier	(Safepreservation,	Spain),	which	was	hermetically	sealed	at	both	ends	prior	to	a	fast	plunge	in	liquid	 nitrogen.	 Note	 that	 the	 loading,	 sealing	 and	 cooling	 of	 the	vitrification	device	were	performed	during	the	60	seconds	of	exposure	to	VS,	 and	not	afterwards.	The	process	of	 loading	 the	vitrification	carrier	 is	described	 thoroughly	 elsewhere	 (Gallardo	 et	 al.,	 2016).	 For	 re-warming,	the	 capillary	 was	 transferred	 to	 a	 37	 °C	 water	 bath,	 stirred	 for	 two	seconds,	 dried	 in	 sterile	 cloth	 and	 cut,	 releasing	 the	 oocytes	 in	 a	 1	 M	sucrose	 solution.	 After	 60	 seconds,	 oocytes	 were	 transferred	 to	 a	 0.5	M	sucrose	solution	for	three	minutes	and	eventually	placed	for	5	minutes	in	a	CPA-free	 solution.	 According	 to	 previous	 published	 measurements	employing	the	same	closed	vitrification	carrier,	the	zygotes	were	subjected	to	warming	rates	of	200,000	°C/min	(Gallardo	et	al.,	2016).	The	 survival	 of	 the	 oocytes	 and	 zygotes	was	 assessed	 immediately	 after	completing	 the	 warming	 and	 rehydration	 process:	 those	 whose	morphological	 appearance	 remained	 similar	 to	 fresh	 after	 vitrification	were	 considered	 positive	 for	 survival	 (A.	 S.	 I.	 R.	 Medicine,	 2012).	 As	 an	additional	 viability	 indicator,	 post-warming	 mitosis	 resumption	 and	cleavage	were	assessed	after	24	hours	of	culture.	Results	were	compared	with	a	control	group	of	27	abnormal	zygotes	not	subjected	to	vitrification.	Embryo	culture	was	carried	out	in	pre-equilibrated	embryo-tested	60	mm	Petri	 dishes,	 containing	 30	 µL	 drops	 of	 G1-Plus	 medium	 (Vitrolife,	Sweden)	with	a	mineral	oil	overlay	at	37	°C	and	6%	CO2.			
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4.2.3	Results	
4.2.3.1	Modeling	of	the	osmotic		behaviour	of	the	human	Metaphase-
II	oocyte		 	
The	predicted	relative	volume	and	total	intracellular	solute	concentration	of	 oocytes	 subjected	 to	 two	 preparation	 protocols,	 the	 standard	equilibration	 protocol	 (EP)	 and	 a	 short	 dehydration	 protocol	 (DP),	 as	 a	function	of	time	is	shown	in	Figure	1.	Both	protocols	feature	exposure	to	a	non-vitrifying	 solution	 (Sol1;	 7.5%	 v/v	 Me2SO	 and	 7.5%	 v/v	 EG)	 and	 a	vitrifying	solution	(Sol2;	15%	v/v	Me2SO,	15%	v/v	EG	and	0,5M	sucrose).	In	EP,	the	duration	of	exposure	to	Sol1	is	10	minutes,	and	the	duration	of	exposure	to	Sol2	is	1	minute.	 In	DP,	the	duration	of	the	exposure	to	both	Sol1	and	Sol2	is	1	minute	each.	In	 both	 protocols,	 model	 predictions	 show	 that	 after	 exposure	 to	 Sol1,	oocytes	experience	fast	dehydration,	shrinking	to	a	minimum	of	44.8%	of	their	 isotonic	 volume	 after	 29.4	 seconds	 of	 exposure.	 At	 the	 end	 of	 the	exposure	 to	 Sol1	 in	 DP,	 after	 1	minute,	 equilibration	 has	 barely	 started,	with	the	volume	increasing	to	48.6%.	In	the	EP,	exposure	is	prolonged	to	10	minutes	to	allow	for	equilibration,	and	the	oocyte	swells	further,	back	to	79.4%	of	its	isotonic	volume.	Intracellular	osmolarity,	however,	is	very	similar	after	either	1	or	10	minutes	of	exposure	to	Sol1	(Table	1	&	Figure	1).	Models	 show	 the	 oocyte	 subjected	 to	 the	 EP	 shrinking	 to	 49.9%	 of	 its	isotonic	volume	after	1	minute	of	 exposure	 to	 the	Sol2,	whereas	oocytes	subjected	to	DP,	with	a	previous	shorter	exposure	to	Sol1,	are	expected	to	shrink	to	39.2%.		A	similar	total	intracellular	molarity	is	reached	at	the	end	of	EP	and	DP,	with	5.40	and	5.37	mol/L,	respectively.	However,	in	the	EP,	Me2SO	and	EG	contribute	to	92.5%	of	the	intracellular	molarity,	vs.	88.5%	in	 the	 DP	 protocol.	 The	 normalised	water	 volume,	 on	 the	 other	 hand,	 is	lower	after	DP	compared	to	EP	(17.7	vs.	26.6,	respectively)	(Table	1).	
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4.2.3.2	In	Vivo	Oocyte	Osmotic	Behaviour	The	 in	 vivo	 recordings	 of	 human	 oocytes	 exposed	 to	 EP	 and	 DP	 show	 a	milder	 initial	 osmotic	 response	 of	 the	 oocytes	 to	 Sol1.	 The	 minimum	relative	volume	attained	was	of	~60%	 in	EP	and	DP,	 and	 it	 took	 slightly	longer	than	predicted	to	do	so	(~40	seconds	of	exposure	to	Sol1).	Oocytes	subjected	 to	EP	recovered	~80%	of	 their	 initial	 isotonic	volume	after	10	minutes	of	exposure	 to	Sol1,	and	then	shrank	to	~65%	after	1	minute	of	exposure	to	Sol2.	Oocytes	subjected	to	DP	shrank	to	~50%	after	1	minute	of	exposure	to	Sol2.		
	
a)	 b)	 c)	 d)	 e)	
Duration	of	exposure		
Intracellular	Molarity		
CPAs'	contribution	to	total	intracellular	molarity	
	Relative	Volume		
Normalized	water	volume		
	 (min)	 mol/L	 (%)	 (%)	 (%)	Equilibration	Protocol	 Sol1	 10	 2.61	 92.1	 79.4	 63.7	Sol2	 1	 5.40	 92.5	 49.9	 26.6	Dehydration	Protocol	 Sol1	 1	 2.56	 83.5	 48.6	 31.6	Sol2	 1	 5.37	 88.5	 39.2	 17.7		Table	 4.	 Comparison	 of	 the	 results	 of	 the	 2-P	 model	 for	 relevant	 osmotic	 parameters	between	 equilibration	 and	 dehydration	 protocols.	 a)	 Time	 elapsed	 since	 oocytes	 are	initially	exposed	to	each	solution;	b)	Intracellular	molarity	of	the	oocyte;	c)	Contribution	of	CPA	permeation	 to	 the	 total	 intracellular	molarity;	d)	Relative	volume	of	 the	oocyte	as	a	ratio	of	 the	 isotonic	 total	 cell	volume;	e)	Water	volume	 in	 the	oocyte	as	a	 fraction	of	 the	initial	 water	 volume	 of	 the	 oocyte.	 The	 molarity	 of	 Sol1	 and	 Sol2	 is	 2,4	 mol/L	 and	 5,3	mol/L,	respectively.	
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	Figure	 14:	 Simulation	 of	 the	 relative	 volume	 and	 intracellular	 solute	concentration	of	human	M-II	oocytes	with	EP	and	DP.	Relative	volume	as	solid	 line,	 intracellular	 solute	 concentration	 as	 dotted	 line.	 Exposure	 to	solution	1	(S1;	7.5%	v/v	Me2SO	and	7.5%	v/v	EG)	starts	at	t=0,	and	the	change	 to	 solution	 2	 (S2;	 15%	 v/v	 Me2SO,	 15%	 v/v	 EG	 and	 0,5M	sacarose)	is	demarcated	in	the	X	axis	by	a	vertical	striped	line.	
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4.2.3.3	 Survival	 and	 viability	 of	 human	 oocytes	 and	 zygotes	 to	
vitrification	 and	 warming	 with	 SafeSpeed	 carrier	 after	 the	 short	
preparation	protocol	As	shown	in	Table	2,	all	oocytes	and	zygotes	subjected	to	the	experimental	vitrification	 protocol	 DP	 were	 positive	 for	 survival	 (30/30	 and	 27/27,	respectively).	The	observed	 survival	of	 the	oocytes	was	 compared	 to	 the	expected	benchmark	outcome	of	95%	survival	 in	a	normal	population	of	oocytes,	 based	 on	 recent	 consensus	 (A.	 S.	 I.	 R.	 Medicine,	 2012).	 Of	 27	tripronuclear	 zygotes	 subjected	 to	 vitrification	 with	 DP,	 25	 resumed	development	and	had	cleaved	after	24	hours	of	culture,	compared	to	24	of	27	fresh	tripronuclear	zygotes	used	as	a	control	(p=1).		
4.2.4	Discussion:	
The	 survival	 and	 viability	 of	 unfertilised	 human	 oocytes	 prepared	 for	vitrification	with	 the	 dehydration	 protocol	 shows	 that	 their	 intracellular	solute	concentration	was	sufficiently	high	for	the	vitrification	procedure	to	be	successful	at	the	cooling	and	warming	rates	obtained.		Despite	 non-fertilized	 human	 oocytes,	 that	 have	 remained	 in	 in	 vitro	incubation	 for	 >24	 hours,	 are	 reported	 to	 be	 more	 resilient	 to	 a	vitrification	 procedure	 than	 their	 fresh	 counterparts	 (Vajta	 et	 al.,	 2009),	the	survival	and	mitosis	resumption	of	the	abnormally	fertilised	zygotes	is	reassuring	regarding	the	effectivity	of	 the	approach.	 	This	outcome	could	to	some	extent	be	expected,	as	according	to	the	2-P	model	used	to	predict	the	 osmotic	 behaviour	 of	 human	oocytes,	 the	 intracellular	molarity	 after	the	standard	EP,	with	11	minutes	of	duration,	and	the	DP,	with	a	duration	of	2	minutes,	was	similar.			
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	Figure	 15:	 In	 vivo	 recording	 of	 the	 volumetric	 excursion	 of	 human	M-II	oocytes	 subjected	 to:	 Dehydration	 protocol	 (DP);	 Equilibration	 Protocol	(EP)	 of	 preparation	 for	 vitrification.	 Exposure	 to	 S1	 starts	 at	 t=0,	 the	change	 to	 S2	 is	 demarcated	 at	 the	 X	 axis.	 An	 example	 of	 the	 oocyte's	morphology	at	relevant	timeframes	is	shown	below	each	graphic.	
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No.	of	oocytes	positive	for	survival	after	2	hours	/																																											No.	of	oocytes	subjected	to	vitrification	 30/30	(100)	No.	of	zygotes	positive	for	survival	after	2	hours	/																																		No.	tripronuclear	zygotes	subjected	to	vitrification	 27/27	(100)	No.	of	cleaved	embryos	after	24	hours	/																																		No.	tripronuclear	zygotes	subjected	to	vitrification	 24/27	(88,8)	No.	of	cleaved	embryos	after	24	hours	/																																		No.	of	fresh	tripronuclear	zygotes		 25/27	(92,6)		Table	 5.	 Survival	 and	 viability	 of	 human	 oocytes	 and	 zygotes	 after	preparation	for	vitrification	with	the	short	protocol	and	vitrification	with	the	SafeSpeed	carrier.		However,	 the	 exact	 composition	 of	 the	 cytosolic	 medium	 after	 each	preparation	 protocol	 may	 differ:	 in	 DP	 the	 contribution	 of	 permeating	cryoprotectants	Me2SO	and	EG	 to	 the	 final	 cytosolic	 solute	 concentration	was	slightly	lower	than	in	the	EP.	On	the	other	hand,	SP	resulted	in	lower	intracellular	active	water	content	in	the	oocyte	compared	to	EP.	Relevant	parameters	that	determine	the	glass-forming	tendency	of	the	cytosol,	such	as	 the	 viscosity	 and	 the	 degree	 of	 hydrogen	 bonding	 between	 present	water	 and	 intracellular	macromolecules,	 could	 for	 this	 reason	 also	differ	between	oocytes	prepared	to	vitrification	with	each	protocol	(Jin	&	Mazur,	2014;	Rall,	1987).	It	should	also	be	considered	that	we	employed	a	carrier	that	 is	 reported	 to	 produce	 higher	 rates	 of	 cooling	 and	 warming	 than	others	(Castelló	et	al.,	2018;	Gallardo	et	al.,	2016;	Kuwayama	et	al.,	2005;	Larman	 &	 Gardner,	 2011;	 Risco	 et	 al.,	 2007;	 Schiewe	 et	 al.,	 2015;	
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Vanderzwalmen	 et	 al.,	 2009),	 which	 may	 compensate	 a	 possible	 lower	intracellular	 glass	 forming	 tendency	 in	 the	 cells	 after	 DP	 (Yavin	 &	 Arav,	2007;	Jin	&	Mazur,	2015).	The	 osmotic	 pressure	 and	 ensuing	 volumetric	 excursions	 that	 cells	undergo	 during	 preparation	 for	 vitrification	might	 also	 be	 higher	 during	DP.	The	oocyte	is	not	given	time	to	equilibrate	and	regain	volume,	and	as	a	result	 the	 total	relative	volume	of	 the	oocyte	at	 the	moment	of	cooling	 is	10%	 lower,	 compared	 to	 a	 standard	 equilibration	 protocol.	 Even	 if	 cell	shrinkage	is	indeed	desirable	as	it	results	in	a	more	stable	cytoplasm	(Fahy	et	al.,	1984),	it	is	well	known	that	osmotic	stress	can	seriously	jeopardise	the	developmental	potential	of	oocytes,	causing	disruption	in	cytoskeleton	structures,	especially	depolimerisation	of	 the	meiotic	spindle	(Agca	et	al.,	2000;	Hotamisligil,	Toner,	&	Powers,	1996;	Mullen	et	al.,	2004;	Vincent	&	Johnson,	 1992).	However,	 the	 exact	 osmotic	 tolerance	 limit	 of	 oocytes	 is	unclear	 (McWilliams,	 Gibbons,	 &	 Leibo,	 1995)	 and	 it	 has	 been	conservatively	 estimated	 in	 previous	 attempts	 at	 optimisation	 of	preparation	 protocols	 (Karlsson	 et	 al.,	 2014;	 Mullen	 et	 al.,	 2004;	Vanderzwalmen	et	al.,	2013).	On	the	other	hand,	 the	reduced	duration	of	the	exposure	to	cryoprotectants	in	DP	reduces	the	risks	of	CPA's	chemical	toxicity	(Fahy	et	al.,	1987;	Fahy	et	al.,	1984).	Ultimately,	the	developmental	ability	of	oocytes	and	embryos	is	the	indicator	of	the	safety	and	efficiency	of	 a	 vitrification	 procedure	 (Agca	 et	 al.,	 2000;	 Castelló	 et	 al.,	 2018;	 De	Munck	 et	 al.,	 2015),	 and	 such	 tests	 would	 be	 necessary	 to	 confirm	 the	validity	 of	 the	 proposed	 protocol	 for	 human	 oocyte	 and	 embryo	cryopreservation.		When	the	relative	volume	of	an	oocyte	is	calculated	from	a	bidimensional	framegrab	 of	 the	 shrinking-swelling	 process,	 several	 assumptions	 are	made,	 so	 the	 permeability	 parameters	 inferred	 from	 these	 observations	might	 not	 be	 completely	 accurate	 (Mullen	 et	 al.,	 2008;	 Paynter,	 et	 al;	1999a,b).	Also,	the	biophysical	parameters	of	oocytes	seem	to	present	high	
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intervariability,	 potentially	 associated	 with	 many	 factors	 (Paynter	 et	 al.,	2005;	Hunter	et	al.,	1992).	For	 these	reasons,	permeability	models	might	not	 reflect	 in	 an	 entirely	 accurate	 fashion	 the	 biological	 reality	 of	 the	process.	 In	 spite	 of	 that,	 we	 found	 a	 satisfactory	 agreement	 from	 our	 in	
silico	 and	 in	vitro	 results,	 revealing	 that	 the	point	of	minimum	volume	of	the	 shrink-swell	 curve	 is	 attained	within	 one	minute	 of	 exposure	 to	 the	hypertonic	solutions	employed	(Gallardo	et	al.,	2017).	Interestingly,	at	this	point,	 the	 osmotic	 effect	 of	 water	 loss	 and	 CPA	 intake	 was	 close	 to	completion.	Hence,	 limiting	the	exposure	of	the	cells	to	the	non-vitrifying	and	vitrifying	hypertonic	solutions	to	this	point	of	minimum	volume	could	be	a	more	efficient	approach	to	prepare	them	for	vitrification,	compared	to	a	prolonged	exposure	to	allow	for	partial	osmotic	equilibration.	Under	this	premise,	 we	 were	 able	 to	 successfully	 reduce	 the	 necessary	 time	 to	prepare	 human	 oocytes	 and	 zygotes	 for	 vitrification	 to	 a	 mere	 two	minutes.	 	 Similar	 time-efficient	 dehydration-based	 protocols	 comprising	short	 sequential	 exposures	 to	 increasingly	 hypertonic	 solutions	 could	be	fine-tuned	for	its	application	to	other	mammalian	gametes	and	embryos	as	well	as	more	complex	models.									
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5.	Main	findings	of	this	thesis	Over	the	last	ten	years,	the	late	Peter	Mazur's	group	developed	a	research	line	 that	 progressively	 established	 the	 relevance	 and	 dominance	 of	 the	warming	rate	as	the	most	critical	variable	determining	survival	of	cells	to	vitrification	 (Mazur	 &	 Paredes,	 2016;	 Seki,	 Jin,	 &	 Mazur,	 2014;	 Seki	 &	Mazur,	 2009,	 2012).	 Their	 research	 gradually	 shifted	 the	 attention	 of	cryobiologists	in	the	context	of	AHR	away	from	the	cooling	rate.	It	would	not	be	fair	to	say,	though,	that	cryobiologists	working	in	AHR	neglected	the	importance	 of	 warming	 rates;	 Rall	 and	 Fahy	 (Rall,	 1987;	 Rall	 &	 Fahy,	1985)	suggested	their	importance	right	from	the	technique's	inception.	In	spite	 of	 that,	 this	 was	 barely	 acknowledged	 in	 subsequent	 manuscripts	describing	vitrification	procedures,	whereas	the	cooling	rate	was	carefully	examined.	However,	 one	 could	 argue	 that	 the	 change	 of	 paradigm	 towards	 the	dominance	 of	 warming	 rates	 has	 limited	 to	 a	 theoretical	 shift.	 The	 way	vitrification	 is	 carried	 out	 —the	 protocols	 of	 preparation	 of	 cells,	 the	carriers—	have	 not	 experimented	much	 change,	 at	 least	 at	 the	 bench.	 If	anything,	 Seki	 and	 Mazur's	 research	 has	 provided	 a	 more	 thorough	explanation	as	to	why	some	already	existing	vitrification	carriers	work.	On	one	hand,	we	find	that	the	success	of	open	carriers	could	be	put	down	to	the	fact	that	they	were	already	more	efficient	 in	warming	than	in	cooling	(≈40,000	and	≈20,000	°C/min,	respectively).	On	the	other	hand,	the	use	of	carriers	 hermetically	 sealed	 into	 a	 container	 is	 plausible	 because	 their	warming	rates	compensate	for	the	impaired	cooling	(≈2,000	°C/min):	the	carrier	 is	 insulated	during	 cooling,	 but	 is	warmed	 in	 a	 similar	 fashion	 to	open	 systems,	 by	 direct	 transfer	 of	 the	 carrier	 to	 a	 volume	 (1-4	mL)	 of	"warming	solution"	(Vajta	et	al.,	2015).			
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Whether	 open	 and	 hermetically	 closed	 approaches,	 with	 their	 different	warming	 rates,	 provide	 equivalent	 clinical	 results	 is	 a	 matter	 of	controversy:	 a	 recent	 meta-analysis	 shows	 that	 despite	 similar	 survival,	the	ability	to	implant	and	develop	a	healthy	pregnancy	of	embryos	vitrified	with	systems	with	lower	cooling	rates	seems	to	be	impaired	(Youm	et	al.,	2017).	 This	 could	 be	 interpreted	 as	 the	 warming	 rates	 not	 being	 fast	enough	 to	 fully	 compensate	 for	 the	 impaired	 cooling.	 The	 resulting	damage,	 even	 if	 it	 is	 subtle	 enough	 not	 to	 reduce	 survival	 rates,	 may	undermine	the	embryo’s	developmental	potential	at	a	late	stage.	That	said,	the	safety	of	closed	vitrification	carriers	has	been	extensively	studied	(De	Munck,	 Belva,	 Van	 de	 Velde,	 Verheyen,	 &	 Stoop,	 2016;	 De	 Munck	 et	 al.,	2015;	 De	 Munck,	 Verheyen,	 Van	 Landuyt,	 Stoop,	 &	 Van	 de	 Velde,	 2013;	Panagiotidis	 et	 al.,	 2013;	 Papatheodorou	 et	 al.,	 2016;	 Stoop	 et	 al.,	 2012;	Vanderzwalmen,	et	al.,	2010a)	The	 capillary-based	 SafeSpeed	 is	 a	 vitrification	 carrier	 that	 not	 only	provides	higher	warming	rates	(200,000	°C/min),	but	also	higher	cooling	rates	 (120,000	 °C/min)	 than	other	 carriers,	 including	previous	 capillary-based	carriers	(Kuwayama,	2007;	Kuwayama	et	al.,	2005).	It	could	thus	be	assumed	 that	 for	a	given	cytosolic	 solute	 concentration,	 the	SafeSpeed	 is	operating	more	 safely	 (no	pun	 intended)	 than	other	 carriers,	well	 above	the	 critical	 cooling	 and	warming	 threshold	 for	 lethal	 ice	 formation.	 It	 is	from	 this	 conceptual	point,	 and	motivated	by	 Jin	&	Mazur's	 success	with	laser-assisted	warming,	that	we	decided	to	explore	the	opportunities	that	these	optimised	rates	of	cooling	and	warming	provided.		Another	 finding	 of	 Mazur	 that	 has	 not	 been	 exploited	 for	 current	vitrification	protocols	was	the	role	of	free,	unbound,	water	content	inside	the	 cell.	 Jin	 &	 Mazur	 (2014)	 were	 able	 to	 attain	 a	 cytosolic	 solute	concentration	 in	 murine	 oocytes	 adequate	 for	 vitrification	 by	 using	 the	non-permeant	 osmotic	 agent	 sucrose	 to	 dehydrate	 the	 oocytes,	 proving	that	 	 survival	 to	vitrification	depended	more	on	 the	active	water	content	
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prior	 to	 cooling	 and	 warming	 than	 the	 type	 and	 concentration	 of	cryoprotectants	 in	 the	 cell	 interior.	 They,	 once	 again,	 shifted	 the	 focus	from	 permeating	 cryoprotectants	 to	 decreasing	 water	 content.	 Survival	rates	 to	vitrification	were	only	satisfactory,	however,	when	oocytes	were	subjected	 to	 a	 laser	 pulse	 that	 produced	 warming	 rates	 of	 107	 °C/min,	unattainable	with	 vitrification	 carriers	 appropriate	 for	 use	 in	 the	human	assisted	reproduction	context.	Other	authors	have	optimised	protocols	of	preparation	 of	 human	 oocytes	 and	 embryos	 for	 vitrification,	 yet	 focused	on	CPA	permeation	rather	than	dehydration,	trying	to	minimise	water	loss	and	 volumetric	 changes	 to	 avoid	 osmotic	 harm	 (Karlsson	 et	 al.,	 2014;	Mullen	et	al.,	2008;		Vanderzwalmen	et	al.,	2009)	As	a	clinical	embryologist,	I	knew	first	hand	that	a	desirable	improvement	of	 the	 vitrification	 protocols	 could	 be	 to	 reduce	 the	 total	 time	 the	procedure	 takes,	 from	 the	 moment	 the	 embryos	 are	 removed	 from	 the	culture	plate	to	the	time	the	carrier	is	stored.	The	number	of	embryos	and	oocytes	that	are	cryopreserved	rises	each	year,	and	the	duration	of	current	protocols	 limits	 the	 efficiency	 and	 scalability	 of	 the	 technique.	Furthermore,	the	preparation	of	the	cells	to	vitrification	by	exposure	to	the	hypertonic	vitrification	solutions	 is	very	 time	consuming	and	delicate,	 as	embryos	 are	 exposed	 to	 suboptimal	 temperatures	 (23	 -	 25	 °C)	 and	 a	potentially	 cytotoxic	 medium.	 After	 predicting	 the	 osmotic	 response	 of	human	Metaphase-II	 oocytes	 with	 a	 two	 parameter	 permeability	model,	and	 reproducing	 the	 in	 silico	 predictions	 by	 in	 vivo	 recording	 the	osmometric	behaviour	of	human	oocytes,	we	came	to	the	conclusion	that	long	 exposure	 times	 to	 hypertonic	 solutions	 may	 be	 unnecessary	 and	inefficient.		Most	 of	 the	 sought-after	 osmotic	 effect	 (dehydration,	 CPA	 permeation)	upon	 exposure	 of	 a	 cell	 to	 a	 hypertonic	 solution	 for	 its	 preparation	 for	vitrification	 happens	 during	 the	 first	 seconds	 of	 exposure,	 ending	 when	the	cell	reaches	the	minimum	volume	point	of	the	shrink-swell	curve.	We	
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propose	that	a	series	of	exposure	to	hypertonic	with	such	duration	would	be	the	most	time-efficient	way	to	prepare	a	cell	for	vitrification.	In	the	case	of	 human	oocytes,	we	 test	 a	 protocol	 based	 on	 this	 premise	with	 a	 total	duration	of	two	minutes:	a	>80%	reduction	from	the	average	12	minutes’	duration	 that	 it	 takes	 to	prepare	oocytes	 for	vitrification.	This	procedure	was	intellectually	protected,	and	may	be	successfully	exploited	in	diverse	areas.		In	the	foreseeable	future,	the	need	for	cryopreservation	of	human	oocytes	and	embryos	will	persist.	During	fertility	treatment,	a	woman	is	subjected	to	hormone	 stimulation	 in	order	 to	 induce	 superovulation	and	 recover	a	high	number	of	mature	oocytes.	This	high	number	of	oocytes	is	necessary	because	only	a	few	of	those	will	get	fertilised,	and	then	a	fraction	of	those	will	 develop	 into	 good	 quality	 embryos.	 Then	 again,	 from	 that	 cohort	 of	embryos,	ideally	only	one	is	transferred	into	the	uterus	to	avoid	the	risk	of	a	multiple	pregnancy.	The	other	embryos	of	the	cohort	must	be	preserved,	not	 only	 for	 ethical	 reasons	 but	 because	we	 are	 unable	 to	 predict	 if	 the	chosen	embryo	will	implant,	produce	a	pregnancy	and	develop	to	term.	As	long	 as	AHR	 remains	 burdened	with	 such	 inefficiencies,	 vitrification	will	remain	a	key	element	of	fertility	programmes,	and	for	that	reason	it	must	be	continually	critically	analysed	and	improved	to	guarantee	is	safety	and	effectiveness.								
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6.	Future	Perspectives	
6.1	Automatization	of	the	procedure	
The vitrification of human oocytes and embryos is a manual procedure, with 
several operator-dependent parameters that can hardly be standardised. The 
care in the pipetting of the cells in the solutions, the meticulousness with which 
they are rinsed from non-vitrifying solutions prior to loading in the vitrification 
carrier, the volume of solution in which embryos are suspended in the carrier, 
their disposition, and even the quenching motion and storage-related handling 
are all factors that may affect the outcome of a vitrification procedure. All 
these aspects require a steep learning curve, and even though learning 
resources are abundant these days, not all centres of assisted reproduction can 
rely on their vitrification programmes. Even for experienced embryologists, 
there might be inter-procedure variability. Considering the hundreds or 
thousands of times the procedure is carried out, absolute reproducibility of the 
protocol is not assured. 
Another factor that makes automated vitrification enticing is the time 
consuming nature of the process. As previously stated, it must be carried out in 
a controlled setting, and with batches of a limited number of samples, always 
by a single operator, to avoid putting the efficiency of the procedure at risk 
through manipulation mistakes and to guarantee traceability. As a result, for a 
vitrification machine to be a feasible and attractive alternative to the current 
state of the art, it must offer a high degree of automation, considerably 
reducing the manual intervention of the operator; improve the workflow in the 
IVF laboratory; increase the number of samples that can be cryopreserved 
within a certain workspace and time; and do so without impairing the 
outcomes.  
Currently, there are two efforts towards automation in an advanced state of 
development. The "Gavi" device (Genea Biomedics, Australia) employs 
microfluidics to automate the exposure of the samples to CPA solutions, yet the 
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operations of quenching and warming are still completely manual, so it can 
only be regarded as a semi-automation. The advantages it offers time-wise per 
cryopreservation batch are consequently limited, and the cassette-format 
vitrification carrier is incompatible with many conventional cryogenic storage 
setups. However, outcomes of blastocyst vitrification with this system seem to 
be comparable to currently employed open systems. Another approach that 
deserves attention is the "Sarah" device (FertileSafe, Israel), which employs 
specially adapted 0.25 mL cryostraws to expose embryos to different 
preparation solutions, quenching in liquid nitrogen and warming in a sucrose 
solution. However, details regarding the time to complete the procedure and the 
degree of automation of the process have not been publicly disseminated, even 
if it shows promising results with other mammalian embryos (Ledda et al., 
2018).  
  
 Figure	16.	Functional	3D	render	scheme	of	a	possible	automation	set-up	for	 the	 SafeSpeed	 straw.	 A	 rotating	 arm	 holds	 it	 vertically	 and	 can	transport	 the	device	to	and	from	different	wells.	The	straw	is	connected	to	 a	 microfluidic	 solenoid	 valve	 for	 media	 exchange.	 This	 image	 is	 a	simplification,	for	industrial	protection	reasons.	
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The SafeSpeed straw is a design that is susceptible of being adapted and 
incorporated in an automated vitrification device, a goal that is currently being 
pursued. The objective is to achieve a high degree of automation; the cells to be 
cryopreserved will be manually placed into a well from where they will be 
prepared for vitrification and loaded by controlled aspiration in a previously 
identified carrier, then sealed and safely quenched in liquid nitrogen for manual 
storage (Figure 16). The automation of the reverse process of automatic 
warming, recovery and CPA dilution of sealed carriers is also desirable. 
6.2	X-Ray	Computed	Tomography	
Current protocols to prepare oocytes and embryos for vitrification are based as 
much on rigorous theoretical formulations of the cells' osmotic behaviour as on 
empirical trial-and-error evidence accumulated over the years for the many 
factors that influence the vitrification outcome (Leibo et al., 2008). Considering 
that the degree of permeation of a certain CPA inside the cell over time will 
depend on temperature, time of exposure, presence of other solutes in the 
solution, etc., the variables soon grow exponentially. Mathematical tools for 
permeability modelling are alternatively a very useful approach to predict and 
optimize CPA exposure, yet they will only represent the biophysical reality to a 
certain extent, excluding operator-related variability and also are often misused 
(Katkov, 2011). The total intracellular concentration of solutes in an oocyte or 
embryo blastomer can also be indirectly deducted judging by their osmotic 
behaviour when exposed to a solution of known molarity (Vanderzwalmen et 
al., 2013). 
X-ray computed tomography can be used to measure the concentration of 
Me2SO inside solutions and tissues; the attenuation of the CT signal is 
proportional to the CPA concentration (Corral et al., 2015; ES2529265A1). 
With a spatial resolution of 50 µm, this technology could be used to assess the 
solute concentration within an oocyte at cryogenic temperatures and detect ice 
formation. Additionally, it could be used to determine the human Metaphase-II 
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oocyte's permeability parameters with greater accuracy. All this can lead to 
further improvements and optimisation in preparation protocols. 
6.3	Introducing	modifications	of	vitrification	protocols	in	the	clinical	
IVF	practice	Currently,	 developments	 of	 the	 techniques	 employed	 to	 vitrify	reproductive	 cells	 are	 governed	 by	 the	 premise	 that	 a	 compromise	between	safety	and	efficacy	shall	be	maintained	(De	Munck	&	Vajta,	2017).	The	technique	ought	to	be	as	aseptic	and	effective	as	possible.	One	could	argue	that	SafeSpeed,	as	a	closed	carrier,	meets	this	criterion	of	improving	efficiency	 —thermal	 efficiency,	 at	 least—	 without	 compromising	 safety,	and	as	 such	 could	be	 regarded	as	an	advancement	 in	 the	 right	direction.	The	use	of	the	synthetic	polymer	hydroxypropyl	cellulose	also	represents	a	safer	and	more	stable	alternative	to	human	or	animal	derived	proteins.	The	same	could	be	said	about	our	attempts	at	shortening	the	vitrification	protocol:	 if	 the	 oocytes	 and	 embryos	 prove	 to	 be	 equally	 competent	 as	with	 a	 longer	 protocol,	 reducing	 the	 duration	 of	 exposure	 to	 potentially	cytotoxic	cryoprotectants	and	suboptimal	temperatures	ought	to	be	safer.		Ultimately,	 for	 every	 relevant	 modification	 of	 the	 procedure,	 a	 well	designed	 validation	 route	 should	 be	 carried	 out	 before	 its	 use	 in	 the	clinical	context,	 from	the	preclinical	stage	in	mammal	models,	to	donated	human	 material,	 through	 to	 clinical	 controlled	 prospective	 studies	 with	follow-up	(Harper	et	al.,	2011).							
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Abstract  
Purpose Hydroxypropyl cellulose (HPC), a polysaccharide that forms a 
viscous gel under low temperatures, is a promising substitute of the blood-
derived macromolecules traditionally used in cryopreservation solutions. The 
performance of a protein-free, fully synthetic set of vitrification and warming 
solutions was assessed in a matched pair analysis with donor oocytes.  
Methods A prospective study including 219 donor MII oocytes was carried 
out, comparing the laboratory outcomes of oocytes vitrified with HPC-based 
solutions and their fresh counterparts. The primary performance endpoint was 
the fertilization rate. Secondary parameters assessed were embryo quality on 
days 2 and 3.  
Results 70/73 (95.9%) vitrified MII oocytes exhibited morphologic survival 2 
h post-warming, with 49 (70.0%) presented normal fertilization, compared to 
105 of 146 (71.9%) MII fresh oocytes. Similar embryo quality was observed in 
both groups. A total of 18 embryos implanted, out of 38 embryos transferred 
(47.3%), resulting in 13 newborns.  
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Introduction  
The ability to efficiently cryopreserve oocytes and embryos by vitrification [1] 
has become essential in the field of human assisted reproduction. There are two 
main factors which influence the efficacy of vitrification: (i) the 
cooling/warming rates (which are influenced by the type of vitrification device 
used) and (ii) the glass-forming tendency (which is determined by the 
composition of the solution) [2–8]. Of course, each of these two factors 
depends on multiple parameters [9, 10]. With current techniques, the rates of 
survival of embryos and oocytes to the vitrification process have reached very 
high levels [11–13].  
Human oocyte vitrification is a routine procedure today [14]. Historically, it 
has presented a greater challenge than embryo vitrification for many reasons. 
Oocytes’ low surface to volume ratio, and the low permeability coefficient of 
their plasma membrane, hinders the exchange between cryoprotectant agents 
(CPAs) and water [15, 16]. However, this issue has been overcome by the 
synergic combination of permeating CPAs, mainly ethylene glycol and 
dimethyl sulfoxide, and non-permeating CPAs, such as sucrose and trehalose, 
and adjusting the concentration and the exposure time to CPAs needed to 
achieve a successful vitrification with currently attainable cooling and warming 
rates [17–22].  
Another component of the solutions used for vitrification and warming is the 
macromolecular supplementation. It increases the viscosity of the solution to 
enhance the glass-forming tendency, enables the in vitro manipulation required 
for the vitrification procedure, and prevents the attachment of the gametes and 
embryos to the surfaces of pipettes, dishes, and devices used in the process 
[23]. Protein supplementation with human serum albumin has traditionally 
been employed for this task, alone or in the form of synthetic serum substitute 
(SSS), or dextran se- rum supplement (DSS), and it is still used in most 
commercial formulations. However, as a human-source material, it presents 
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risks of contamination and production variability associated with it [24], so a 
replacement synthetic component has been sought. The international regulatory 
policies are also encouraging the use of solutions free of human or animal 
components.  
The fully synthetic macromolecule hydroxypropyl cellulose (HPC) has been a 
successful candidate: it is a variable length polysaccharide that, with certain 
molecular weights, when added to a solution, can achieve very similar physical 
properties to the albumin-based formulations, forming a viscous gel under low 
temperatures. It is listed as pharmacopeia and is a common food additive and 
drug excipient [25]. Preliminary studies have shown promising results of HPC 
supplementation of vitrification solutions on murine oocytes and blastocysts in 
terms of survival and embryo development [26, 27]. Recently, direct 
comparative studies revealed the similarity of HPC and SSS-based 
formulations for human oocytes vitrification [25, 28].  
In the present study, we use a formulation of protein- free vitrification and 
warming solutions for the vitrification of oocytes from an egg donation 
program. Laboratory outcomes of vitrified-warmed oocytes are compared 
against fresh oocytes from the same donor from a different stimulation cycle. 
This design allows us to evaluate the impact of vitrification on the 
developmental abilities of donor oocytes and assess the performance of an 
HPC-based vitrification formulation for its use in daily laboratory practice.  
Materials and methods  
Study design and outcome measures  
A matched pair analysis within donor was performed, involving results from 
219 MII oocytes from 19 oocyte donors between June 2014 and January 2015. 
Each recipient was assigned with two cohorts of oocytes from the same donor; 
one composed by six to nine fresh oocytes from a synchronized donation cycle 
(control group), and the other cohort composed two to five oocytes were 
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vitrified/rewarmed oocytes from a previous cycle of the same donor 
(experimental group). Both groups of oocytes underwent ICSI in parallel. The 
primary end-point was the fertilization rate of fresh and vitrified oocytes, with 
secondary assessments of embryo quality performed on day 2 and day 3.  
Study population  
All donors included on the study complied with the regula- tions on ART 
donors, described elsewhere [29], and the following inclusion criteria: over 18 
and under 30 years old, good physical and psychological health, no personal 
nor familiar history for hereditary diseases, normal karyotype, negative tests 
for sexually transmitted diseases, and without any medical or gynecological 
disorders. Donors were subjected to a short agonist stimulation treatment and 
were excluded in case of a response to stimulation <12 oocytes. All recipients 
for the egg donation program were offered to participate in the study, until the 
quota was filled. Couples with a severe male factor surgically extracted 
spermatozoa and very severe oligoastenozoospermia (motile sperm count 
<500.000/ml after preparation) were not included.  
Ethical considerations  
All recipients were informed thoroughly about the protocol of the study and 
signed an informed consent form. The study was conducted as described in the 
protocol, which was developed in accordance to the principles of Helsinki and 
the national Policy of Good Clinical Practice (ISO 14155:2011), and was 
approved by the internal review board of the institutional research committee.  
Donor and recipient stimulation  
To synchronize the donation, donors took contraceptive pills during the 
previous month to the stimulation. Stimulation dose was decided according to 
donor’s BMI (150–200 daily IU of rFSH, alpha folitropin, Gonal-F, Merck). 
On day 5 of stimulation, analysis of the estradiol levels and ultrasound scans 
was performed for dose adjustment. When a follicle reached 14 mm, they 
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started GnRH antagonist treatment with 0.25 mg Cetrotide (Cetrorelix, Merck) 
until at least three follicles reached 20 mm, when ovulation was triggered with 
0.3 mg of triptoreline GnRH agonist (Decapeptyl; IpsenPharma).  
Recipients were kept on contraceptive pills for the synchronized donation. 
Once discontinued, after menstruation, they started endometrial substitutive 
treatment with 6 mg daily of estradiol hemihydrate (Estradot, Novartis, 
Switzerland). On the day of the donor’s ovarian puncture, they began taking 
progesterone vaginal or oral supplement, 600 mg daily (Utrogestan, Seid, 
Spain), continued until the results of the embryo transfer were known.  
Ovarian puncture  
A total of 19 oocyte donation cycles were included in the study. Oocyte 
recovery was performed by eco-guided ovarian puncture. An ultrasound 
transducer was placed into the vaginal fornix to visualize the ovary and 
follicles, and a single lumen ovum aspiration needle (Cook Medical) was 
inserted in the transducer and advanced into the ovarian follicles, where 
oocytes were recovered by aspiration with a syringe, until all the follicles had 
been punctured.  
Embryology procedures  
Two hours post-retrieval, the fresh control group of oocytes was denuded using 
hyaluronidase (HYASE-10X, Vitrolife), and the experimental group of oocytes 
was rewarmed as described below. Both control and experimental groups 
underwent ICSI simultaneously, 38–40 h post-hCG in the case of fresh oocytes 
and 2 h post-warming in the case of vitrified oocytes. Embryos were cultured 
on microdrops (G-IVF, G1Plus, G2Plus, Vitrolife) under mineral oil (tissue 
culture oil, Sage, CooperSurgical) until the third day of development, when 
they were either transferred, cryopreserved, or kept on culture up to day 6, 
according to their quality.  
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Vitrification protocol  
Vitrification solutions were supplemented with 0.06– 0.125 mg/ml of 
hydroxypropyl cellulose (pharmaceutical standard, 80,000 Da average 
molecular weight, Sigma Aldrich) and did not contain albumin or any other 
proteins. Vitrification of the experimental group oocytes was performed at 
laboratory room temperature (RT), in our case 23–26 ± 0.5 °C, with SafeSpeed 
vitrification media (SafePreservation). The vitrification kit consists of three 
solutions: washing solution (WS, no CPAs), equilibration solution (ES 7.5% 
ethylene glycol and 7.5% dimethyl sulfoxide) and vitrification solution (VS 
15% ethylene glycol and 15% dimethyl sulfoxide) [30].  
All solutions were exposed at least for an hour to laboratory RT. Oocytes were 
gradually exposed to the cryoprotective agents by placing them in a first 
droplet of 50 μl of WS, which was joined with the tip of the pipette to another 
droplet of 50 μl of ES. After 2 min, both droplets were joined with a third ES 
drop and allowed an additional 2 min of CPA diffusion to the primary droplet 
where the oocytes were located. Afterwards, oocytes were transferred to 100 μl 
of ES, where they remained up to 10 min, until the oocytes appeared to be fully 
re-expanded. Once the equilibration was complete, oocytes were transferred to 
a 200-μl droplet of VS and washed at least three times to eliminate any leftover 
ES. Then the oocytes were placed on the thin plastic strip of a Cryotop 
cryodevice, as described by Kuwayama et al. [31], and plunged vertically in 
liquid nitrogen. The amount of time the oocytes remained in VS for washing 
and loading purposes before plunging in liquid nitrogen was approximately 60 
s.  
Warming protocol  
SafeSpeed warming media consists in three solutions: thawing solution (TS) (1 
M sucrose), dilution solution (DS) (0.5 M sucrose), and WS (no CPAs) [30]. 
For at least 1 h, closed vials of DS and WS were exposed to laboratory RT, and 
TS vial was placed in the incubator at 37 °C. The vitrification straw containing 
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the oocytes was transferred from a styrofoam box with liquid nitrogen to a 
double-well dish (Becton-Dickinson, 60 × 15 mm Falcon Center-Well Organ 
Culture Dish) containing 1 ml of TS at 37 °C. The liquid nitrogen container 
and the double-well dish used for warming were placed as close as possible 
(10–20 cm) to allow for a fast transfer (less than a second), to facilitate a high 
warming rate. After 1 min, oocytes were carefully moved to a 200-μl droplet of 
DS, where they remained 3 min. Two washing steps of 5 and 1 min, 
respectively, were performed in 200 μl droplets of WS. Warmed oocytes 
remained in culture for 2 h prior to ICSI.  
Primary outcomes  
Morphological survival  
Morphological survival was dictated 2 h post-warming. Oocytes evaluation 
was based on the integrity of oocyte features, such as intact polar corpuscle, 
normal oolemma, and absence of vacuoles [32]. Oocytes clearly degenerated or 
considered not suitable for ICSI were deemed non-viable.  
Fertilization rate  
Fertilization rate was defined as the proportion of oocytes with two pronuclei at 
the time of fertilization check (17 ± 1 h post- insemination) [32]. The number 
of oocytes showing no signal of fertilization, abnormal fertilization (1 or >2 
pronuclei), and degenerated oocytes was recorded.  
Secondary outcomes  
Embryo development was checked at 44 ± 2 h (day 2) and 68 ± 2 h (day 3) 
post-ICSI. For comparative purposes, the embryo assessment algorithm 
proposed by Cobo et al. [33] was used, considering day 2 good quality embryos 
as those pre- senting 2–4 blastomeres, ≤15% type I–II fragmentation, and no 
multinucleation. Day 3 good quality embryos were those with 6–8 blastomeres 
and ≤20% type I–II fragmentation.  
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Clinical outcomes  
Clinical pregnancy was confirmed by ultrasound visualization of a gestational 
sac with fetal heartbeat. The implantation rate was calculated as the ratio of 
gestational sacs with fetal heartbeat by the number of embryos transferred. The 
live birth rate was calculated as live birth events per embryo transfer, with twin 
deliveries considered as a single event. Any perinatal complications were 
recorded.  
Statistical analysis  
The study was designed to detect a difference of 15% in the primary endpoint, 
fertilization rate, and between vitrified and fresh donor oocytes (N = 216 
ICSI’ed), with a power of 80% and a significance level (α) of 0.05. The 
correlation between qualitative ordinal variables was analyzed using chi-square 
and Fisher’s exact test. All statistical analysis was performed using the IBM 
SPSS statistics 17.0 package.  
Results  
The number of subjects included in the study, their age, and the number of 
oocytes assigned to the recipients is shown on Table 1.  
Primary endpoint: fertilization rates  
Out of 73 vitrified MII oocytes, 70 (95.9%) presented morphologic survival 2 h 
post-warming, and 49 of them (70.0%) presented normal fertilization, 
compared to 105 (71.9%) of 146 MII fresh oocytes (p > 0.05) (Table 2).  
Secondary endpoints: embryo quality and development  
Table 2 reveals no differences (p > 0.05) in cleavage rates or the embryo 
quality of vitrified or fresh oocytes on day 2 or day 3.  
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Clinical results  
Clinical results of the cycles were collected without comparative purposes and 
are shown on Table 3. They were not subjected to statistical analysis due to the 
low sample size. Thirty-eight embryos were transferred in total, with a total 
implantation rate of 44.7% and a clinical pregnancy rate of 52.6%, resulting in 
12 live birth events.  
 
Table 1 Characteristics of the donors and recipients included in the study and 
the ratio of control/experimental oocytes assigned. Oocytes from some donors 
were assigned to more than one recipient. In the row labeled as number, the 
values represent the number of donors or recipients. In the rest of the rows, 
data is presented as mean (SD).  
 
Discussion  
It is well established that human or animal-derived protein supplementation of 
the solutions used for gamete and embryo vitrification has a positive effect on 
the survival rates obtained [24]. Solutions are typically supplemented with 10–
20% of SSS or DSS—albumin and glycoprotein solutions—that, among other 
things, provide viscosity to the solution and a surfactant property that enables 
the handling and pipetting of the gametes/embryos [23]. These formulations 
have been used for years and are currently in use with very satisfactory results. 
However, there is an interest in replacing blood-derived components from the 
vitrification solutions with synthetic substitutes, such as HPC. 
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Table 2 Oocyte distribution and laboratory outcomes. Results expressed as 
percentages (%). Morphological survival was dictated 2 h post-warming. Oocytes 
evaluation was based on the integrity of oocyte features, such as intact polar 
corpuscle, normal oolemma, and absence of vacuoles. Fertilization rate was defined 
as the proportion of oocytes with two pronuclei at the time of fertilization check (17 ± 
1 h post- insemination). Day 2 good quality embryos were those presenting 2–4 
blastomeres, ≤15% type I–II fragmentation, and no multinucleation. Day 3 good 
quality embryos were those with 6–8 blastomeres and ≤20% type I–II fragmentation  
 
Desirable advantages that are sought in HPC-supplemented, protein-free 
solutions are reduced production cost and variability, and eliminating the 
hypothetical risk of viral contamination associated with protein purified from 
blood [24]. The addition of hydroxypropyl cellulose instead of serum to 
vitrification solutions can provide the same viscosity that enables in vitro 
manipulation and enhances the glass-forming tendency of the solution, without 
the aforementioned drawbacks [25, 28].  
The present study is a direct comparison of the laboratory outcomes of two 
groups of oocytes: a control group of fresh oocytes and an experimental group 
of vitrified oocytes using an HPC-supplemented set of vitrification and 
warming solutions. Oocytes from both groups derived from the same donor 
were microinjected and cultured in parallel by the same team of embryologists 
in the same environment, minimizing the number of variables influencing the 
outcomes of fertilization and embryo development. 
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Table 3 Report of the total clinical outcomes of the study patients, and 
comparison between transfers performed with embryos from the control 
group of fresh oocytes, embryos from the experimental group of 
vitrified oocytes, and mixed transfers in which an embryo of each group 
was replaced  
As mentioned, the two cohorts, even if from the same donor, were recovered 
from two different stimulation cycles: a source of variability in terms of oocyte 
quality. Nonetheless, the fact that no differences were observed in between 
both groups reveals that the process of vitrification and warming did not impair 
the capacity of the oocytes to fertilize and develop. This outcome is in 
agreement with the literature [25, 28] and supports the efficacy of HPC-based 
vitrification solutions.  
The primary outcome, the fertilization rate of fresh and vitrified oocytes, was 
compared without finding any significant differences. The biological process of 
fertilization, represented by the apparition of the two pronuclei, requires the 
intervention of complex oocyte machinery that could be dam- aged during 
vitrification. A successful fertilization event was used as primary endpoint to 
assess the survival post- vitrification and warming [12, 13]. A successful 
fertilization event was used as primary endpoint to assess the survival post-
vitrification and warming [12, 13]. In addition, a similar rate of good quality 
embryo formation on day 2 and 3 occurred between groups. For completeness, 
a complete follow-up to delivery is also included.  
The results obtained in our experiments for survival, fertilization, and cleavage 
outcomes obtained match the vitrification key performance indicators (KPIs) 
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recently set [32, 34]. Our results are also comparable with previously reported 
data demonstrating comparable viability and development of vitrified oocytes 
to fresh controls [33, 35].  
Up to now, other authors had presented data showing the effectiveness of 
protein-free, HPC-supplemented solutions combined with ethylene glycol, 
dimethyl sulfoxide, and trehalose as the non-permeant cryoprotectant agent. 
They have compared its results with protein-based solutions: Inoue [26] and 
Kuwayama [27] presented results from bovine embryos and oocytes and 
human oocytes, showing comparable survival rates using HPC and SSS 
supplemented solutions. Mori et al. [25] compared media supplemented at 1 
and 5% (v/v) with a stock solution of 60 mg HPC/ml Milli-Q water against 5–
20% SSS supplementation, describing similar physical properties and survival 
rates in mouse and human oocytes and blastocysts with both solutions. Most 
recently, a retrospective study by Coello et al. [28] compared the use of 
solutions supplemented with 0.06 mg HPC/ml and trehalose against 20% SSS 
+ sucrose, showing similar laboratory and clinical outcomes. Our results are the 
first report of the combination of HPC as a surfactant agent and sucrose as the 
osmotic agent; as up to now, it only had been tested in combination with 
trehalose.  
Larger prospective randomized studies comparing the outcomes of oocyte 
vitrification with protein vs. HPC supplementation, in which embryos are 
cultured to blastocyst stage and the live birth rate is used as a primary endpoint, 
are the ultimate comparative test and would be necessary. Yet the results 
reported in this article add to the growing body of evidence documenting 
efficacy of the use of fully synthetic, protein-free vitrification solutions.  
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Abstract	Although	it	was	qualitatively	pointed	out	by	Fahy	et	al.	(1984),	the	key	role	of	 the	 warming	 rates	 in	 non-equillibrium	 vitrification	 has	 only	 recently	been	 quantitatively	 established	 for	 murine	 oocytes	 by	 Mazur	 and	 Seki	(2011).	 In	 this	 work	 we	 study	 the	 performance	 of	 a	 closed	 vitrification	device	 designed	 under	 the	 new	 paradigm,	 for	 the	 vitrification	 of	 human	oocytes.		The	 vitrification	 carrier	 consists	 of	 a	 main	 straw	 in	 which	 a	 specifically	designed	 capillary	 is	 mounted	 and	 where	 the	 oocytes	 are	 loaded	 by	aspiration.	 It	 can	 be	 hermetically	 sealed	 before	 immersion	 in	 liquid	nitrogen	for	vitrification,	and	it	is	warmed	in	a	sterile	water	bath	at	37	C.	Measured	 warming	 rates	 achieved	 with	 this	 design	 were	 of	 600.000	oC/min	 for	 a	 standard	 DMEM	 solution	 and	 200.000	 oC/min	 with	 the	vitrification	solution	for	human	oocytes.		A	 cohort	 of	 143	 donor	 MII	 sibling	 human	 oocytes	 was	 split	 into	 two	groups:	control	(fresh)	and	vitrified	with	SafeSpeed	device.	Similar	results	were	 found	 in	 both	 groups:	 survival	 (97.1%),	 fertilization	 after	 ICSI	(74.7%	in	control	vs.	77.3%	in	vitrified)	and	good	quality	embryos	at	day	three	(54.3%	in	control	vs.	58.1%	in	vitrified)	were	settled	as	performance	indicators.	The	pregnancy	rate	was	3/6	(50%)	for	the	control,	2/3	(66%)	for	vitrified	and	4/5	(80%)	for	mixed	transfers.							
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1.	Introduction		Human	oocyte	cryopreservation	by	vitrification	is	very	efficient,	and	is	no	longer	considered	as	experimental	[23].	As	stated	by	the	American	Society	of	Reproductive	Medicine	guidelines	on	MII	oocyte	cryopreservation,	there	is	enough	evidence	on	its	safety,	with	a	high	similarity	between	laboratory	and	clinical	outcomes	from	fresh	and	vitrified	oocytes.	However,	hitherto	most	 reported	 data	 comes	 from	 studies	 using	 open,	 plastic-strip	vitrification	 systems	 [3,25,33];	 therefore	 it	 is	 still	 in	doubt	whether	 such	efficiency	 levels	 can	 be	 achieved	 with	 a	 closed	 vitrification	 device	[6,7,14,19,20,34,35],	 in	which	 the	biological	 sample	does	not	 have	direct	contact	with	liquid	nitrogen	[35].	According	to	the	paradigm	of	vitrification	under	which	open	systems	were	designed	 [2,35],	 the	 efficacy	 of	 a	 vitrification	 carrier	 depends	mostly	 on	the	cooling	rate	achieved	[1,15].	Therefore,	open	carriers	rely	on	the	direct	exposure	 of	 the	 oocytes	 with	 liquid	 nitrogen	 to	 maximize	 such	 cooling	rates	 [31].	A	drawback	of	 this	 approach	 is	 the	hypothetical	possibility	of	contamination	 by	 infectious	 microorganisms	 present	 in	 the	 liquid	nitrogen,	 and	 the	 risk	of	 cross-contamination	between	patients’	 samples.	That	said,	there	is	plenty	of	literature	reporting	on	the	efficacy	of	plastic-strip	 open	 systems	 on	 both	 oocytes	 and	 embryos	 and	 no	 cases	 of	contamination	 have	 been	 reported	 [35].	 Also,	 numerous	 strategies	 to	improve	 the	 biosafety	 of	 these	 systems	 have	 been	 developed	[9,13,16,21,22],	and	it	is	even	discussed	whether	there	is	a	real	probability	of	cross-contamination	in	the	clinical	practice	[5,35].		To	 overcome	 biosafety	 issues,	 closed	 devices	 have	 been	 designed	 to	guarantee	asepsis,	providing	isolation	to	the	liquid	nitrogen.	However	this	feature	compromises	their	cooling/warm-	ing	rates	and	whether	they	are	as	 efficient	 as	 open	 systems	 is	 a	 subject	 of	 debate	 [14,19,20,35].	Regardless	of	this,	the	most	recent	literature	suggests	that	the	vitrification	paradigm	has	changed:	studies	in	murine	model	have	established	that	the	
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cooling	rate	is	"of	less	consequence"	for	a	successful	vitrification	than	that	of	the	warming	rate,	which	now	appears	to	be	the	dominant	variable	over	the	 cooling	 rate	 [17,30,31],	 and	 even	 over	 the	 CPA	 concentration	 of	 the	vitrification	solution	[12,32].	Whether	this	translates	to	human	oocytes	is	not	 fully	 established,	but	 it	 is	being	acknowledged	 in	 recent	publications	[6].		The	 introduction	 of	 this	 new	 degree	 of	 freedom	 —the	 warming	 rate—	makes	possible,	at	least	in	principle,	the	specific	design	of	a	closed	system	in	which	the	central	idea	is	not	the	cooling	rate	(as	is	the	case	in	the	open	devices)	 but	 the	warming	 rate.	 SafeSpeed	 is	 a	 closed	 vitrification	 carrier	(Safepreservation,	Spain)	 that	has	been	recently	designed	under	 the	new	vitrification	 paradigm	 for	 a	 maximized	 warming	 rate:	 the	 biological	samples	 are	 loaded	 on	 a	 thin,	 flexible,	 thermally	 efficient	 capillary	 that	yields	 not	 only	 high	 cooling	 rates,	 but	 most	 importantly,	 very	 high	warming	rates	[27].		In	this	manuscript	a	description	of	the	closed	carrier	for	vitri-	fication	and	the	 experiments	 to	 measure	 the	 thermal	 rates	 achieved	 with	 it	 are	provided.	 Afterwards,	 the	 protocol	 and	 the	 outcomes	 when	 used	 for	vitrification	of	donor	oocytes	in	an	IVF	programme	are	presented.		
2.	Materials	and	methods		
2.1.	SafeSpeed	closed	vitrification	carrier		The	SafeSpeed	is	a	carrier	for	the	vitrification	of	biological	samples	(Fig.	1).	The	device	is	composed	by	a	thin	capillary,	which	is	assembled	into	a	main	straw	with	 a	 diameter	 of	 24	mm	and	135	mm	of	 length.	The	 rear	 of	 the	straw	 can	 be	 connected	 to	 an	 aspiration	 system,	 necessary	 to	 load	 the	samples	 inside	the	capillary,	using	two	placement	marks	as	reference	 for	its	final	position	(Fig.	1).	Once	the	biological	sample	is	loaded	by	aspiration	the	 device	 is	 sealed	 at	 both	 ends	—the	 capillary	 and	 the	 rear	 end—	 to	make	it	hermetically	closed.	Then,	it	is	ready	to	be	subjected	to	cooling	by	
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plunging	 the	 capillary	 into	 liquid	 nitrogen.	 For	 subsequent	 storage,	 a	slideable	transparent	plastic	cover	protects	the	capillary.	For	re-warming,	the	device	is	quickly	transferred	from	the	liquid	nitrogen	to	a	37	°C	water	bath.	 Safepreservation,	 Spain,	 commercially	 produces	 this	 device,	 and	 it	holds	 the	 CE	 marking	 as	 a	 product	 for	 the	 cryopreservation	 of	 human	oocytes	and	embryos.		
2.2.	Measurement	of	thermal	performance	of	the	vitrification	carrier		
i)	 Set-up:	 For	 determining	 the	 warming	 rate	 we	 used	 a	 tem-	 perature	measuring	system	consisting	of	an	ultra-fine	thermo-	couple	probe	(COCO-001;	OMEGA	Engineering	Inc.,	USA).	After	the	corresponding	amplification,	the	signal	was	 introduced	 in	one	of	 the	analogic	 input	channels	of	a	DAC	converter	 (USB.1208LS;	 Measurement	 Computing	 Inc.,	 USA).	 A	 program	written	 in	Labview	6.0	(reading	rate	600	Hz)	gives	us	 the	whole	 thermal	history	of	the	thermocouple	junction.		
	Fig.	 1.	 SafeSpeed	 Carrier.	 Detailed	 outline	 of	 the	 SafeSpeed	 carrier	 and	 its	components.	The	capillary	where	the	oocytes	are	introduced	is	assembled	into	a	main	 straw	 with	 a	 sealable	 rear-end	 and	 a	 slide	 cover	 for	 protection	 of	 the	capillary	during	storage.	1:	Sealable	rear-end.	2:	Labelling	area.	3:	Slide	protector	cover.	4:	Ultra-thin	capillary.	4.1:	Sample	placement	marks,	4.2:	Sealing	mark.			The	 thermocouple	 was	 introduced	 inside	 the	 SafeSpeed	 device,	 and	 the	copper-constantan	junction	was	carefully	placed	in	the	position	where	the	oocyte	is	allocated.	Then,	the	SafeSpeed	device	was	filled	with	the	solution	and	 sealed	 at	 the	 tip	 of	 the	 capillary.	 Next,	 the	 device	 was	 quenched	 in	liquid	nitrogen,	held	10	s	(a	time	that	is	more	than	2	orders	of	magnitude	higher	 than	 that	 necessary	 to	 reach	 the	 thermal	 equilibrium	 with	 the	
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cryogenic	 media),	 and	 subsequently	 re-warmed	 in	 a	 37	 °C	 water	 bath,	exactly	as	in	the	standard	vitrification/warming	protocol	for	oocytes.			
ii)	Warming	 rates	 in	 relation	 to	 the	 time	 of	 flight:	 To	determine	 the	correlation	 between	 the	 time	 of	 flight	 (the	 motion	 from	 the	 exit	 of	 the	liquid	nitrogen	to	the	entrance	into	the	water	bath)	and	the	warming	rates	achieved,	 the	 motion	 of	 the	 capillary	 was	 recorded	 at	 480	 frames	 per	second	(Fig.	2).	The	ultra-fast	video	camera,	CASIO	EX-ZR100,	allowed	us	to	visualize,	with	a	temporal	resolution	of	milliseconds,	the	position	of	the	carrier	device,	and	in	particular,	the	position	of	the	thermocouple	junction,	placed,	 as	 explained	 above,	 in	 the	 position	 where	 the	 oocyte/embryo	would	remain.	Its	optical	properties	are:	12.1	megapixels,	Objective/focal	distance	 (f):	3.0	 to	5.9/f	1⁄4	4.24e53.0	mm	and	12.5X	optical	 zoom.	The	number	 frames	per	second	(fps)	can	be	chosen	between	120,	240,	480	y	1000.	 In	 our	 case	we	used	480	 fps	 as	 the	best	 compromise	between	 the	spatial	and	temporal	resolution	of	the	camera.		With	Sony	Vegas	(Sony,	USA)	we	determined,	frame	by	frame	(Fig.	3),	the	time	of	flight:	the	lapse	of	time	for	the	thermocouple	junction	to	be	taken	from	liquid	nitrogen	to	the	water	bath	(Fig.	4).	With	a	second	algorithm	in	Matlab	 we	 determined	 the	 warming	 rate.	 Afterwards,	 by	 making	 the	matching	 of	 these	 two	 sets	 of	 data	 (warming	 rate	 and	 time	of	 flight)	we	established	its	correlation.	The	average	warming	rate	was	calculated	in	the	temperature	interval	from	-150	°C	to	-20	°C.		
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		Fig.	 2.	 Set	 up	 for	 image	 acquisition	 of	 the	 re-warming	 motion.	 The	 following	elements	are	shown:	a)	Liquid	nitrogen	container	filled	to	the	rim.	b)	Removable	sterilized	water	bath	at	37	C.	c)	High	speed	(1000	fps)	video	camera	(CASIO	EX-ZR100).	 The	 full	 motion	 of	 the	 transfer	 of	 the	 capillary	 containing	 the	thermocouple	 from	 the	 liquid	nitrogen	 to	 the	warm	water	bath	 is	 recorded	by	the	camera.					
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iii)	Warming	rates	in	relation	to	the	vitrification	solution:	In	order	to	compare	 the	 warming	 rates	 of	 different	 cryoprotectants	 a	 set	 of	experiments	 were	 carried	 out	 loading	 the	 capillary	 with	 the	 following	solutions:	 a)	 Standard	 DMEM	 culture	media,	 (Dulbecco’s	 Modified	 Eagle	Medium,	GIBCO)	b)	DMEM	with	1.	5M	1,2-	propanediol	and	0.3	M	sucrose,	c)	 VS	 vitrification	 solution	 (Safe-	 Speed	 vitrification	 solutions,	Safepreservation,	 Spain)	 with	 15%	 ethylene	 glycol	 and	 15%	 dimethyl	sulfoxide	(v/v).		
2.3.	Clinical	study	design		143	 MII	 sibling	 oocytes	 from	 donation	 cycles	 between	 January	 and	November	 2014	 were	 included	 in	 this	 prospective	 randomized	 study.	Participants	of	the	study	were	14	recipients	of	the	egg	donation	program	in	Ginemed	Clinicas,	 Seville,	 Spain.	Each	 recipient	was	assigned	with	one	cohort	 of	 sibling	 oocytes	 from	 the	 same	 donor.	 Half	 of	 the	 cohort	 was	composed	 of	 fresh	 oocytes	 from	 a	 synchronic	 donation	 cycle	 (control	group)	and	the	other	half	were	vitrified/warmed	oocytes	from	a	previous	cycle	 of	 the	 same	 donor	 (experimental	 group).	Both	 groups	 of	 oocytes	were	 fertilized	 and	 underwent	 culture	 in	 parallel.	 The	 laboratory	outcomes	of	both	groups	were	compared:	 the	primary	performance	end-point	of	the	study	was	the	fertilization	rate	of	 fresh	and	vitrified	oocytes.	Secondary	 parameters	 assessed	 were:	 cleavage	 rates,	 embryo	 quality	 in	day	 2	 and	 day	 3,	 and	 percentage	 of	 discarded	 embryos.	 Pregnancy	 and	implantation	rate	were	also	included	in	the	follow	up	of	the	study.		
2.4.	Study	population		All	donors	 included	 in	 the	study	 fulfilled	 the	Spanish	regulations	on	ART	donors	 (RD	1301/2006),	described	elsewhere	 [33]	and	 fulfilled	Ginemed	Clínicas	 inclusion	criteria:	over	18	and	under	30	years	old,	good	physical	and	 psychological	 health,	 no	 personal	 nor	 family	 history	 of	 hereditary	diseases,	 normal	 karyotype,	 negative	 tests	 for	 sexually	 transmitted	
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diseases	and	without	any	medical	or	gynecological	disorders.	Donors	were	subjected	 to	 a	 short	 agonist	 stimulation	 treatment	 and	were	 excluded	 in	case	of	a	response	to	stimulation	<12	oocytes.	All	recipients	who	attended	Ginemed	Clínicas	for	an	egg	donation	program	were	consecutively	offered	to	participate	in	the	study,	until	the	quota	was	filled.	Cases	of	couples	with	a	 severe	male	 factor,	 such	 as	 surgically	 extracted	 spermatozoa	 and	 very	severe	 oligoastenozoospermia	 (motile	 sperm	 count	 <500.000/ml	 after	preparation)	were	not	included.		
	Fig.	 3.	Determination	 of	 the	 time	 of	 flight.	 Frame	by	 frame	 visualization	 of	 the	video	enables	(Sony	Vegas	software),	with	a	temporal	resolution	of	milliseconds,	the	 determination	 of	 the	 exact	 lapse	 of	 time	 between	 the	 exit	 from	 liquid	nitrogen	and	the	entrance	in	the	warm	water	bath.					
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		Fig.	 4.	 The	 motion	 performed	 for	 the	 warming	 process.	 a)	 Liquid	 nitrogen	container	 filled	 to	 the	 rim.	 b)	 Removable	 sterilized	 water	 bath	 at	 37	 C.	 The	carrier	 device	 with	 the	 capillary	 submerged	 in	 liquid	 nitrogen	 is	 quickly	transferred	 from	 a)	 to	 b)	 (white	 arrow).	 Note	 that	 the	 warm	 water	 bath	 is	situated	 at	 a	 close	 distance	 (2	 cm)	 to	 the	 liquid	 nitrogen	 container	 and	 at	 the	same	height	to	enable	a	fast	motion	and	a	reduced	time	of	flight.			
2.5.	Ethical	considerations		All	 recipients	were	 informed	 thoroughly	 about	 the	 protocol	 of	 the	 study	and	 signed	 an	 informed	 consent	 form.	 The	 study	 was	 conducted	 as	described	 in	 the	 protocol,	 which	 was	 developed	 in	 accordance	 to	 the	principles	of	Helsinki	and	the	Spanish	Policy	of	Good	Clinical	Practice	(ISO	14155:2011),	 and	 was	 approved	 by	 the	 Internal	 Review	 Board	 of	 the	Research	Committee	of	Ginemed	Clínicas.		
2.6.	Donor	stimulation		For	 the	 donation,	 donors	 took	 contraceptive	 pills	 during	 the	 previous	month	 to	 the	 stimulation.	 Five	 days	 after	 finishing	 con-	 traceptives,	stimulation	began	with	150e200	IU	daily	of	r-FSH	(alpha	follitropin,	Gonal-F,	 Merck,	 Spain),	 depending	 on	 BMI.	 After	 day	 five,	 determination	 of	estradiol	levels	and	ultrasound	scans	were	performed	for	dose	adjustment.	When	a	 follicle	 reached	14	mm,	 they	 started	GnRH	antagonist	 treatment	with	 0.25	 mg	 Cetrotide	 (Cetrorelix,	 Merck,	 Spain)	 until	 at	 least	 three	follicles	reached	20	mm.	At	this	point,	ovulation	was	triggered	with	0.3	mg	of	triptoreline	GnRH	agonist	(Decapeptyl;	IpsenPharma,	Spain).		2.7.	Recipient	stimulation		
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Recipients	were	kept	on	contraceptive	pills	for	the	synchronized	donation.	Once	suspended,	when	menstruation	happened,	endo-	metrial	substitutive	treatment	 started	 with	 6	 mg	 daily	 of	 estradiol	 hemihydrate	 (Estradot,	Novartis,	Switzerland).	After	14	days	of	treatment,	it	was	assessed	that	an	optimal	endometrium	had	been	achieved.	On	the	day	of	the	retrieval	from	the	donor,	 the	partner	of	 the	receiving	patient	delivered	a	sperm	sample	for	 IVF.	 At	 that	 time,	 they	 began	 taking	 progesterone	 vaginal	 or	 oral	supplement,	 600	mg	 daily	 (Utrogestan,	 Seid,	 Spain),	 continued	 until	 the	results	of	the	embryo	transfer	were	known.		
2.8.	Ovarian	puncture		Oocyte	 recovery	 was	 performed	 by	 eco-guided	 ovarian	 punc-	 ture.	 An	ultrasound	 transducer	was	placed	 into	 the	vaginal	 fornix	 to	visualize	 the	ovary	 and	 follicles,	 and	 a	 single	 lumen	 ovum	 aspira-	 tion	 needle	 (Cook	Medical,	 IN,	 USA)	was	 inserted	 in	 the	 transducer	 and	 advanced	 into	 the	ovarian	 follicles,	 where	 oocytes	 were	 recovered	 by	 aspiration	 with	 a	syringe,	until	all	the	follicles	had	been	punctured.		
2.9.	Embryology	procedures		Two	 hours	 post-retrieval,	 oocytes	 were	 denuded	 using	 hyal-	 uronidase	(HYASE-10X,	Vitrolife,	Sweden).	Embryos	from	both	groups	were	cultured	on	micro	drops	 (G-IVF,	G1Plus,	G2Plus,	Vitrolife,	 Sweden)	under	mineral	oil	 (Tissue	 Culture	 Oil,	 Sage,	 Cooper	 Surgical,	 USA),	 under	 controlled	temperature,	 humidity	 and	CO2	 concentration	 (37	C,	 95%	RH,	 6%	CO2).	Both	 control	 and	 experimental	 groups	 underwent	 ICSI	 simultaneously,	38e40	h	post-hCG.	Immediately	after	denudation,	oocytes	from	the	experi-	mental	group	were	vitrified.		
2.10.	 Vitrification	Vitrification	 was	 performed	 at	 laboratory	 room	
temperature		(RT),	 in	 our	 case	 23	 ±	 0.5	 C.	 SafeSpeed	 vitrification	 media	 kit	(Safepreservation,	Spain)	was	used.	It	consists	 in	three	solutions:	WS	(no	
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CPAs),	 ES	 (7.5%	 ethylene	 glycol	 and	 7.5%	 dimethyl	 sulfoxide)	 and	 VS	(described	 above;	 15%	 ethylene	 glycol	 and	 15%	dimethyl	 sulfoxide).	 All	solutions	were	 exposed	 at	 least	 for	 an	 hour	 to	 labo-	 ratory	 RT.	 Oocytes	were	gradually	exposed	to	the	CPAs:	they	were	placed	in	a	first	droplet	of	50	ml	of	WS	(Washing	Solution),	which	was	then	joined	using	the	tip	of	the	pipette	 to	 another	 droplet	 of	 50	ml	 of	 ES	 (Equilibration	 Solution).	 After	two	 minutes,	 both	 drop-	 lets	 were	 joined	 with	 a	 third	 of	 the	 same	 ES,	waiting	another	2	min,	allowing	the	diffusion	of	the	CPAs.		Afterwards,	 oocytes	 were	 transferred	 to	 a	 100	 ml	 droplet	 of	 ES,	 where	they	 remained	 from	 6	 to	 10	 min,	 until	 they	 appeared	 to	 be	 fully	 re-expanded.	Once	the	equilibration	was	complete,	oocytes	were	transferred	to	 a	 200	 ml	 droplet	 of	 VS	 and	 washed	 by	 pipetting,	 to	 eliminate	 any	leftover	ES.		Immediately	 after,	 they	were	 loaded	by	aspiration	 inside	 the	 capillary	of	the	 SafeSpeed	 device	 (Safepreservation,	 Spain):	 Oocytes	 were	 placed	 in	between	the	two	black	security	marks	of	the	capillary	(Fig.	1).	Then,	both	ends	 of	 the	 device,	 the	 capillary	 and	 the	 rear	 part,	 were	 sealed	 with	 a	dedicated	 sealer	 (SafeSealer,	 Spain).	 The	 SafeSpeed	 was	 then	 quenched	into	a	liquid	nitrogen	bath,	deep	enough	(20	cm	of	depth),	to	allow	a	deep	plunging	 without	 risks	 of	 hitting	 its	 bottom.	 The	 capillary	 was	 then	protected	by	pulling	down	the	slide	cover,	before	releasing	it	in	the	liquid	nitrogen	bath.		
2.11.	Warming		SafeSpeed	 warming	 media	 consists	 of	 three	 solutions:	 TS	 (Thawing	solution,	 1	 M	 sucrose),	 DS	 (Diluent	 solution;	 0.5	 M	 su-	 crose)	 and	 WS	(Washing	solution,	CPA-free).	For	at	least	one	hour,	closed	vials	of	DS	and	WS	 were	 exposed	 to	 laboratory	 room	 tem-	 perature,	 and	 TS	 vial	 was	placed	in	the	incubator	at	37	C.		
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For	warming,	a	 recipient	containing	sterilized	water	at	37	C	 is	placed	on	the	side	of	the	liquid	nitrogen	recipient	containing	the	straw,	at	a	distance	of	2	 cm	and	with	 its	 rim	at	 the	 same	height.	All	 these	details	 are	 critical	parts	 of	 the	 strategy	 to	maximize	 the	warming	 rate,	 as	 explained	 in	 the	“Results”	section.	The	slide	cover	must	be	pulled	up	to	expose	the	capillary	containing	 the	 oocytes,	 and	 the	 rear	 end	 of	 the	 SafeSpeed	 device	 is	 cut	open.	The	straw	is	transferred,	minimizing	the	flight	time	(see	Fig.	5),	from	the	liquid	nitrogen	bath	to	the	warm	water	bath,	where	it	is	stirred	for	one	second	in	the	water	and	then	removed,	drying	the	capillary	carefully	 in	a	sterile	tissue	afterwards.		The	carrier	was	then	connected	to	the	aspiration	system,	the	capillary	cut	over	the	sealed	area,	and	the	oocytes	expelled	in	a	200	ml	droplet	of	TS.	In	the	TS	 solution	oocytes	were	washed	 to	eliminate	any	 leftover	VS	media	with	a	stripper	tip	of	the	appropriate	diameter	(170	mm).	Within	60	s	they	were	 transferred	 very	 gently	 to	 a	 200	 ml	 droplet	 of	 DS,	 where	 they	remained	 3	 min,	 followed	 by	 two	 washing	 steps	 of	 5	 and	 1	 min(s),	performed	in	200	ml	droplets	of	WS.	Afterwards	they	were	cultured	(37	C,	6%	CO2)	 for	2	h	 to	allow	meiotic	spindle	reformation	before	undergoing	ICSI.		
2.12.	Primary	performance	indicators		
Morphological	survival		Morphological	survival	was	assessed	2	h	post-thawing.	Oocytes	evaluation	was	 based	 on	 the	 integrity	 of	 oocyte	 features,	 such	 as	 intact	 polar	 body,	normal	 oolemma,	 absence	 of	 vacuoles,	 etc.	 [18].	 Oocytes	 clearly	degenerated	or	considered	not	suitable	for	ICSI	were	considered	negative	for	survival.		
Fertilization	Rate		Fertilization	 rate	 was	 defined	 as	 the	 proportion	 of	 oocytes	 with	 2	pronuclei	at	the	time	of	 fertilization	check	(17	±	1	h	post	 insemi-	nation)	
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[18].	The	number	of	oocytes	showing	no	signal	of	 fecundation,	abnormal	fecundation	(1	or	>2	pronuclei)	and	degenerated	oocytes	was	registered.		
2.13.	Secondary	performance	indicators		Embryo	development	was	checked	at	44	±	2	h	(Day	2)	and	68	±	2	h	(Day	3)	post-ICSI.	The	embryo	assessment	 algorithm	proposed	by	Cobo	et	 al.	 [3]	was	 used,	 considering	 that	 the	 embryos	 were	 of	 good	 quality	 on	 the	second	day	of	development	if	they	presented	2-4	blastomeres,	15%	type	I-II	 fragmentation	and	no	multinucleation.	On	day	3,	good	quality	embryos	were	those	with	6-8	blastomeres	and	20%	type	I-II	fragmentation.		
2.14.	Clinical	results		To	confirm	clinical	pregnancy,	the	serum	level	of	ß-hCG	was	measured	12-14	 days	 post-transfer.	 Implantation	 was	 confirmed	 by	 ultrasound	visualization	of	a	gestational	sac.		
2.15.	Statistical	analysis		The	 baseline	 quantitative	 variables	 are	 presented	 as	 mean	 ±	 standard	deviation,	 and	 the	 qualitative	 variables	 are	 presented	 as	 their	 absolute	value	 and	 percentage.	 To	 test	 the	 association	 between	 the	 exposure	 to	vitrification/warming	and	each	laboratory	endpoint,	Pearson’s	Chi-Square	test	and	Fisher’s	exact		
3.	Results		
3.1.	Warming	rates	with	SafeSpeed	closed	vitrification	carrier		
i)	Warming	rates	in	relation	to	the	time	of	flight:	Fig.	5	represents	the	typical	behavior	of	 the	warming	rate	 (for	VS)	as	a	 function	of	 the	 time	 it	takes	the	capillary	to	complete	the	motion	from	liquid	nitrogen	to	water:	there	is	an	exponential	in-	crease	in	the	warming	rate	as	the	time	of	flight	is	 reduced,	 with	 a	 critical	 point	 around	 300	 ms.	 Longer	 time	 of	 flights	translate	 in	 lower	warming	 rates	 that	 could	 compromise	 the	outcome	of	the	recovery	of	the	oocyte	[17].		
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ii)	Warming	rates	in	relation	to	the	CPA	cocktail		The	average	(mean	±	SEM)	value	obtained	was	200.000	±	10.000	oC/min	for	 VS,	 450.000	 ±	 10.000	 oC/min	 for	 1.5	 M	 1,2-propanediol	 and	 0.3	 M	sucrose	 and	 600.000	 ±	 20.000	 oC/min	 for	 CPA-free	 culture	 media.	 All	times	of	flight	used	for	calculations	were	below	300	ms.			
	Fig.	5.	Relevance	of	the	re-warming	step.	The	graph	shows	the	typical	behavior	of	the	 warming	 rate	 (oC/min)	 vs.	 the	 time	 of	 flight	 (the	 time	 to	 complete	 the	warming	motion	from	liquid	nitrogen	to	the	37	C	water	bath)	for	VS	vitrification	solution.	 There	 is	 an	 exponential	 increase	 of	 the	 warming	 rate	 as	 the	 time	 of	flight	is	reduced.	A	plateau	seems	to	be	reached	for	time	of	flights	below	300	ms;	in	 this	 area,	 the	 average	warming	 rate	 for	 VS	 vitrification	 solution	 is	 200.000	oC/min.		
3.2.	Clinical	study	results		
3.2.1.	Study	subjects		The	number	of	subjects	included	in	the	study,	their	age,	and	the	number	of	oocytes	assigned	to	the	recipients	are	shown	on	Table	1.			
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Table	1.	Baseline	characteristics	data	Patients	 14	Age	(years)	 42.3	(5.7)	Number	 of	 oocytes	assigned	 9,1	(1.4)	Table	1:	Baseline	characteristics	of	the	recipients	of	the	egg	donation	programme	participating	in	the	study.	Data	as	mean	(SD).		
3.2.2.	Primary	endpoint:	survival	and	fertilization	rates		Out	 of	 68	 vitrified	 MII	 oocytes,	 66	 (97.1%)	 presented	 morpho-	 logical	survival	 2	 h	 post	 warming,	 and	 51	 of	 them	 (77.3%)	 presented	 normal	fertilization,	compared	to	56	of	75	(74.7%)	fresh	oocytes	(p	>	0.05)	(Table	2).		
3.2.3.	Secondary	endpoints:	embryo	quality	and	development		Table	 2	 also	 summarizes	 the	 embryo	 development	 at	 day	 3:	 our	 results	showed	 similar	 cleavage	 rates	 and	 similar	 number	 of	 good	 quality	embryos	 (58.1%	 from	 vitrified	 oocytes	 against	 a	 54.3%	 from	 fresh	oocytes)	 on	 both	 groups	 (p	 >	 0.05).	 The	 total	 number	 of	 embryos	 that	were	 appropriate	 for	 transfer	 or	 cryopreservation	 was	 also	 similar	whether	they	originated	from	fresh	or	vitrified/warmed	oocytes.		
3.2.4.	Clinical	results		As	 shown	 in	 Table	 3,	 there	were	 6	 cases	where	 only	 embryos	 from	 the	fresh	 group	 were	 transferred.	 In	 3	 transfers	 only	 embryos	 from	 the	vitrified/warmed	 group	 were	 transferred.	 And	 there	 were	 5	 mixed	transfers	with	embryos	from	both	groups.	Similar	implantation	rates	were	obtained	 within	 groups,	 with	 9	 out	 of	 14	 recipients	 achieving	 clinical	pregnancy.		
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Table	2.	Laboratory	outcomes	
	 Fresh	 Vitrified/	Warmed	 OR	(95%	CI)	 P	Survival	 -	 66/68	(97.1)	 -	 -	Normal	Fertilization	 56/75	(74.7)	 51/66	(77.3)	 1.15	(0.53	to	2.51)	 0.72	Non-Fertilized	 11/75	(14.7)	 7/66	(10.6)	 0.69	(0.25	to	1.90)	 0.39	Abnormal	Fertilization	 5/75	(6.6)	 4/66	(6.05)	 0.90	(0.23	to	3.51)	 0.88	Degenerated	after	ICSI	 3/75	(4.0)	 4/66	(6.05)	 1.55	(0.33	to	7.18)	 0.58	Day	 3	Cleavage	rate	 46/56	(80.3)	 43/51	(84.3)	 1.16	(0.42	to	3.23)	 0.76	Day	 3	 Good	Quality	Embryo	Rate	 25/46	(54.3)	 25/43	(58.1)	 1.17	(0.50	to	2.70)	 0.72	Transferred	or	Cryopreserved	 40/46	(86.9)	 38/43	(88.4)	 1.14	(0.32	to	4.04)	 0.84		Table	2:	Comparison	of	the	primary	(fertilization	rate)	and	secondary	endpoints	of	 fresh	 and	 vitrified	 sibling	 oocytes.	 Data	 expressed	 as	 absolute	 values	 and	percentage	(%),	OR	(95%	CI)	and	p-value.					
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Table	3.	Clinical	outcomes	
	 Embryo	Transfers	
	 Fresh	Group	 Mixed	Transfers	
Vitrified	/Warmed	Group	Nº	of	transfers	 6	 5	 3	Mean	 nº	 of	 embryos	transferred	 2.17	(0.41)	 2.33	(0.51)	 2.33	(0.58)	Implantation	 Rate	(per	embryo	transferred)	 3/13	(23.1)	 4/14	(28.6)	 2/7	(28.6)	Pregnancy	 rate		(per	transfer)	 3/6	(50.0)	 4/5	(80.0)	 2/3	(66.0)	Total	Pregnancy	rate	 9	/14	(64.3)		Table	3:	Clinical	results	of	the	embryo	transfers	performed.	Data	as	mean	(SD)	or		absolute	values	and	percentages	(%).		
4.	Discussion		The	average	warming	 rate	obtained	with	 the	 closed	carrier	was	600.000	°C/min	when	using	a	CPA-free	DMEM	culture	media,	450.000	°C/min	for	a	1.5	M	 1,2-propanediol,	 0.3	M	 sucrose,	 and	 200.000	 °C/min	 using	 the	 VS	vitrification	 solution	 for	 human	 oocytes,	when	 the	warming	motion	was	completed	 in	under	300	ms.	The	correlation	between	warming	rates	and	time	of	flight	between	the	liquid	nitrogen	and	the	warm	water	bath	fits	in	our	experiments	to	a	potential	curve	of	the	form:		𝐵(º𝐶/𝑚𝑖𝑛) ≈ 10! 𝑡!!		where	 B	 is	 the	 warming	 rate	 in	 (ºC/min)	 and	 t	 is	 the	 time	 of	 flight,	 in	milliseconds	(ms).	The	exponential	increase	of	the	warming	rate	(B)	with	
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the	 reduction	 of	 the	 duration	 of	 the	 warming	 motion	 (t),	 shows	 the	relevancy	 of	 performing	 a	 fast	 rewarming	 of	 the	 vitrification	 carrier,	 as	described	in	the	section	warming	of	this	work.		The	 warming	 rate	 measurement	 experiments	 with	 DMEM	 and	 DMEM	supplemented	with	1.5	M	1,2-propanediol	and	0.3	M	sucrose	were	done,	even	 if	 this	was	not	 the	 cryoprotectant	 solution	used	 in	 this	manuscript,	because	there	is	reported	evidence	of	the	capability	of	vitrification	of	this	solution	in	similar	devices	[11,	26].	Other	authors	have	also	explored	the	use	 of	 low	CPA	 formulations	 combined	with	 an	 increase	 in	 the	warming	rates	[12].	The	use	of	SafeSpeed	for	oocyte	vitrification	with	this	and	other	low	 concentration	 cryoprotectant	 cocktails	 is,	 however,	 something	 to	 be	explored.		The	vitrification	and	subsequent	warming	of	donor	oocytes	in	this	closed	carrier	did	not	impair	their	competence:	the	primary	outcome,	fertilization	rate,	 was	 similar	 to	 fresh	 sibling	 oocytes,	 as	 well	 as	 their	 cleavage,	development	and	reproductive	outcomes.	The	vitrification	carrier	used	in	this	study	was	recently	designed	under	the	new	paradigm	of	vitrification	that	Seki	and	Mazur	have	developed	in	their	latest	publications	in	a	murine	model	 [12,17,30e32].	 According	 to	 it,	 the	warming	 rate	 is	 the	 dominant	variable	 affecting	 survival	 in	 the	 vitrification	 process.	 This	 is	 because	 in	the	 warming	 step	 there	 is	 risk	 of	 recrystallization	 of	 intracellular	 ice,	which	can	grow	to	a	size	 that	will	ultimately	compromise	 the	viability	of	the	cryopreserved	cell	[17,31].			It	 must	 be	 acknowledged	 that	 most	 open	 vitrification	 systems	 yield	excellent	 results	 for	 the	 cryopreservation	 of	 human	 oocytes	 [36].	 The	ability	 to	 cryopreserve	 oocytes	with	 such	 success	 has	 resulted	 in	 a	wide	and	ever	growing	array	of	applications	[4],	which	have	had	a	tremendous	positive	impact	on	the	assisted	reproduction	technologies.	The	reason	for	the	success	of	plastic-strip	open	systems	is	that,	through	their	design,	they	inherently	achieve	a	high	warming	rate	too	[32],	although	their	design	was	
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not	necessarily	optimized	 for	 such	an	end.	However,	 there	are	published	strategies	 for	 achieving	 very	 high	 warming	 rates	 also	 in	 open	 devices	consisting	 in	 using	 an	 infrared	 laser	 pulse	 against	 the	 oocyte	 [12].	 The	laser	 approach	 has	 already	 been	 successfully	 used	 for	 avoiding	devitrification	of	the	sample	during	a	cryopreservation	protocol	[10].		In	the	SafeSpeed	carrier	the	warming	rate	is	maximized	by	the	following	factors:	the	warming	is	performed	in	a	significant	volume	of	warm	water,	in	 a	 very	 fast	 motion,	 and	 the	 capillary	 yields	 excellent	 thermal	performance	 [27].	 The	 fact	 that	 the	 oocytes	 are	 encapsulated	 inside	 a	capillary	 is	 not	 a	 drawback,	 but	 on	 the	 contrary,	 it	 enables	 this	improvement	 in	the	warming	rate	by	allowing	the	possibility	of	warming	in	 bigger	 volumes	 of	 warm	 media/water	 without	 the	 risk	 of	 losing	 the	oocytes/embryos.	 It	 also	minimizes	 the	 risk	 of	 contamination	 associated	with	direct	contact	with	liquid	nitrogen	[14],	even	though	capillary-based	vitrification	systems	require	careful	manipulation	to	be	completely	aseptic	[35].		Other	authors	have	 reported	 improvements	 in	 the	vitrification	outcomes	of	 human	 oocytes	 with	 protocol	 modifications	 directed	 to	 increase	 the	warming	 rate	 in	 human	 [6].	 Nevertheless,	 it	 is	 yet	 to	 be	 determined	 to	which	 extent	 each	 variable	 (CPA	 concentration	 and	 toxicity,	 cooling	 rate	and	 warming	 rate)	 plays	 a	 role	 in	 the	 survival	 of	 a	 human	 oocyte	 to	vitrification	and	how	they	interact	to	find	a	perfect	combination	amongst	them	[8,24,28].	Overall,	the	application	of	ultra-fast	vitrification	on	human	assisted	 reproduction	 is	 very	 successful,	 and	 it	 has	become	a	key	 tool	 in	daily	 clinical	 practice	 [4].	 Current	 results	 are	 satisfactory	 [36]	 but	 as	we	gain	a	better	understanding	of	the	principles	that	make	vitrification	work,	the	 techniques	must	keep	 improving	 too	and	with	 these	experiments	we	aimed	to	take	a	step	in	such	direction;	towards	a	safer,	more	effective,	less-time	 consuming,	 less	 technically	 demanding,	 and	 ultimately,	 a	 universal	protocol	for	the	vitrification	of	human	gamete	and	embryos.		
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Glossary	of	ART	terminology	
• Assisted	 reproductive	 technology	 (ART):	 all	 treatments	 or	 pro-	cedures	 that	 include	 the	 in	vitro	handling	of	both	human	oocytes	and	sperm	or	of	embryos	for	the	purpose	of	establishing	a	pregnancy.	This	includes,	but	is	not	limited	to,	in	vitro	fertilization	and	embryo	transfer,	gamete	 intrafallopian	 transfer,	 zygote	 intrafallopian	 transfer,	 tubal	embryo	 transfer,	 gamete	 and	 embryo	 cryopreservation,	 oocyte	 and	embryo	 donation,	 and	 gestational	 surrogacy.	 ART	 does	 not	 include	assisted	insemination	(artificial	insemination)	using	sperm	from	either	a	woman’s	partner	or	a	sperm	donor.	
• Blastocyst:	 an	embryo,	5	or	6	days	after	 fertilization,	with	an	 in-	ner	cell	mass,	 outer	 layer	 of	 trophectoderm,	 and	 a	 fluid-filled	blasto-	 cele	cavity.		
• Clinical	 pregnancy:	 a	 pregnancy	 diagnosed	 by	 ultrasonographic	visualization	of	one	or	more	gestational	sacs	or	definitive	clinical	signs	of	pregnancy.	It	 includes	ectopic	pregnancy.	Note:	Multiple	gestational	sacs	are	counted	as	one	clinical	pregnancy.		
• Controlled	 ovarian	 stimulation	 (COS)	 for	 ART:	 pharmaco-	 logic	treatment	in	which	women	are	stimulated	to	induce	the	devel-	opment	of	 multiple	 ovarian	 follicles	 to	 obtain	 multiple	 oocytes	 at	 follicular	aspiration.		
• Cryopreservation:	the	freezing	or	vitrification	and	storage	of	gametes,	zygotes,	embryos,	or	gonadal	tissue.		
• Embryo:	 the	 product	 of	 the	 division	 of	 the	 zygote	 to	 the	 end	 of	 the	embryonic	 stage,	 8	weeks	 after	 fertilization.	 (This	 definition	does	not	include	 either	 parthenotes—generated	 through	 partheno-	 genesis—nor	products	of	somatic	cell	nuclear	transfer.)		
• Embryo	 transfer	 (ET):	the	procedure	in	which	one	or	more	embryos	are	placed	in	the	uterus	or	fallopian	tube.		
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• Fertilization:	 the	 penetration	 of	 the	 ovum	 by	 the	 spermatozoon	 and	combination	 of	 their	 genetic	 material	 resulting	 in	 the	 formation	 of	 a	zygote.		
• Frozen-thawed	embryo	transfer	cycle	(FET):	an	ART	proce-	dure	in	which	cycle	monitoring	is	carried	out	with	the	intention	of	transfering	frozen-thawed	 embryo(s).	 Note:	 An	 FET	 cycle	 is	 initi-	 ated	 when	specific	medication	is	provided	or	cycle	monitoring	is	started	with	the	intention	to	treat.		
• Gestational	 sac:	 a	 fluid-filled	 structure	 associated	 with	 early	pregnancy,	which	may	be	located	inside	or	outside	the	uterus	(in	case	of	an	ectopic	pregnancy).		
• Implantation:	 the	 attachment	 and	 subsequent	 penetration	 by	 the	zona-free	 blastocyst	 (usually	 in	 the	 endometrium)	 that	 starts	 5	 to	 7	days	after	fertilization.		
• Implantation	rate:	the	number	of	gestational	sacs	observed	divided	by	the	number	of	embryos	transferred.		
• In	 vitro	 fertilization	 (IVF):	 an	 ART	 procedure	 that	 involves	extracorporeal	fertilization.		
• Infertility	(clinical	definition):	a	disease	of	the	reproductive	sys-	tem	defined	by	the	failure	to	achieve	a	clinical	pregnancy	after	12	months	or	more	of	regular	unprotected	sexual	intercourse.		
• Intracytoplasmic	 sperm	 injection	 (ICSI):	 a	 procedure	 in	 which	 a	single	spermatozoon	is	injected	into	the	oocyte	cytoplasm.		
• Live	 birth:	 the	complete	expulsion	or	extraction	 from	 its	mother	of	a	product	 of	 fertilization,	 irrespective	of	 the	duration	of	 the	pregnancy,	which,	after	such	separation,	breathes	or	shows	any	other	evidence	of	life,	such	as	heart	beat,	umbilical	cord	pulsation,	or	definite	movement	of	 voluntary	 muscles,	 irrespective	 of	 whether	 the	 umbilical	 cord	 has	been	cut	or	the	placenta	is	attached.		
128	
• Micromanipulation:	 a	 technology	 that	 allows	 micro-operative	procedures	 to	 be	 performed	 on	 the	 spermatozoon,	 oocyte,	 zygote,	 or	embryo.		
• Oocyte	donation	 cycle:	a	cycle	 in	which	oocytes	are	collected	from	a	donor	for	clinical	application	or	research.		
• Oocyte	 recipient	 cycle:	 an	 ART	 cycle	 in	 which	 a	 woman	 receives	oocytes	from	a	donor.		
• Preimplantation	 genetic	 diagnosis	 (PGD):	 analysis	 of	 polar	 bodies,	blastomeres,	 or	 trophectoderm	 from	oocytes,	 zygotes,	 or	 embryos	 for	the	 detection	 of	 specific	 genetic,	 structural,	 and/or	 chromo-	 somal	alterations.		
• Vitrification:	 an	ultra-rapid	 cryopreservation	method	 that	pre-	 vents	ice	formation	within	the	suspension	which	is	converted	to	a	glass-like	solid.		
• Zygote:	a	diploid	cell	resulting	from	the	fertilization	of	an	oocyte	by	a	spermatozoon,	which	subsequently	divides	to	form	an	embryo.		
 
Glossary terms from International Committee for Monitoring Assisted 
Reproductive Technology (ICMART) and the World Health Organization 
(WHO) revised glossary of ART terminology (Zegers-Hochschild et al. 2009). 
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